Weight B-intervention
Lifting I-intervention
and O
Physical B-condition
Function I-condition
Among O
Survivors O
of O
Breast O
Cancer O
: O
A O
Post O
Hoc O
Analysis O
of O
a O
Randomized O
Controlled O
Trial O
. O
Survivors O
of O
breast O
cancer O
may O
experience O
deterioration O
of O
physical O
function O
. O
This O
is O
important O
because O
poor O
physical O
function O
may O
be O
associated O
with O
premature O
mortality O
, O
injurious O
falls O
, O
bone O
fracture O
, O
and O
disability O
. O
We O
conducted O
a O
post O
hoc O
analysis O
to O
explore O
the O
potential O
efficacy O
of O
slowly O
progressive O
weight O
lifting O
to O
reduce O
the O
incidence O
of O
physical O
function O
deterioration O
among O
survivors O
of O
breast O
cancer O
. O
Between O
October O
2005 O
and O
August O
2008 O
, O
we O
conducted O
a O
single O
- O
blind O
, O
12 O
-month O
, O
randomized O
controlled O
trial O
of O
twice O
- O
per O
- O
week O
slowly O
progressive O
weight O
lifting O
or O
standard B-control
care I-control
among O
295 B-total-participants
survivors B-eligibility
of I-eligibility
nonmetastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
In O
this O
post O
hoc O
analysis O
of O
data O
from O
the O
Physical O
Activity O
and O
Lymphedema O
Trial O
, O
we O
examined O
incident O
deterioration O
of O
physical O
function O
after O
12 O
months O
, O
defined O
as O
a O
â‰¥ O
10 O
-point O
decrease O
in O
the O
physical O
function O
subscale O
of O
the O
Medical O
Outcomes O
Short O
- O
Form O
36 O
-item O
questionnaire O
. O
The O
proportion O
of O
participants O
who O
experienced O
incident B-outcome
physical I-outcome
function I-outcome
deterioration I-outcome
after B-outcome
12 I-outcome
months I-outcome
was O
16.3 B-cv-bin-percent
% I-cv-bin-percent
( O
24 B-cv-bin-abs
/ O
147 B-control-participants
) O
in O
the O
control O
group O
and O
8.1 B-iv-bin-percent
% I-iv-bin-percent
( O
12 B-iv-bin-abs
/ O
148 B-intervention-participants
) O
in O
the O
weight O
lifting O
group O
( O
relative O
risk O
, O
0.49 O
; O
95 O
% O
CI O
, O
0.25 O
to O
0.96 O
; O
P O
= O
. O
04 O
) O
. O
No O
serious O
or O
unexpected O
adverse B-outcome
events I-outcome
occurred O
that O
were O
related O
to O
weight O
lifting O
. O
Slowly O
progressive O
weight O
lifting O
compared O
with O
standard O
care O
reduced O
the O
incidence B-outcome
of I-outcome
physical I-outcome
function I-outcome
deterioration I-outcome
among O
survivors O
of O
breast O
cancer O
. O
These O
data O
are O
hypothesis O
generating O
. O
Future O
studies O
should O
directly O
compare O
the O
efficacy O
of O
weight O
lifting O
with O
other O
modalities O
of O
exercise O
, O
such O
as O
brisk O
walking O
, O
to O
appropriately O
inform O
the O
development O
of O
a O
confirmatory O
study O
designed O
to O
preserve O
physical O
function O
among O
survivors O
of O
breast O
cancer O
. O

A O
randomized O
controlled O
Phase O
II O
trial O
of O
vinorelbine B-intervention
plus I-intervention
capecitabine I-intervention
versus O
docetaxel B-control
plus I-control
capecitabine I-control
in O
anthracycline O
- O
pretreated O
women O
with O
metastatic O
breast O
cancer O
. O
Previous O
studies O
have O
shown O
that O
vinorelbine O
/ O
capecitabine O
( O
NX O
) O
and O
docetaxel O
/ O
capecitabine O
( O
TX O
) O
chemotherapy O
has O
a O
certain O
effect O
in O
advanced O
breast O
cancer O
. O
However O
, O
there O
are O
few O
clinical O
studies O
directly O
comparing O
TX O
and O
NX O
regimen O
chemotherapy O
, O
especially O
in O
patients O
with O
advanced O
breast O
cancer O
previously O
treated O
with O
anthracycline O
and O
taxane O
. O
The O
purpose O
of O
this O
Phase O
II O
study O
was O
to O
compare O
survival O
and O
side O
effects O
between O
patients O
with O
anthracycline- O
and O
taxane O
- O
resistant O
advanced O
breast O
cancer O
treated O
with O
NX O
and O
those O
treated O
with O
TX O
chemotherapy O
. O
From O
February O
2012 O
to O
March O
2014 O
, O
a O
total O
number O
of O
97 B-total-participants
patients O
were O
randomly O
assigned O
to O
NX O
( O
n O
= O
55 B-intervention-participants
) O
or O
TX O
( O
n O
= O
42 B-control-participants
) O
. O
Baseline O
characteristics O
were O
relatively O
well O
- O
balanced O
in O
the O
two O
treatment O
arms O
. O
The O
clinical O
trial O
registration O
number O
( O
clincaltrials O
. O
gov O
) O
is O
NCT O
01635465 O
. O
After O
a O
median O
follow O
- O
up O
of O
46.0 O
months O
, O
there O
was O
no O
significant O
difference O
between O
the O
NX O
and O
TX O
arms O
in O
objective B-outcome
response I-outcome
rate I-outcome
( O
17.9 B-iv-bin-percent
% I-iv-bin-percent
vs. O
21.1 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.686 O
) O
and O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
6 B-iv-cont-median
months I-iv-cont-median
vs. O
7 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
0.560 O
) O
. O
The O
overall B-outcome
survival I-outcome
period O
of O
the O
TX O
arm O
was O
longer O
than O
that O
of O
the O
NX O
arm O
( O
32 B-iv-cont-median
months I-iv-cont-median
vs. O
27 B-cv-cont-median
months I-cv-cont-median
) O
but O
without O
statistical O
significance O
. O
Both O
regimens O
were O
well B-outcome
- I-outcome
tolerated I-outcome
. O
The O
main O
toxicities O
were O
neutropenia B-outcome
, O
leukopenia B-outcome
, O
and O
anemia B-outcome
. O
In O
the O
TX O
arm O
, O
hand B-outcome
- I-outcome
foot I-outcome
syndrome I-outcome
occurred O
more O
frequently O
than O
in O
the O
NX O
arm O
( O
P O
< O
0.01 O
) O
, O
but O
frequencies O
of O
other O
minor O
adverse B-outcome
effects I-outcome
were O
similar O
between O
the O
two O
arms O
. O
NX O
and O
TX O
regimens O
are O
both O
alternative O
treatments O
for O
patients O
with O
anthracycline- O
and O
taxane O
- O
resistant O
advanced O
breast O
cancer O
, O
but O
the O
safety O
profile O
was O
more O
favorable O
and O
manageable O
with O
the O
NX O
regimen O
. O
ClinicalTrials O
. O
gov O
NCT O
01635465 O
. O
Registered O
09 O
July O
2012 O
. O

Multicenter O
phase O
II O
randomized O
trial O
evaluating O
antiangiogenic B-intervention
therapy I-intervention
with I-intervention
sunitinib I-intervention
as O
consolidation O
after O
objective O
response O
to O
taxane O
chemotherapy O
in O
women O
with O
HER O
2 O
- O
negative O
metastatic O
breast O
cancer O
. O
The O
aim O
of O
this O
study O
is O
to O
test O
the O
hypothesis O
that O
antiangiogenic O
treatment O
with O
sunitinib O
consolidation O
can O
prolong O
remissions O
induced O
by O
taxane O
- O
based O
chemotherapy O
in O
women O
with O
metastatic O
breast O
cancer O
. O
The O
method O
involves O
a O
two O
- O
arm O
open O
- O
label O
( O
2 O
:1 O
randomization O
) O
multicenter O
, O
randomized O
phase O
II O
trial O
evaluating O
the O
efficacy O
of O
sunitinib O
( O
arm O
A O
) O
versus O
no B-control
therapy I-control
( O
arm O
B O
) O
in O
patients B-eligibility
with I-eligibility
HER- I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
achieved I-eligibility
an I-eligibility
objective I-eligibility
response I-eligibility
to I-eligibility
taxane I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
. O
The O
results O
of O
this O
study O
indicates O
that O
the O
primary O
endpoint O
of O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
> I-outcome
or I-outcome
= I-outcome
5 I-outcome
months I-outcome
was O
achieved O
in O
10 B-iv-bin-abs
of O
36 B-intervention-participants
patients O
( O
28 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
arm O
A O
and O
4 B-cv-bin-abs
of O
19 B-control-participants
patients O
( O
21 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
arm O
B O
. O
The O
median B-outcome
PFS I-outcome
was O
2.8 B-iv-cont-median
and O
3.1 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
. O
A O
protocol O
amendment O
to O
the O
sunitinib O
dosing O
schedule O
was O
made O
because O
53 O
% O
( O
17 O
/ O
32 O
) O
of O
patients O
treated O
at O
a O
starting O
dose O
of O
50 O
mg O
( O
4 O
weeks O
on O
/ O
2 O
weeks O
off O
) O
required B-outcome
dose I-outcome
reduction I-outcome
. O
Changing O
the O
starting O
dose O
to O
sunitinib O
37.5 O
mg O
continuously O
resulted O
in O
dose B-outcome
reductions I-outcome
in O
44 O
% O
( O
7 O
/ O
16 O
) O
of O
patients O
. O
Grades B-outcome
III I-outcome
- I-outcome
IV I-outcome
toxicity I-outcome
occurred O
in O
69 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
in O
arm O
A O
( O
fatigue B-outcome
31 B-iv-bin-percent
% I-iv-bin-percent
, O
musculoskeletal B-outcome
pain I-outcome
11 B-iv-bin-percent
% I-iv-bin-percent
, O
neutropenia B-outcome
and I-outcome
thrombopenia I-outcome
8 B-outcome
% I-outcome
) O
and O
11 B-cv-bin-percent
% I-cv-bin-percent
in O
arm O
B O
. O
The O
proof O
- O
of O
- O
principle O
study O
does O
not O
confirm O
the O
hypothesis O
that O
sunitinib O
consolidation O
therapy O
can O
lead O
to O
a O
predefined O
clinically O
relevant O
proportion O
of O
patients O
with O
PFS O
of O
> O
or O
= O
5 O
months O
after O
an O
objective O
response O
to O
taxanes O
. O
Furthermore O
, O
toxicity O
was O
significant O
. O

Dressing B-intervention
Wear I-intervention
Time I-intervention
after O
Breast O
Reconstruction O
: O
A O
Randomized O
Clinical O
Trial O
. O
The O
evidence O
to O
support O
dressing O
standards O
for O
breast O
surgery O
wounds O
is O
empiric O
and O
scarce O
. O
This O
two O
- O
arm O
randomized O
clinical O
trial O
was O
designed O
to O
assess O
the O
effect O
of O
dressing O
wear O
time O
on O
surgical O
site O
infection O
( O
SSI O
) O
rates O
, O
skin O
colonization O
and O
patient O
perceptions O
. O
A O
total O
of O
200 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
undergoing I-eligibility
breast I-eligibility
reconstruction I-eligibility
were O
prospectively O
enrolled O
. O
Patients O
were O
randomly O
allocated O
to O
group O
I O
( O
dressing O
removed O
on O
the O
first O
postoperative O
day O
, O
n O
= O
100 B-intervention-participants
) O
or O
group O
II O
( O
dressing O
removed O
on O
the O
sixth O
postoperative O
day O
, O
n O
= O
100 B-intervention-participants
) O
. O
SSIs O
were O
defined O
and O
classified O
according O
to O
criteria O
from O
the O
Centers O
for O
Disease O
Control O
and O
Prevention O
. O
Samples O
collected O
before O
placing O
the O
dressing O
and O
after O
1 O
day O
( O
group O
I O
) O
and O
6 O
days O
( O
both O
groups O
) O
were O
cultured O
for O
skin O
colonization O
assessments O
. O
Patients O
preferences O
and O
perceptions O
with O
regard O
to O
safety O
, O
comfort O
and O
convenience O
were O
recorded O
and O
analyzed O
. O
A O
total O
of O
186 B-total-participants
patients O
completed O
the O
follow O
- O
up O
. O
The O
global O
SSI B-outcome
rate I-outcome
was O
4.5 O
% O
. O
Six B-iv-bin-abs
patients O
in O
group O
I O
and O
three B-cv-bin-abs
in O
group O
II O
had O
SSI B-outcome
( O
p O
= O
0.497 O
) O
. O
Before O
dressing O
, O
the O
groups O
were O
similar O
with O
regard O
to O
skin B-outcome
colonization I-outcome
. O
At O
the O
sixth O
day O
, O
there O
was O
a O
higher O
colonization B-outcome
by I-outcome
coagulase I-outcome
- I-outcome
negative I-outcome
staphylococci I-outcome
in O
group O
I O
( O
p O
< O
0.0001 O
) O
. O
Patients O
preferred O
to O
keep O
dressing O
for O
six O
days O
( O
p O
< O
0.0001 O
) O
, O
and O
considered O
this O
a O
safer O
choice O
( O
p O
< O
0.05 O
) O
. O
Despite O
group O
I O
had O
a O
higher O
skin B-outcome
colonization I-outcome
by O
coagulase O
- O
negative O
staphylococci O
on O
the O
sixth O
postoperative O
day O
, O
there O
was O
no O
difference O
in O
SSI B-outcome
rates I-outcome
. O
Patients O
preferred O
keeping O
dressing O
for O
six O
days O
and O
considered O
it O
a O
safer O
choice O
. O
ClinicalTrials.gov O
NCT O
01148823 O
. O

Tamoxifen B-intervention
plus I-intervention
tegafur I-intervention
- I-intervention
uracil I-intervention
( I-intervention
TUFT I-intervention
) I-intervention
versus O
tamoxifen B-control
plus I-control
Adriamycin I-control
( I-control
doxorubicin I-control
) I-control
and I-control
cyclophosphamide I-control
( I-control
ACT I-control
) I-control
as O
adjuvant O
therapy O
to O
treat O
node O
- O
positive O
premenopausal O
breast O
cancer O
( O
PreMBC O
) O
: O
results O
of O
Japan B-location
Clinical O
Oncology O
Group O
Study O
9404 O
. O
A O
prospective O
randomized O
clinical O
trial O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
tamoxifen O
plus O
doxorubicin O
and O
cyclophosphamide O
compared O
to O
tamoxifen O
plus O
tegafur O
- O
uracil O
as O
an O
adjuvant O
therapy O
to O
treat O
node O
- O
positive O
premenopausal O
breast O
cancer O
( O
PreMBC O
) O
. O
Eligibility O
criteria O
included O
pathologically B-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
( I-eligibility
n I-eligibility
= I-eligibility
1 I-eligibility
- I-eligibility
9 I-eligibility
) I-eligibility
preMBC I-eligibility
with I-eligibility
curative I-eligibility
resection I-eligibility
, I-eligibility
in I-eligibility
stages I-eligibility
I I-eligibility
- I-eligibility
IIIA I-eligibility
. O
Patients O
were O
randomized O
to O
receive O
either O
tamoxifen O
20 O
mg O
/ O
day O
plus O
tegafur O
- O
uracil O
400 O
mg O
/ O
day O
( O
TU O
) O
for O
2 O
years O
or O
six O
courses O
of O
a O
28 O
-day O
cycle O
of O
doxorubicin O
40 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
500 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
along O
with O
tamoxifen O
( O
ACT O
) O
given O
for O
2 O
years O
as O
adjuvant O
therapy O
. O
Primary O
endpoint O
was O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
and O
secondary O
endpoint O
was O
recurrence B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
RFS I-outcome-measure
) I-outcome-measure
. O
In O
total O
, O
169 B-total-participants
patients O
were O
recruited O
( O
TU O
arm O
87 B-intervention-participants
, O
ACT O
arm O
82 B-control-participants
) O
between O
October O
1994 O
and O
September O
1999 O
. O
The O
HR O
for O
OS B-outcome
was O
0.76 O
( O
95 O
% O
CI O
0.35 O
, O
1.66 O
, O
log O
- O
rank O
p O
= O
0.49 O
) O
and O
that O
for O
RFS B-outcome
was O
0.77 O
( O
95 O
% O
CI O
0.44 O
, O
1.36 O
, O
log O
- O
rank O
p O
= O
0.37 O
) O
, O
with O
ACT O
resulting O
in O
a O
better O
HR O
. O
The O
5 B-outcome
-year I-outcome
OS I-outcome
was O
79.7 B-iv-bin-percent
% I-iv-bin-percent
for O
patients O
in O
the O
TU O
arm O
and O
83 B-cv-bin-percent
% I-cv-bin-percent
for O
those O
in O
the O
ACT O
arm O
. O
The O
5 B-outcome
-year I-outcome
RFS I-outcome
was O
66.1 B-iv-bin-percent
% I-iv-bin-percent
for O
patients O
in O
the O
TU O
arm O
and O
70.6 B-cv-bin-percent
% I-cv-bin-percent
for O
those O
in O
the O
ACT O
arm O
. O
A O
higher O
proportion O
of O
patients O
in O
the O
ACT O
arm O
experienced O
grade B-outcome
3 I-outcome
leucopenia I-outcome
( O
0 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
TU O
arm O
, O
4 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
ACT O
arm O
) O
. O
There O
were O
no O
significant O
differences O
in O
the O
efficacy O
of O
TU O
and O
ACT O
as O
adjuvant O
therapy O
. O

Dressing B-intervention
wear I-intervention
time I-intervention
after O
breast O
reconstruction O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
One O
of O
the O
major O
risk O
variables O
for O
surgical O
site O
infection O
is O
wound O
management O
. O
Understanding O
infection O
risk O
factors O
for O
breast O
operations O
is O
essential O
in O
order O
to O
develop O
infection O
- O
prevention O
strategies O
and O
improve O
surgical O
outcomes O
. O
The O
aim O
of O
this O
trial O
is O
to O
assess O
the O
influence O
of O
dressing O
wear O
time O
on O
surgical B-condition
site I-condition
infection I-condition
rates I-condition
and I-condition
skin I-condition
colonization I-condition
. O
Patients O
' O
perception O
at O
self O
- O
assessment O
will O
also O
be O
analyzed O
. O
This O
is O
a O
two O
- O
arm O
randomized O
controlled O
trial O
. O
Two B-total-participants
hundred I-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
undergoing I-eligibility
immediate I-eligibility
or I-eligibility
delayed I-eligibility
breast I-eligibility
reconstruction I-eligibility
will O
be O
prospectively O
enrolled O
. O
Patients O
will O
be O
randomly O
allocated O
to O
group O
I O
( O
dressing O
removed O
on O
postoperative O
day O
one O
) O
or O
group B-control
II I-control
( I-control
dressing I-control
removed I-control
on I-control
postoperative I-control
day I-control
six I-control
) I-control
. O
Surgical O
site O
infections O
will O
be O
defined O
by O
standard O
criteria O
from O
the O
Centers O
for O
Disease O
Control O
and O
Prevention O
( O
CDC O
) O
. O
Skin O
colonization O
will O
be O
assessed O
by O
culture O
of O
samples O
collected O
at O
predefined O
time O
points O
. O
Patients O
will O
score O
dressing O
wear O
time O
with O
regard O
to O
safety O
, O
comfort O
and O
convenience O
. O
The O
evidence O
to O
support O
dressing O
standards O
for O
breast O
surgery O
wounds O
is O
empiric O
and O
scarce O
. O
CDC O
recommends O
protecting O
, O
with O
a O
sterile O
dressing O
for O
24 O
to O
48 O
hours O
postoperatively O
, O
a O
primarily O
closed O
incision O
, O
but O
there O
is O
no O
recommendation O
to O
cover O
this O
kind O
of O
incision O
beyond O
48 O
hours O
, O
or O
on O
the O
appropriate O
time O
to O
shower O
or O
bathe O
with O
an O
uncovered O
incision O
. O
The O
results O
of O
the O
ongoing O
trial O
may O
support O
standard O
recommendations O
regarding O
dressing O
wear O
time O
after O
breast O
reconstruction O
. O
ClinicalTrials.gov O
identifier O
: O
http: O
/ O
/ O
NCT O
01148823 O
. O

Novel B-intervention
hyaluronan I-intervention
formulation I-intervention
for O
preventing O
acute B-condition
skin I-condition
reactions I-condition
in O
breast O
during O
radiotherapy O
: O
a O
randomized O
clinical O
trial O
. O
We O
conducted O
a O
randomized O
, O
double O
- O
blind O
, O
vehicle O
- O
controlled O
clinical O
trial O
to O
investigate O
the O
use O
of O
a O
new O
proprietary O
hyaluronan O
( O
HA O
) O
formulation O
for O
the O
prevention O
of O
acute O
skin O
toxicity O
in O
breast O
cancer O
patients O
undergoing O
radiotherapy O
( O
RT O
) O
. O
Thirty B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
whole I-eligibility
breast I-eligibility
RT I-eligibility
were O
enrolled O
. O
Each O
patient O
was O
randomly O
assigned O
to O
HA O
formulation O
( O
study O
cream O
, O
S O
) O
on O
the O
medial O
or O
lateral O
half O
of O
the O
irradiated O
breast O
and O
the O
control B-control
cream I-control
( I-control
placebo I-control
, I-control
P I-control
) I-control
on O
the O
other O
half O
. O
The O
primary O
endpoint O
was O
physician B-outcome-measure
's I-outcome-measure
evaluation I-outcome-measure
of I-outcome-measure
skin I-outcome-measure
symptoms I-outcome-measure
at O
week O
5 O
during O
RT O
and O
week O
2 O
post O
- O
RT O
. O
We O
also O
collected O
patients O
' O
independent O
assessment O
of O
skin O
after O
RT O
, O
patient O
's O
product O
preference O
, O
and O
an O
independent O
physician O
panel O
assessment O
of O
skin O
reactions O
based O
on O
photographs O
. O
Twenty B-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
evaluable O
. O
On O
physician O
's O
evaluation O
, O
there O
was O
no O
significant O
difference O
in O
radiation B-outcome
dermatitis I-outcome
between O
S O
and O
P O
and O
no O
overall O
preference O
to O
either O
cream O
at O
week O
5 O
during O
or O
week O
2 O
post O
- O
RT O
. O
More O
patients O
preferred O
S O
in O
evaluating O
skin B-outcome
appearance I-outcome
and I-outcome
skin I-outcome
reactions I-outcome
, O
but O
this O
did O
not O
reach O
statistical O
significance O
. O
Univariate O
analysis O
showed O
that O
physicians O
had O
an O
overall O
preference O
to O
the O
S O
cream O
at O
week O
2 O
post O
- O
RT O
in O
patients O
with O
larger O
breasts O
. O
On O
the O
independent O
panel O
assessment O
, O
3 O
reviewers O
saw O
no O
significant O
difference O
in O
radiation O
toxicity O
, O
whereas O
one O
reviewer O
reported O
better O
skin O
outcome O
with O
S O
cream O
at O
week O
5 O
. O
We O
found O
a O
nonstatistically O
significant O
patient O
preference O
but O
overall O
no O
significant O
radioprotective O
effects O
for O
this O
HA O
formulation O
compared O
with O
placebo O
except O
in O
patients O
with O
larger O
breasts O
. O
The O
study O
was O
registered O
at O
www.clinicaltrials.gov O
( O
NCT O
02165605 O
) O
. O

Sentinel B-intervention
lymph I-intervention
node I-intervention
biopsy I-intervention
in O
patients O
with O
multifocal O
breast O
cancer O
. O
Multifocal O
or O
multicentric O
breast O
cancer O
has O
been O
suggested O
as O
a O
contraindication O
for O
sentinel O
node O
biopsy O
( O
SNB O
) O
. O
However O
, O
recent O
studies O
have O
demonstrated O
that O
all O
quadrants O
of O
the O
breast O
drain O
through O
common O
afferent O
channels O
to O
a O
common O
axillary O
sentinel O
node O
. O
This O
should O
mean O
that O
the O
presence O
of O
multifocal O
tumour O
should O
not O
affect O
the O
lymphatic O
drainage O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
feasibility O
and O
accuracy O
of O
SNB O
in O
patients O
with O
multifocal O
breast O
cancer O
using O
a O
peritumoural O
injection O
technique O
for O
sentinel O
lymph O
node O
( O
SN O
) O
mapping O
. O
In O
the O
ALMANAC O
multicentre O
trial O
validation O
phase O
, O
we O
took O
SNB O
samples O
from O
842 B-total-participants
patients B-eligibility
with I-eligibility
node I-eligibility
negative I-eligibility
, I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
with O
use O
of O
a O
blue O
dye O
and O
radiolabelled O
colloid O
mapping O
technique O
at O
the O
peritumoural O
injection O
site O
. O
All O
patients O
underwent O
standard O
axillary O
treatment O
after O
SNB O
. O
Seventy O
- O
five O
of O
the O
842 O
patients O
had O
multifocal O
lesions O
on O
final O
histopathologic O
examination O
. O
The O
following O
analysis O
is O
focused O
on O
patients O
with O
multifocal O
lesions O
. O
A O
mean O
number O
of O
2.4 O
SNs B-outcome
were O
identified O
in O
71 B-iv-bin-abs
of O
75 B-intervention-participants
patients O
( O
identification O
rate O
: O
94.7 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Thirty B-iv-bin-abs
- I-iv-bin-abs
one I-iv-bin-abs
patients O
had O
a O
positive B-outcome
SN I-outcome
, O
40 B-iv-bin-abs
a O
negative B-outcome
SN I-outcome
. O
Standard O
axillary O
treatment O
confirmed B-outcome
the I-outcome
SN I-outcome
to I-outcome
be I-outcome
negative I-outcome
in O
37 B-iv-bin-abs
of O
40 B-intervention-participants
patients O
, O
whereas O
three B-iv-bin-abs
patients O
revealed O
positive B-outcome
non I-outcome
- I-outcome
sentinel I-outcome
lymph I-outcome
nodes I-outcome
( O
false O
- O
negative O
rate O
: O
8.8 O
% O
) O
. O
Overall O
SN O
biopsy O
accurately B-outcome
predicted I-outcome
axillary I-outcome
lymph I-outcome
node I-outcome
status I-outcome
in O
68 B-iv-bin-abs
of O
71 B-intervention-participants
patients O
( O
95.8 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
SNB O
accurately O
staged O
the O
axilla O
in O
multifocal O
breast O
cancer O
and O
may O
become O
an O
alternative O
to O
complete O
axillary O
lymph O
node O
dissection O
in O
node O
negative O
patients O
with O
multifocal O
breast O
cancer O
. O

Use O
of O
anastrozole B-intervention
for O
breast O
cancer O
prevention O
( O
IBIS O
- O
II O
) O
: O
long O
- O
term O
results O
of O
a O
randomised O
controlled O
trial O
. O
Two O
large O
clinical O
trials O
have O
shown O
a O
reduced O
rate O
of O
breast O
cancer O
development O
in O
high O
- O
risk O
women O
in O
the O
initial O
5 O
years O
of O
follow O
- O
up O
after O
use O
of O
aromatase O
inhibitors O
( O
MAP O
. O
3 O
and O
International O
Breast O
Cancer O
Intervention O
Study O
II O
[ O
IBIS O
- O
II O
] O
) O
. O
Here O
, O
we O
report O
blinded O
long O
- O
term O
follow O
- O
up O
results O
for O
the O
IBIS O
- O
II O
trial O
, O
which O
compared O
anastrozole O
with O
placebo B-control
, O
with O
the O
objective O
of O
determining O
the O
efficacy O
of O
anastrozole O
for O
preventing O
breast O
cancer O
( O
both O
invasive O
and O
ductal O
carcinoma O
in O
situ O
) O
in O
the O
post O
- O
treatment O
period O
. O
IBIS O
- O
II O
is O
an O
international O
, O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O
Postmenopausal B-eligibility
women I-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
of I-eligibility
developing I-eligibility
breast I-eligibility
cancer I-eligibility
were O
recruited O
and O
were O
randomly O
assigned O
( O
1 O
:1 O
) O
to O
either O
anastrozole O
( O
1 O
mg O
per O
day O
, O
oral O
) O
or O
matching O
placebo O
daily O
for O
5 O
years O
. O
After O
treatment O
completion O
, O
women O
were O
followed O
on O
a O
yearly O
basis O
to O
collect O
data O
on O
breast O
cancer O
incidence O
, O
death O
, O
other O
cancers O
, O
and O
major O
adverse O
events O
( O
cardiovascular O
events O
and O
fractures O
) O
. O
The O
primary O
outcome O
was O
all B-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
. O
3864 B-total-participants
women O
were O
recruited O
between O
Feb O
2 O
, O
2003 O
, O
and O
Jan O
31 O
, O
2012 O
. O
1920 B-intervention-participants
women O
were O
randomly O
assigned O
to O
5 O
years O
anastrozole O
and O
1944 B-control-participants
to O
placebo O
. O
After O
a O
median O
follow O
- O
up O
of O
131 O
months O
( O
IQR O
105 O
- O
156 O
) O
, O
a O
49 O
% O
reduction O
in O
breast B-outcome
cancer I-outcome
was O
observed O
for O
anastrozole O
( O
85 B-iv-bin-abs
vs O
165 B-cv-bin-abs
cases O
, O
hazard O
ratio O
[ O
HR O
] O
0 O
Â· O
51 O
, O
95 O
% O
CI O
0 O
Â· O
39 O
- O
0 O
Â· O
66 O
, O
p O
< O
0 O
Â· O
0001 O
) O
. O
The O
reduction B-outcome
was O
larger O
in O
the O
first B-outcome
5 I-outcome
years I-outcome
( O
35 B-iv-bin-abs
vs O
89 B-cv-bin-abs
, O
0 O
Â· O
39 O
, O
0 O
Â· O
27 O
- O
0 O
Â· O
58 O
, O
p O
< O
0 O
Â· O
0001 O
) O
, O
but O
still O
significant O
after B-outcome
5 I-outcome
years I-outcome
( O
50 B-iv-bin-abs
vs O
76 B-cv-bin-abs
new O
cases O
, O
0 O
Â· O
64 O
, O
0 O
Â· O
45 O
- O
0 O
Â· O
91 O
, O
p= O
0 O
Â· O
014 O
) O
, O
and O
not O
significantly O
different O
from O
the O
first O
5 O
years O
( O
p= O
0 O
Â· O
087 O
) O
. O
Invasive B-outcome
oestrogen I-outcome
receptor I-outcome
- I-outcome
positive I-outcome
breast I-outcome
cancer I-outcome
was O
reduced O
by O
54 O
% O
( O
HR O
0 O
Â· O
46 O
, O
95 O
% O
CI O
0 O
Â· O
33 O
- O
0 O
Â· O
65 O
, O
p O
< O
0 O
Â· O
0001 O
) O
, O
with O
a O
continued O
significant O
effect O
in O
the O
period O
after O
treatment O
. O
A O
59 O
% O
reduction B-outcome
in I-outcome
ductal I-outcome
carcinoma I-outcome
in I-outcome
situ I-outcome
was O
observed O
( O
0 O
Â· O
41 O
, O
0 O
Â· O
22 O
- O
0 O
Â· O
79 O
, O
p= O
0 O
Â· O
0081 O
) O
, O
especially O
in O
participants O
known O
to O
be O
oestrogen O
receptor O
- O
positive O
( O
0 O
Â· O
22 O
, O
0 O
Â· O
78 O
- O
0 O
Â· O
65 O
, O
p O
< O
0 O
Â· O
0001 O
) O
. O
No O
significant O
difference O
in O
deaths B-outcome
was O
observed O
overall O
( O
69 B-iv-bin-abs
vs O
70 B-cv-bin-abs
, O
HR O
0 O
Â· O
96 O
, O
95 O
% O
CI O
0 O
Â· O
69 O
- O
1 O
Â· O
34 O
, O
p= O
0 O
Â· O
82 O
) O
or O
for B-outcome
breast I-outcome
cancer I-outcome
( O
two B-iv-bin-abs
anastrozole O
vs O
three B-cv-bin-abs
placebo O
) O
. O
A O
significant O
decrease O
in O
non B-outcome
- I-outcome
breast I-outcome
cancers I-outcome
was O
observed O
for O
anastrozole O
( O
147 B-iv-bin-abs
vs O
200 B-cv-bin-abs
, O
odds O
ratio O
0 O
Â· O
72 O
, O
95 O
% O
CI O
0 O
Â· O
57 O
- O
0 O
Â· O
91 O
, O
p= O
0 O
Â· O
0042 O
) O
, O
owing O
primarily O
to O
non O
- O
melanoma O
skin O
cancer O
. O
No O
excess O
of O
fractures B-outcome
or O
cardiovascular B-outcome
disease I-outcome
was O
observed O
. O
This O
analysis O
has O
identified O
a O
significant O
continuing O
reduction O
in O
breast O
cancer O
with O
anastrozole O
in O
the O
post O
- O
treatment O
follow O
- O
up O
period O
, O
with O
no O
evidence O
of O
new O
late O
side O
- O
effects O
. O
Further O
follow O
- O
up O
is O
needed O
to O
assess O
the O
effect O
on O
breast O
cancer O
mortality O
. O
Cancer O
Research O
UK O
, O
the O
National O
Health O
and O
Medical O
Research O
Council O
Australia O
, O
Breast O
Cancer O
Research O
Foundation O
, O
Sanofi O
Aventis O
, O
and O
AstraZeneca O
. O

FemZone O
trial O
: O
a O
randomized O
phase O
II O
trial O
comparing O
neoadjuvant B-control
letrozole I-control
and O
zoledronic B-intervention
acid I-intervention
with I-intervention
letrozole I-intervention
in O
primary O
breast O
cancer O
patients O
. O
The O
objective O
of O
this O
prospectively O
randomized O
phase O
II O
trial O
( O
Trial O
registration O
: O
EUCTR O
2004 O
- O
004007 O
- O
37 O
- O
DE O
) O
was O
to O
compare O
the O
clinical O
response O
of O
primary B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
to O
neoadjuvant O
therapy O
with O
letrozole O
alone O
( O
LET O
) O
or O
letrozole O
and O
zoledronic O
acid O
( O
LET O
+ O
ZOL O
) O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
LET O
2.5 O
mg O
/ O
day O
( O
n O
= O
79 B-control-participants
) O
or O
the O
combination O
of O
LET O
2.5 O
mg O
/ O
day O
and O
a O
total O
of O
seven O
infusions O
of O
ZOL O
4 O
mg O
every O
4 O
weeks O
( O
n O
= O
89 B-intervention-participants
) O
for O
6 O
months O
. O
Primary O
endpoint O
was O
clinical B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
as O
assessed O
by O
mammogram O
readings O
. O
The O
study O
was O
terminated O
prematurely O
due O
to O
insufficient O
recruitment O
. O
We O
report O
here O
on O
an O
exploratory O
analysis O
of O
this O
data O
. O
Central O
assessment O
of O
tumor O
sizes O
during O
the O
treatment O
period O
was O
available O
for O
131 B-total-participants
patients O
( O
66 B-control-participants
LET O
, O
65 B-intervention-participants
LET O
+ O
ZOL O
) O
. O
Clinical B-outcome
responses I-outcome
( I-outcome
complete I-outcome
or I-outcome
partial I-outcome
) I-outcome
were O
seen O
in O
54.5 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
: O
41.8 O
- O
66.9 O
) O
of O
the O
patients O
in O
the O
LET O
arm O
and O
69.2 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
56.6 O
- O
80.1 O
) O
of O
those O
in O
the O
LET O
+ O
ZOL O
arm O
( O
P O
= O
0.106 O
) O
. O
A O
multivariate O
model O
showed O
an O
OR B-outcome
of O
1.72 O
( O
95 O
% O
CI O
: O
0.83 O
- O
3.59 O
) O
for O
the O
experimental O
arm O
. O
No O
increase O
in O
the O
clinical B-outcome
response I-outcome
rate I-outcome
was O
observed O
with O
the O
addition O
of O
ZOL O
to O
a O
neoadjuvant O
treatment O
regimen O
with O
LET O
. O
However O
a O
trend O
towards O
a O
better O
reponse O
in O
the O
LET O
+ O
ZOL O
arm O
could O
be O
observed O
. O
This O
trend O
is O
consistent O
with O
previous O
studies O
that O
have O
investigated O
the O
addition O
of O
ZOL O
to O
chemotherapy O
, O
and O
it O
may O
support O
the O
evidence O
for O
a O
direct O
antitumor O
action O
of O
zoledronic O
acid O
. O

Autologous B-intervention
bone I-intervention
marrow I-intervention
stromal I-intervention
cells I-intervention
transplantation I-intervention
for O
the O
treatment O
of O
secondary O
arm O
lymphedema O
: O
a O
prospective O
controlled O
study O
in O
patients O
with O
breast O
cancer O
related O
lymphedema O
. O
To O
determine O
the O
short- O
and O
long O
- O
term O
effect O
of O
bone O
marrow O
stromal O
cells O
( O
BMSCs O
) O
transplantation O
as O
a O
treatment O
for O
breast O
cancer O
- O
related O
lymphedema O
. O
To O
contrast O
it O
with O
complex O
decongestive O
physiotherapy O
( O
CDT O
) O
. O
Fifteen B-intervention-participants
women B-eligibility
with I-eligibility
lymphedema I-eligibility
, I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
and I-eligibility
/ I-eligibility
no I-eligibility
radiotherapy I-eligibility
5 I-eligibility
years I-eligibility
before I-eligibility
, O
served O
as O
the O
experimental O
group O
and O
received O
BMSC O
transplantation O
; O
35 B-control-participants
patients O
were O
measured O
as O
the O
control O
group O
treated O
with O
CDT B-control
. O
They O
were O
kept O
on O
follow O
- O
up O
for O
1 O
year O
. O
Two O
patients O
in O
the O
CDT O
Group O
failed O
to O
keep O
follow O
- O
up O
. O
Before B-outcome
treatment I-outcome
, O
patients O
had O
average B-outcome
volume I-outcome
of I-outcome
edema I-outcome
in O
the O
affected O
arm O
of O
1166.2 B-iv-cont-mean
ml I-iv-cont-mean
in O
BMSC O
Group O
and O
1091.0 B-cv-cont-mean
ml I-cv-cont-mean
in O
the O
CDT O
Group O
. O
With O
therapy O
, O
there O
was O
an O
average B-outcome
decrease I-outcome
in I-outcome
lymphedema I-outcome
volume I-outcome
of O
730.7 B-iv-cont-mean
, O
887.9 B-iv-cont-mean
and O
958.6 B-iv-cont-mean
ml I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
714.8 B-cv-cont-mean
, O
657.9 B-cv-cont-mean
and O
571.3 B-cv-cont-mean
ml I-cv-cont-mean
in O
the O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
Before B-outcome
treatment I-outcome
, O
the O
percentage B-outcome
of I-outcome
lymphedema I-outcome
was O
28.6 B-iv-cont-mean
% I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
26.8 B-cv-cont-mean
% I-cv-cont-mean
in O
the O
CDT O
Group O
. O
After B-outcome
treatment I-outcome
, O
there O
was O
a O
decrease O
of O
64.6 B-iv-cont-mean
, O
78.5 B-iv-cont-mean
and O
81.0 B-iv-cont-mean
% I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
67.2 B-cv-cont-mean
, O
60.4 B-cv-cont-mean
and O
54.5 B-cv-cont-mean
% I-cv-cont-mean
in O
the O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
When O
asked O
to O
quantify O
subjectively O
their O
pain B-outcome
on O
a O
numeric O
scale O
from O
0 O
to O
5 O
, O
the O
average O
score O
of O
these O
patients O
was O
3.4 B-iv-cont-mean
in O
the O
BMSC O
group O
and O
4.0 B-cv-cont-mean
in O
the O
CDT O
Group O
. O
The O
average B-outcome
score I-outcome
was O
reduced O
to O
1.6 B-iv-cont-mean
, O
0.8 B-iv-cont-mean
and O
0.6 B-iv-cont-mean
in O
the O
BMSC O
Group O
and O
to O
1.2 B-cv-cont-mean
, O
1.7 B-cv-cont-mean
and O
1.6 B-cv-cont-mean
in O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
Autologous O
BMSCs O
transplantation O
for O
the O
treatment O
of O
breast O
cancer O
related O
lymphedema O
is O
effective O
and O
feasible O
. O

Phase O
III O
open O
- O
label O
randomized O
study O
of O
eribulin B-intervention
mesylate I-intervention
versus O
capecitabine B-control
in O
patients O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
previously O
treated O
with O
an O
anthracycline O
and O
a O
taxane O
. O
This O
phase O
III O
randomized O
trial O
( O
ClinicalTrials O
. O
gov O
identifier O
: O
NCT O
00337103 O
) O
compared O
eribulin O
with O
capecitabine O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Women B-eligibility
with I-eligibility
MBC I-eligibility
who I-eligibility
had I-eligibility
received I-eligibility
prior I-eligibility
anthracycline- I-eligibility
and I-eligibility
taxane I-eligibility
- I-eligibility
based I-eligibility
therapy I-eligibility
were O
randomly O
assigned O
to O
receive O
eribulin O
or O
capecitabine O
as O
their O
first- O
, O
second- O
, O
or O
third O
- O
line O
chemotherapy O
for O
advanced O
/ O
metastatic O
disease O
. O
Stratification O
factors O
were O
human O
epidermal O
growth O
factor O
receptor- O
2 O
( O
HER O
2 O
) O
status O
and O
geographic O
region O
. O
Coprimary O
end O
points O
were O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
and O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
. O
Median B-outcome
OS I-outcome
times I-outcome
for O
eribulin O
( O
n O
= O
554 B-intervention-participants
) O
and O
capecitabine O
( O
n O
= O
548 B-control-participants
) O
were O
15.9 B-iv-cont-median
and O
14.5 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.88 O
; O
95 O
% O
CI O
, O
0.77 O
to O
1.00 O
; O
P O
= O
. O
056 O
) O
. O
Median B-outcome
PFS I-outcome
times I-outcome
for O
eribulin O
and O
capecitabine O
were O
4.1 B-iv-cont-median
and O
4.2 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
( O
HR O
, O
1.08 O
; O
95 O
% O
CI O
, O
0.93 O
to O
1.25 O
; O
P O
= O
. O
30 O
) O
. O
Objective B-outcome
response I-outcome
rates I-outcome
were O
11.0 B-iv-bin-percent
% I-iv-bin-percent
for O
eribulin O
and O
11.5 B-cv-bin-percent
% I-cv-bin-percent
for O
capecitabine O
. O
Global B-outcome
health I-outcome
status I-outcome
and O
overall B-outcome
quality I-outcome
- I-outcome
of I-outcome
- I-outcome
life I-outcome
scores I-outcome
over O
time O
were O
similar O
in O
the O
treatment O
arms O
. O
Both O
treatments O
had O
manageable O
safety O
profiles O
consistent O
with O
their O
known O
adverse O
effects O
; O
most O
adverse O
events O
were O
grade O
1 O
or O
2 O
. O
In O
this O
phase O
III O
study O
, O
eribulin O
was O
not O
shown O
to O
be O
superior O
to O
capecitabine O
with O
regard O
to O
OS O
or O
PFS O
. O

The O
Living O
Well O
after O
Breast O
Cancer O
â„¢ O
Pilot O
Trial O
: O
a O
weight B-intervention
loss I-intervention
intervention I-intervention
for O
women O
following O
treatment O
for O
breast O
cancer O
. O
Obesity O
is O
associated O
with O
poor O
prognosis O
and O
risk O
of O
treatment O
side O
- O
effects O
in O
breast O
cancer O
survivors O
. O
This O
pilot O
study O
assessed O
the O
feasibility O
, O
acceptability O
, O
safety O
and O
efficacy O
of O
a O
telephone O
- O
delivered O
weight O
loss O
intervention O
, O
among B-eligibility
women I-eligibility
( I-eligibility
BMI I-eligibility
25 I-eligibility
- I-eligibility
40 I-eligibility
kg I-eligibility
/ I-eligibility
m I-eligibility
2 I-eligibility
) I-eligibility
following I-eligibility
treatment I-eligibility
for I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
, O
on O
weight B-outcome-measure
loss I-outcome-measure
( O
primary O
outcome O
) O
, O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
and O
treatment B-outcome-measure
- I-outcome-measure
related I-outcome-measure
side I-outcome-measure
- I-outcome-measure
effects I-outcome-measure
( O
vs O
usual B-control
care I-control
) O
. O
Ninety B-total-participants
women O
( O
mean O
Â± O
SD O
age O
: O
55.3 B-age
Â± I-age
8.7 I-age
years I-age
; O
BMI O
: O
31.0 O
Â± O
4.3 O
kg O
/ O
m O
2 O
; O
15.9 O
Â± O
2.9 O
months O
postdiagnosis O
) O
, O
recruited O
from O
a O
state O
- O
based O
cancer O
registry O
, O
were O
randomized O
to O
a O
weight O
loss O
( O
diet O
and O
physical O
activity O
) O
intervention O
( O
n O
= O
45 B-intervention-participants
) O
or O
usual O
care O
( O
n O
= O
45 B-control-participants
) O
. O
Data O
collected O
at O
baseline O
and O
6 O
months O
included O
weight O
, O
body O
composition O
, O
quality O
of O
life O
, O
fatigue O
and O
body O
image O
. O
Acceptability O
and O
satisfaction O
were O
assessed O
in O
intervention O
participants O
. O
Oncologists O
provided O
consent O
to O
contact O
82.6 O
% O
of O
patients O
, O
with O
84.1 O
% O
of O
those O
women O
contacted O
and O
eligible O
consenting O
to O
participate O
. O
Compared O
with O
usual O
care O
, O
mean B-outcome
weight I-outcome
loss I-outcome
was O
significantly O
greater O
in O
the O
intervention O
arm O
( O
- B-iv-cont-mean
3.1 I-iv-cont-mean
kg I-iv-cont-mean
[ O
95 O
% O
CI O
, O
- O
5.4 O
to O
- O
0.7 O
] O
; O
- O
3.7 O
% O
baseline O
weight O
[ O
95 O
% O
CI O
, O
- O
6.6 O
to O
- O
0.9 O
] O
) O
, O
as O
were O
reductions B-outcome
in I-outcome
fat I-outcome
mass I-outcome
( O
- B-iv-cont-mean
2.1 I-iv-cont-mean
kg I-iv-cont-mean
[ O
95 O
% O
CI O
, O
- O
4.2 O
to O
- O
0.1 O
] O
) O
and O
waist B-outcome
circumference I-outcome
( O
- B-iv-cont-mean
4.0 I-iv-cont-mean
cm I-iv-cont-mean
[ O
95 O
% O
CI O
, O
- O
6.6 O
to O
- O
1.3 O
] O
) O
. O
No O
other O
statistically O
significant O
intervention O
effects O
were O
observed O
. O
Participants O
were O
highly O
satisfied B-outcome
with O
the O
intervention O
overall O
and O
it O
is O
timing O
in O
relation O
to O
diagnosis O
/ O
treatment O
. O
One O
reported O
adverse B-outcome
event I-outcome
( I-outcome
musculoskeletal I-outcome
injury I-outcome
) I-outcome
was O
attributable O
to O
the O
intervention O
. O
This O
weight O
loss O
intervention O
was O
feasible B-outcome
, O
acceptable B-outcome
, O
safe B-outcome
and O
effective B-outcome
for O
women O
1 O
- O
2 O
years O
after O
a O
breast O
cancer O
diagnosis O
. O
The O
effect O
of O
weight O
loss O
on O
quality O
of O
life O
and O
treatment O
- O
related O
side O
- O
effects O
should O
be O
examined O
further O
in O
fully O
- O
powered O
studies O
. O

Multidisciplinary O
Approach O
to O
Novel O
Therapies O
in O
Cardio O
- O
Oncology O
Research O
( O
MANTICORE O
101 O
-Breast O
) O
: O
A O
Randomized O
Trial O
for O
the O
Prevention O
of O
Trastuzumab B-condition
- I-condition
Associated I-condition
Cardiotoxicity I-condition
. O
Purpose O
The O
primary O
toxicity O
of O
trastuzumab O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
-overexpressing O
( O
HER O
2 O
- O
positive O
) O
breast O
cancer O
is O
dose O
- O
independent O
cardiac O
dysfunction O
. O
Angiotensin O
- O
converting O
enzyme O
inhibitors O
and O
Î² O
- O
blockers O
are O
recommended O
first O
- O
line O
agents O
for O
heart O
failure O
. O
We O
hypothesized O
that O
angiotensin O
- O
converting O
enzyme O
inhibitors O
and O
Î² O
- O
blockers O
could O
prevent O
trastuzumab O
- O
related O
cardiotoxicity O
. O
Patients O
and O
Methods O
In O
this O
double O
- O
blinded O
, O
placebo O
- O
controlled O
trial O
, O
patients B-eligibility
with I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
positive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
treatment O
with O
perindopril B-intervention
, I-intervention
bisoprolol I-intervention
, O
or O
placebo B-control
( O
1 O
:1 O
:1 O
) O
for O
the O
duration O
of O
trastuzumab O
adjuvant O
therapy O
. O
Patients O
underwent O
cardiac O
magnetic O
resonance O
imaging O
at O
baseline O
and O
post O
- O
cycle O
17 O
for O
the O
determination O
of O
left O
ventricular O
volumes O
and O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
. O
Cardiotoxicity O
was O
evaluated O
as O
the O
change O
in O
indexed O
left O
ventricular O
end O
diastolic O
volume O
and O
LVEF O
. O
Results O
Thirty B-intervention-participants
- I-intervention-participants
three I-intervention-participants
patients O
received O
perindopril O
, O
31 B-intervention-participants
received O
bisoprolol O
, O
and O
30 B-control-participants
received O
placebo O
. O
Baseline O
demographic O
, O
cancer O
, O
and O
cardiovascular O
profiles O
were O
similar O
between O
groups O
. O
Study O
drugs O
were O
well O
tolerated O
with O
no B-outcome
serious I-outcome
adverse I-outcome
events I-outcome
. O
After O
17 O
cycles O
of O
trastuzumab O
, O
indexed O
left B-outcome
ventricular I-outcome
end I-outcome
diastolic I-outcome
volume I-outcome
increased O
in O
patients O
treated O
with O
perindopril O
( O
+ B-iv-cont-mean
7 I-iv-cont-mean
Â± O
14 B-iv-cont-sd
mL I-iv-cont-sd
/ I-iv-cont-sd
m I-iv-cont-sd
2 I-iv-cont-sd
) O
, O
bisoprolol O
( O
+ B-iv-cont-mean
8 I-iv-cont-mean
mL I-iv-cont-mean
Â± O
9 B-iv-cont-sd
mL I-iv-cont-sd
/ I-iv-cont-sd
m I-iv-cont-sd
2 I-iv-cont-sd
) O
, O
and O
placebo O
( O
+ B-cv-cont-mean
4 I-cv-cont-mean
Â± O
11 B-cv-cont-sd
mL I-cv-cont-sd
/ I-cv-cont-sd
m I-cv-cont-sd
2 I-cv-cont-sd
; O
P O
= O
. O
36 O
) O
. O
In O
secondary O
analyses O
, O
trastuzumab O
- O
mediated O
decline B-outcome
in I-outcome
LVEF I-outcome
was O
attenuated O
in O
bisoprolol O
- O
treated O
patients O
( O
- B-iv-cont-mean
1 I-iv-cont-mean
Â± O
5 B-iv-cont-sd
% I-iv-cont-sd
) O
relative O
to O
the O
perindopril O
( O
- B-iv-cont-mean
3 I-iv-cont-mean
Â± O
4 B-iv-cont-sd
% I-iv-cont-sd
) O
and O
placebo O
( O
- B-cv-cont-mean
5 I-cv-cont-mean
Â± O
5 B-cv-cont-sd
% I-cv-cont-sd
) O
groups O
( O
P O
= O
. O
001 O
) O
. O
Perindopril O
and O
bisoprolol O
use O
were O
independent O
predictors O
of O
maintained O
LVEF O
on O
multivariable O
analysis O
. O
Conclusion O
Perindopril O
and O
bisoprolol O
were O
well O
tolerated O
in O
patients O
with O
HER O
2 O
- O
positive O
early O
breast O
cancer O
who O
received O
trastuzumab O
and O
protected O
against O
cancer O
therapy O
- O
related O
declines O
in O
LVEF O
; O
however O
, O
trastuzumab O
- O
mediated O
left B-outcome-measure
ventricular I-outcome-measure
remodeling I-outcome-measure
- O
the O
primary O
outcome O
- O
was O
not O
prevented O
by O
these O
pharmacotherapies O
. O

Indocyanine B-intervention
green I-intervention
fluorescence I-intervention
- I-intervention
guided I-intervention
lumpectomy I-intervention
of O
nonpalpable O
breast O
cancer O
versus O
wire B-control
- I-control
guided I-control
excision I-control
: O
A O
randomized O
clinical O
trial O
. O
The O
use O
of O
wire O
localization O
( O
WL O
) O
for O
excisions O
of O
nonpalpable O
breast O
cancer O
( O
NBC O
) O
has O
several O
disadvantages O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
use O
of O
indocyanine O
green O
- O
guided O
nonpalpable O
breast O
cancer O
lesion O
localization O
( O
INBCL O
) O
and O
to O
compare O
it O
with O
WL O
. O
A O
total O
of O
62 B-total-participants
patients B-eligibility
with I-eligibility
a I-eligibility
preoperative I-eligibility
histological I-eligibility
diagnosis I-eligibility
of I-eligibility
NBC I-eligibility
lesions I-eligibility
that I-eligibility
could I-eligibility
be I-eligibility
visualized I-eligibility
with I-eligibility
ultrasound I-eligibility
and I-eligibility
mammography I-eligibility
were O
randomized O
to O
INBCL O
or O
WL O
. O
Patients O
with O
preoperatively O
diagnosed O
primary O
ductal O
carcinoma O
in O
situ O
and O
multifocal O
disease O
were O
excluded O
from O
the O
study O
. O
Significance O
was O
considered O
at O
P O
< O
0.05 O
. O
Of O
all O
62 B-total-participants
excision O
, O
32 B-intervention-participants
( O
51.6 O
% O
) O
were O
guided O
by O
INBCL O
and O
30 B-control-participants
( O
48.4 O
% O
) O
by O
WL O
. O
Both O
techniques O
resulted O
in O
100 B-iv-bin-percent
% I-iv-bin-percent
retrieval B-outcome
of I-outcome
the I-outcome
lesions I-outcome
. O
The O
rate B-outcome
of I-outcome
clear I-outcome
margins I-outcome
was O
significantly O
higher O
in O
the O
INBCL O
group O
( O
87.5 B-iv-bin-percent
% I-iv-bin-percent
; O
28 B-iv-bin-abs
/ O
32 B-intervention-participants
) O
compared O
to O
the O
WL O
( O
63.3 B-cv-bin-percent
% I-cv-bin-percent
, O
19 B-cv-bin-abs
/ O
30 B-control-participants
) O
( O
P O
= O
0.026 O
) O
, O
reducing O
the O
requirement O
of O
re O
- O
excision O
. O
When O
results O
of O
the O
excised O
tissue O
are O
taken O
into O
account O
, O
the O
mean B-outcome
volume I-outcome
of I-outcome
the I-outcome
INBCL I-outcome
specimen I-outcome
was O
56 O
cm O
3 O
less O
than O
that O
of O
the O
WL O
group O
, O
although O
this O
was O
not O
significantly O
different O
( O
P O
= O
0.058 O
) O
. O
INBCL O
for O
NBCs O
was O
more O
accurate O
than O
WL O
, O
because O
it O
optimized O
the O
surgeon O
's O
ability O
to O
obtain O
clear O
margins O
. O
A O
smaller O
volume O
of O
the O
tissue O
may O
be O
excised O
by O
using O
INBCL O
technique O
. O
Therefore O
INBCL O
is O
an O
attractive O
alternative O
to O
WL O
. O

Anthracycline B-condition
- I-condition
induced I-condition
cardiotoxicity I-condition
prevention O
with O
angiotensin B-intervention
- I-intervention
converting I-intervention
enzyme I-intervention
inhibitor I-intervention
ramipril I-intervention
in O
women O
with O
low O
- O
risk O
breast O
cancer O
: O
results O
of O
a O
prospective O
randomized O
study O
. O
Anthracyclineâ€‘induced O
cardiotoxicity O
( O
AIC O
) O
remains O
the O
main O
longâ€‘term O
irreversible O
side O
effect O
in O
malignancy O
survivors O
. O
Cardiotoxicity O
prevention O
is O
one O
of O
the O
most O
reasonable O
approaches O
. O
In O
this O
prospective O
randomized O
openâ€‘label O
study O
, O
we O
aimed O
to O
verify O
whether O
ramipril O
protects O
from O
earlyâ€‘onset O
AIC O
in O
women O
with O
breast O
cancer O
( O
BC O
) O
. O
We O
analyzed O
data O
from O
96 B-total-participants
women O
( O
median O
age O
, O
47 B-age
years I-age
) O
with B-eligibility
BC I-eligibility
after I-eligibility
breast I-eligibility
surgery I-eligibility
, I-eligibility
without I-eligibility
significant I-eligibility
cardiovascular I-eligibility
diseases I-eligibility
, I-eligibility
who I-eligibility
were I-eligibility
eligible I-eligibility
for I-eligibility
adjuvant I-eligibility
anthracyclines I-eligibility
. O
They O
were O
randomized O
to O
a O
ramipril O
or O
control B-control
arm I-control
. O
Cardiotoxicity O
was O
estimated O
with O
repeat O
echocardiography O
and O
themeasurement O
of O
troponin O
I O
and O
Nâ€‘terminal O
fragment O
of O
the O
prohormone O
brain O
natriuretic O
peptide O
( O
NTâ€‘proBNP O
) O
levels O
over O
1 O
â€‘year O
followâ€‘up O
. O
Anthracyclineâ€‘induced O
cardiotoxicity O
was O
defined O
as O
a O
decrease O
in O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
, O
elevated O
biomarker O
levels O
, O
and/or O
occurrence O
of O
heart O
failure O
( O
HF O
) O
or O
cardiac O
death O
. O
A O
decrease O
in O
LVEF B-outcome
above I-outcome
10 I-outcome
â€‘percent I-outcome
points I-outcome
occurred O
in O
6.3 B-iv-bin-percent
% I-iv-bin-percent
of O
ramipril O
patients O
and O
18.5 B-cv-bin-percent
% I-cv-bin-percent
ofcontrols O
( O
P O
= O
0.15 O
) O
. O
No O
cases O
of O
HF B-outcome
, O
cardiac B-outcome
death I-outcome
, O
or O
LVEF B-outcome
decline O
below O
50 O
% O
were O
reported O
. O
The O
percentage B-outcome
of I-outcome
patients I-outcome
with I-outcome
elevated I-outcome
NTâ€‘proBNP I-outcome
levels I-outcome
increased O
with O
time O
in O
controls O
( O
P O
= O
0.003 O
) O
and O
remained O
unchanged O
in O
the O
ramipril O
arm O
. O
At O
the O
end O
of O
followâ€‘up O
, O
an O
increase O
in O
NTâ€‘proBNP B-outcome
levels I-outcome
was O
more O
common O
and O
decline O
was O
less O
common O
in O
the O
control O
than O
ramipril O
arm O
( O
P O
= O
0.01 O
) O
. O
No O
significant O
differences O
in O
troponin O
levels O
were O
found O
between O
the O
study O
arms O
. O
Ramipril O
was O
well O
tolerated O
in O
normotensive O
women O
. O
In O
relatively O
young O
women O
with O
BC O
without O
serious O
comorbidities O
, O
who O
received O
anthracyclines O
, O
1 O
â€‘year O
treatment O
with O
ramipril O
exerts O
potentially O
protective O
effects O
on O
cardiotoxicity O
assessed O
with O
NTâ€‘proBNP O
levels O
. O

Neratinib B-intervention
after O
trastuzumab O
- O
based O
adjuvant O
therapy O
in O
patients O
from O
Asia B-location
with O
early O
stage O
HER O
2 O
- O
positive O
breast O
cancer O
. O
Aim O
: O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
neratinib O
as O
extended O
adjuvant O
therapy O
in O
patients O
from O
Asia O
based O
on O
exploratory O
analyses O
of O
the O
Phase O
III O
ExteNET O
trial O
. O
Patients O
& O
methods O
: O
A O
total O
of O
2840 B-total-participants
women B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
neratinib O
240 O
mg O
/ O
day O
or O
placebo B-control
for O
1 O
year O
after O
trastuzumab O
- O
based O
adjuvant O
therapy O
. O
Results O
: O
A O
total O
of O
341 B-total-participants
patients O
were O
from O
Asia O
( O
neratinib O
, O
n O
= O
165 B-intervention-participants
; O
placebo O
, O
n O
= O
176 B-control-participants
) O
. O
2 B-outcome
-year I-outcome
invasive I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
92.8 B-iv-bin-percent
and O
90.8 B-cv-bin-percent
% I-cv-bin-percent
with O
neratinib O
and O
placebo O
, O
respectively O
( O
HR O
: O
0.70 O
; O
95 O
% O
CI O
: O
0.31 O
- O
1.55 O
) O
, O
and O
5 B-outcome
-year I-outcome
rates I-outcome
were O
91.9 B-iv-bin-percent
and O
87.2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
HR O
: O
0.57 O
; O
95 O
% O
CI O
: O
0.27 O
- O
1.13 O
) O
. O
Diarrhea B-outcome
was O
the O
most O
common O
adverse O
event O
with O
neratinib O
. O
Conclusion O
: O
Extended O
adjuvant O
therapy O
with O
neratinib O
reduces O
disease O
recurrences O
in O
Asian O
women O
with O
HER O
2 O
- O
positive O
breast O
cancer O
. O
Trial O
registration O
: O
Clinicaltrials O
. O
gov O
NCT O
00878709 O
. O

Clinical O
usefulness O
of O
eribulin B-intervention
as O
first- O
or O
second O
- O
line O
chemotherapy O
for O
recurrent O
HER O
2 O
- O
negative O
breast O
cancer O
: O
a O
randomized O
phase O
II O
study O
( O
JBCRG- O
19 O
) O
. O
Anthracycline O
( O
A O
) O
or O
taxane O
T O
- O
based O
regimens O
are O
the O
standard O
early O
- O
line O
chemotherapy O
for O
metastatic O
breast O
cancer O
( O
BC O
) O
. O
A O
previous O
study O
has O
shown O
a O
survival O
benefit O
of O
eribulin O
in O
heavily O
pretreated O
advanced O
/ O
recurrent O
BC O
patients O
. O
The O
present O
study O
aimed O
to O
compare O
the O
benefit O
of O
eribulin O
with O
treatment O
of O
physician O
's O
choice O
( O
TPC O
) O
as O
first- O
or O
second O
- O
line O
chemotherapy O
for O
recurrent O
HER O
2 O
- O
negative O
BC O
. O
Patients B-eligibility
with I-eligibility
recurrent I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
BC I-eligibility
previously I-eligibility
receiving I-eligibility
anthracycline I-eligibility
and I-eligibility
taxane I-eligibility
AT I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
in I-eligibility
the I-eligibility
adjuvant I-eligibility
or I-eligibility
first I-eligibility
- I-eligibility
line I-eligibility
setting I-eligibility
were O
eligible O
for O
this O
open O
- O
label O
, O
randomized O
, O
parallel O
- O
group O
study O
. O
Patients O
were O
randomized O
1 O
:1 O
by O
the O
minimization O
method O
to O
receive O
either O
eribulin O
( O
1.4 O
mg O
/ O
m O
2 O
on O
day O
one O
and O
eight O
of O
each O
21 O
-day O
cycle O
) O
or O
TPC B-control
( O
paclitaxel O
, O
docetaxel O
, O
nab O
- O
paclitaxel O
or O
vinorelbine O
) O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O
The O
primary O
endpoint O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
. O
Secondary O
endpoints O
included O
time B-outcome-measure
to I-outcome-measure
treatment I-outcome-measure
failure I-outcome-measure
( I-outcome-measure
TTF I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
duration B-outcome-measure
of I-outcome-measure
response I-outcome-measure
, O
and O
safety B-outcome-measure
( O
UMIN O
000009886 O
) O
. O
Between O
May O
2013 O
and O
January O
2017 O
, O
58 B-total-participants
patients O
were O
randomized O
, O
57 B-total-participants
of O
whom O
( O
26 B-intervention-participants
eribulin O
and O
31 B-control-participants
TPC O
) O
were O
analyzed O
for O
efficacy O
. O
The O
median B-outcome
PFS I-outcome
was O
6.6 B-iv-cont-median
Â  I-iv-cont-median
months I-iv-cont-median
with O
eribulin O
versus O
4.2 B-cv-cont-median
Â  I-cv-cont-median
months I-cv-cont-median
with O
TPC O
( O
hazard O
ratio O
: O
0.72 O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
0.40 O
- O
1.30 O
] O
, O
p O
= O
0.276 O
) O
. O
Median B-outcome
TTF I-outcome
was O
6.0 B-iv-cont-median
Â  I-iv-cont-median
months I-iv-cont-median
with O
eribulin O
versus O
3.6 B-cv-cont-median
Â  I-cv-cont-median
months I-cv-cont-median
with O
TPC O
( O
hazard O
ratio O
: O
0.66 O
[ O
95 O
% O
CI O
, O
0.39 O
- O
1.14 O
] O
, O
p O
= O
0.136 O
) O
. O
Other O
endpoints O
were O
also O
similar O
between O
groups O
. O
The O
most O
common O
grade B-outcome
â€‰ I-outcome
â‰¥ I-outcome
â€‰ I-outcome
3 I-outcome
adverse I-outcome
event I-outcome
was O
neutropenia B-outcome
( O
22.2 B-iv-bin-percent
% I-iv-bin-percent
with O
eribulin O
versus O
16.1 B-cv-bin-percent
% I-cv-bin-percent
with O
TPC O
) O
. O
Eribulin O
seemed O
to O
improve O
PFS O
or O
TTF O
compared O
with O
TPC O
without O
statistical O
significance O
. O
Further O
validation O
studies O
are O
needed O
. O

Ribociclib B-intervention
as O
First O
- O
Line O
Therapy O
for O
HR O
- O
Positive O
, O
Advanced O
Breast O
Cancer O
. O
The O
inhibition O
of O
cyclin O
- O
dependent O
kinases O
4 O
and O
6 O
( O
CDK O
4 O
/ O
6 O
) O
could O
potentially O
overcome O
or O
delay O
resistance O
to O
endocrine O
therapy O
in O
advanced O
breast O
cancer O
that O
is O
positive O
for O
hormone O
receptor O
( O
HR O
) O
and O
negative O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER O
2 O
) O
. O
In O
this O
randomized O
, O
placebo O
- O
controlled O
, O
phase O
3 O
trial O
, O
we O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
selective O
CDK O
4 O
/ O
6 O
inhibitor O
ribociclib O
combined O
with O
letrozole O
for O
first O
- O
line O
treatment O
in O
668 B-total-participants
postmenopausal O
women O
with O
HR O
- O
positive O
, O
HER O
2 O
- O
negative O
recurrent O
or O
metastatic O
breast O
cancer O
who O
had O
not O
received O
previous O
systemic O
therapy O
for O
advanced O
disease O
. O
We O
randomly O
assigned O
the O
patients O
to O
receive O
either O
ribociclib O
( O
600 O
mg O
per O
day O
on O
a O
3 O
-weeks O
- O
on O
, O
1 O
-week O
- O
off O
schedule O
) O
plus O
letrozole O
( O
2.5 O
mg O
per O
day O
) O
or O
placebo B-control
plus I-control
letrozole I-control
. O
The O
primary O
end O
point O
was O
investigator O
- O
assessed O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Secondary O
end O
points O
included O
overall B-outcome-measure
survival I-outcome-measure
, O
overall B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
, O
and O
safety B-outcome-measure
. O
A O
preplanned O
interim O
analysis O
was O
performed O
on O
January O
29 O
, O
2016 O
, O
after O
243 O
patients O
had O
disease O
progression O
or O
died O
. O
Prespecified O
criteria O
for O
superiority O
required O
a O
hazard O
ratio O
of O
0.56 O
or O
less O
with O
P< O
1.29 O
Ã— O
10 O
- O
5 O
. O
The O
duration O
of O
progression O
- O
free O
survival O
was O
significantly O
longer O
in O
the O
ribociclib O
group O
than O
in O
the O
placebo O
group O
( O
hazard O
ratio O
, O
0.56 O
; O
95 O
% O
CI O
, O
0.43 O
to O
0.72 O
; O
P= O
3.29 O
Ã— O
10 O
- O
6 O
for O
superiority O
) O
. O
The O
median O
duration O
of O
follow O
- O
up O
was O
15.3 O
months O
. O
After O
18 B-outcome
months I-outcome
, O
the O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
rate I-outcome
was O
63.0 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
54.6 O
to O
70.3 O
) O
in O
the O
ribociclib O
group O
and O
42.2 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
34.8 O
to O
49.5 O
) O
in O
the O
placebo O
group O
. O
In O
patients O
with O
measurable O
disease O
at O
baseline O
, O
the O
overall B-outcome
response I-outcome
rate I-outcome
was O
52.7 B-iv-bin-percent
% I-iv-bin-percent
and O
37.1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
P O
< O
0.001 O
) O
. O
Common O
grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
that O
were O
reported O
in O
more O
than O
10 O
% O
of O
the O
patients O
in O
either O
group O
were O
neutropenia B-outcome
( O
59.3 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
ribociclib O
group O
vs. O
0.9 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
placebo O
group O
) O
and O
leukopenia B-outcome
( O
21.0 B-iv-bin-percent
% I-iv-bin-percent
vs. O
0.6 B-cv-bin-percent
% I-cv-bin-percent
) O
; O
the O
rates B-outcome
of I-outcome
discontinuation I-outcome
because I-outcome
of I-outcome
adverse I-outcome
events I-outcome
were O
7.5 B-iv-bin-percent
% I-iv-bin-percent
and O
2.1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
. O
Among O
patients O
receiving O
initial O
systemic O
treatment O
for O
HR O
- O
positive O
, O
HER O
2 O
- O
negative O
advanced O
breast O
cancer O
, O
the O
duration O
of O
progression O
- O
free O
survival O
was O
significantly O
longer O
among O
those O
receiving O
ribociclib O
plus O
letrozole O
than O
among O
those O
receiving O
placebo O
plus O
letrozole O
, O
with O
a O
higher O
rate O
of O
myelosuppression O
in O
the O
ribociclib O
group O
. O
( O
Funded O
by O
Novartis O
Pharmaceuticals O
; O
ClinicalTrials O
. O
gov O
number O
, O
NCT O
01958021 O
. O
) O
. O

Randomized O
controlled O
trial O
of O
toremifene B-intervention
120 O
mg O
compared O
with O
exemestane B-control
25 O
mg O
after O
prior O
treatment O
with O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
After O
the O
failure O
of O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
( O
nsAI O
) O
for O
postmenopausal O
patients O
with O
metastatic O
breast O
cancer O
( O
mBC O
) O
, O
it O
is O
unclear O
which O
of O
various O
kinds O
of O
endocrine O
therapy O
is O
the O
most O
appropriate O
. O
A O
randomized O
controlled O
trial O
was O
performed O
to O
compare O
the O
efficacy O
and O
safety O
of O
daily O
toremifene O
120 O
mg O
( O
TOR O
120 O
) O
, O
a O
selective O
estrogen O
receptor O
modulator O
, O
and O
exemestane O
25 O
mg O
( O
EXE O
) O
, O
a O
steroidal O
aromatase O
inhibitor O
. O
The O
primary O
end O
point O
was O
the O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
. O
The O
secondary O
end O
points O
were O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
and O
toxicity B-outcome-measure
. O
Initially O
, O
a O
total O
of O
91 B-total-participants
women O
was O
registered O
in O
the O
study O
and O
randomly O
assigned O
to O
either O
TOR O
120 O
( O
n O
= O
46 B-intervention-participants
) O
or O
EXE O
( O
n O
= O
45 B-control-participants
) O
from O
October O
2008 O
to O
November O
2011 O
. O
Three O
of O
the O
46 O
patients O
in O
the O
TOR O
120 O
arm O
were O
not O
received O
treatment O
, O
2 O
patients O
having O
withdrawn O
from O
the O
trial O
by O
their O
preference O
and O
one O
having O
been O
dropped O
due O
to O
administration O
of O
another O
SERM O
. O
When O
analyzed O
after O
a O
median O
observation O
period O
of O
16.9 O
months O
, O
the O
intention O
- O
to O
- O
treat O
analysis O
showed O
that O
there O
were O
no O
statistical O
difference O
between O
TOR O
120 O
( O
N O
= O
46 B-intervention-participants
) O
and O
EXE O
( O
n O
= O
45 B-control-participants
) O
in O
terms O
of O
CBR B-outcome
( O
41.3 B-iv-bin-percent
% I-iv-bin-percent
vs. O
26.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.14 O
) O
, O
ORR B-outcome
( O
10.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
2.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.083 O
) O
, O
and O
OS B-outcome
( O
Hazard O
ratio O
, O
0.60 O
; O
P O
= O
0.22 O
) O
. O
The O
PFS B-outcome
of O
TOR O
120 O
was O
longer O
than O
that O
of O
EXE O
, O
the O
difference O
being O
statistically O
significant O
( O
Hazard O
ratio O
, O
0.61 O
, O
P O
= O
0.045 O
) O
. O
The O
results O
in O
treatment O
- O
received O
cohort O
( O
N O
= O
88 O
) O
were O
similar O
to O
those O
in O
ITT O
cohort O
. O
Both O
treatments O
were O
well O
- O
tolerated O
with O
no O
severe O
adverse B-outcome
events I-outcome
, O
although O
the O
treatment O
of O
3 B-iv-bin-abs
of O
43 B-intervention-participants
women O
administered O
TOR O
120 O
was O
stopped O
after O
a O
few O
days O
because O
of O
nausea O
, O
general O
fatigue O
, O
hot O
flush O
and O
night O
sweating O
. O
TOR O
120 O
, O
as O
a O
subsequent O
endocrine O
therapy O
for O
mBC O
patients O
who O
failed O
non O
- O
steroidal O
AI O
treatment O
, O
could O
potentially O
be O
more O
beneficial O
than O
EXE O
. O
UMIN O
000001841 O
. O

Observation B-control
versus O
late O
reintroduction O
of O
letrozole B-intervention
as O
adjuvant O
endocrine O
therapy O
for O
hormone O
receptor O
- O
positive O
breast O
cancer O
( O
ANZ O
0501 O
LATER O
) O
: O
an O
open O
- O
label O
randomised O
, O
controlled O
trial O
. O
Despite O
the O
effectiveness O
of O
adjuvant O
endocrine O
therapy O
in O
preventing O
breast O
cancer O
recurrence O
, O
breast O
cancer O
events O
continue O
at O
a O
high O
rate O
for O
at O
least O
10 O
years O
after O
completion O
of O
therapy O
. O
This O
randomised O
open O
label O
phase O
III O
trial O
recruited O
postmenopausal B-eligibility
women I-eligibility
from O
29 O
Australian B-location
and O
New B-location
Zealand I-location
sites O
, O
with B-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
who I-eligibility
had I-eligibility
completed I-eligibility
â‰¥ I-eligibility
4 I-eligibility
years I-eligibility
of I-eligibility
endocrine I-eligibility
therapy I-eligibility
[ O
aromatase O
inhibitor O
( O
AI O
) O
, O
tamoxifen O
, O
ovarian O
suppression O
, O
or O
sequential O
combination O
] O
â‰¥ O
1 O
year O
prior O
, O
to O
oral O
letrozole O
2.5 O
mg O
daily O
for O
5 O
years O
, O
or O
observation B-control
. O
Treatment O
allocation O
was O
by O
central O
computerised O
randomisation O
, O
stratified O
by O
institution O
, O
axillary O
node O
status O
and O
prior O
endocrine O
therapy O
. O
The O
primary O
outcome O
was O
invasive B-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
events I-outcome-measure
( O
new O
invasive O
primary O
, O
local O
, O
regional O
or O
distant O
recurrence O
, O
or O
contralateral O
breast O
cancer O
) O
, O
analysed O
by O
intention O
to O
treat O
. O
The O
secondary O
outcomes O
were O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
, O
and O
safety B-outcome-measure
. O
Between O
16 O
May O
2007 O
and O
14 O
March O
2012 O
, O
181 B-intervention-participants
patients O
were O
randomised O
to O
letrozole O
and O
179 B-control-participants
to O
observation O
( O
median O
age O
64.3 B-age
years I-age
) O
. O
Endocrine O
therapy O
was O
completed O
at O
a O
median O
of O
2.6 O
years O
before O
randomisation O
, O
and O
47.5 O
% O
had O
tumours O
of O
> O
2 O
cm O
and/or O
node O
positive O
. O
At O
3.9 O
years O
median O
follow O
- O
up O
( O
interquartile O
range O
3.1 O
- O
4.8 O
) O
, O
2 B-iv-bin-abs
patients O
assigned O
letrozole O
( O
1.1 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
17 B-cv-bin-abs
patients O
assigned O
observation O
( O
9.5 B-cv-bin-percent
% I-cv-bin-percent
) O
had O
experienced O
an O
invasive B-outcome
breast I-outcome
cancer I-outcome
event I-outcome
( O
difference O
8.4 O
% O
, O
95 O
% O
confidence O
interval O
3.8 O
% O
to O
13.0 O
% O
, O
log O
- O
rank O
test O
P O
= O
0.0004 O
) O
. O
Twenty B-cv-bin-abs
- I-cv-bin-abs
four I-cv-bin-abs
patients O
( O
13.4 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
observation O
and O
14 B-iv-bin-abs
( O
7.7 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
letrozole O
arm O
experienced O
a O
DFS B-outcome
event I-outcome
( O
log O
- O
rank O
P O
= O
0.067 O
) O
. O
Adverse B-outcome
events I-outcome
linked O
to O
oestrogen O
depletion O
, O
but O
not O
serious O
adverse O
events O
, O
were O
more O
common O
with O
letrozole O
. O
These O
results O
should O
be O
considered O
exploratory O
, O
but O
lend O
weight O
to O
emerging O
data O
supporting O
longer O
duration O
endocrine O
therapy O
for O
hormone O
receptor O
- O
positive O
breast O
cancer O
, O
and O
offer O
insight O
into O
reintroduction O
of O
AI O
therapy O
. O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
( O
www.anzctr.org.au O
) O
, O
ACTRN O
12607000137493 O
. O

A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
evaluating O
the O
efficacy O
of O
combination O
olanzapine B-intervention
, I-intervention
ondansetron I-intervention
and I-intervention
dexamethasone I-intervention
for O
prevention O
of O
chemotherapy B-condition
- I-condition
induced I-condition
nausea I-condition
and I-condition
vomiting I-condition
in O
patients O
receiving O
doxorubicin O
plus O
cyclophosphamide O
. O
Since O
most O
of O
Thai B-location
cancer O
patients O
receiving O
high O
emetogenic O
chemotherapy O
do O
not O
have O
access O
to O
neurokinin- O
1 O
( O
NK- O
1 O
) O
receptor O
antagonists O
or O
palonosetron O
as O
recommended O
by O
international O
guidelines O
for O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
prevention O
. O
We O
decided O
to O
evaluate O
the O
efficacy O
of O
olanzapine O
with O
the O
real O
- O
life O
practice O
antiemetic O
drugs O
ondansetron O
and O
dexamethasone O
, O
in O
prevention O
of O
CINV O
resulting O
from O
doxorubicin O
plus O
cyclophosphamide O
regimen O
in O
early O
- O
stage O
breast O
cancer O
patients O
. O
In O
this O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
, O
we O
compared O
olanzapine O
with O
a O
placebo O
in O
combination O
with O
ondansetron O
and O
dexamethasone O
in O
early B-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
receiving I-eligibility
doxorubicin I-eligibility
60 I-eligibility
mg I-eligibility
/ I-eligibility
m I-eligibility
2 I-eligibility
plus I-eligibility
cyclophosphamide I-eligibility
600 I-eligibility
mg I-eligibility
/ I-eligibility
m I-eligibility
2 I-eligibility
. O
The O
intervention O
group O
received O
olanzapine O
10 O
mg O
orally O
while O
the O
control O
group O
received O
a O
matching O
placebo B-control
daily O
on O
day O
1 O
through O
day O
4 O
. O
All O
patients O
received O
ondansetron O
8 O
mg O
and O
dexamethasone O
20 O
mg O
intravenously O
30 O
minutes O
before O
chemotherapy O
administration O
and O
then O
dexamethasone O
10 O
mg O
daily O
orally O
from O
day O
1 O
through O
day O
4 O
. O
The O
primary O
endpoint O
was O
no B-outcome-measure
nausea I-outcome-measure
rate I-outcome-measure
in I-outcome-measure
the I-outcome-measure
early I-outcome-measure
period I-outcome-measure
. O
The O
secondary O
endpoints O
were O
no B-outcome-measure
nausea I-outcome-measure
rate I-outcome-measure
in I-outcome-measure
the I-outcome-measure
delayed I-outcome-measure
and I-outcome-measure
overall I-outcome-measure
periods I-outcome-measure
and O
a O
complete B-outcome-measure
response I-outcome-measure
( I-outcome-measure
no I-outcome-measure
vomiting I-outcome-measure
and I-outcome-measure
no I-outcome-measure
use I-outcome-measure
of I-outcome-measure
rescue I-outcome-measure
drug I-outcome-measure
) I-outcome-measure
. O
Outcomes O
were O
determined O
by O
patients O
' O
self O
- O
reported O
daily O
records O
of O
episodes O
of O
vomiting O
or O
retching O
, O
use O
of O
rescue O
therapy O
and O
daily O
levels O
of O
nausea O
based O
on O
a O
visual O
- O
analogue O
scale O
from O
the O
first O
cycle O
of O
chemotherapy O
. O
A O
total O
of O
39 B-total-participants
female O
patients O
were O
randomized O
in O
a O
1 O
:1 O
ratio O
to O
receive O
olanzapine O
( O
20 B-intervention-participants
patients O
) O
or O
a O
matching O
placebo O
( O
19 B-control-participants
patients O
) O
. O
A O
significantly O
greater O
proportion O
of O
patients O
reported O
no O
nausea B-outcome
in O
the O
olanzapine O
group O
than O
in O
the O
placebo O
group O
in O
both O
the O
early O
period O
( O
0 O
- O
24 O
hours O
after O
chemotherapy O
) O
and O
the O
overall O
period O
( O
0 O
- O
120 O
hours O
after O
chemotherapy O
) O
. O
Patients O
who O
reported O
no B-outcome
nausea I-outcome
in I-outcome
the I-outcome
early I-outcome
period I-outcome
accounted O
for O
50 B-iv-bin-percent
% I-iv-bin-percent
and O
10.5 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
olanzapine O
group O
and O
in O
the O
placebo O
group O
respectively O
( O
P= O
0.008 O
) O
. O
In O
the O
overall B-outcome
period I-outcome
, O
30.0 B-iv-bin-percent
% I-iv-bin-percent
and O
0 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
reported O
no B-outcome
nausea I-outcome
in O
the O
olanzapine O
and O
placebo O
groups O
respectively O
( O
P= O
0.009 O
) O
. O
In O
the O
early O
period O
, O
there O
was O
a O
significantly O
different O
complete B-outcome
response I-outcome
rate I-outcome
between O
two O
treatment O
groups O
; O
75.0 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
olanzapine O
group O
and O
36.8 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
placebo O
group O
( O
P= O
0.016 O
) O
. O
Overall O
treatment B-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
were O
not O
significantly O
different O
between O
the O
two O
study O
groups O
except O
that O
somnolence O
was O
significantly O
more O
common O
in O
the O
olanzapine O
group O
than O
in O
the O
placebo O
group O
. O
Olanzapine O
10 O
mg O
combined O
with O
ondansetron O
and O
dexamethasone O
was O
more O
effective O
than O
a O
placebo O
in O
preventing O
CINV O
resulting O
from O
doxorubicin O
plus O
cyclophosphamide O
in O
early O
- O
stage O
breast O
cancer O
patients O
, O
especially O
in O
the O
first O
24 O
hours O
after O
chemotherapy O
administration O
. O
The O
short O
duration O
of O
olanzapine O
was O
safe O
and O
well O
tolerated O
. O

Physical B-intervention
Activity I-intervention
With I-intervention
and I-intervention
Without I-intervention
Arm I-intervention
Sleeves I-intervention
: O
Compliance O
and O
Quality O
of O
Life O
After O
Breast O
Cancer O
Surgery O
- O
A O
Randomized O
Controlled O
Trial O
. O
After O
breast O
cancer O
surgery O
patients O
are O
at O
higher O
risk O
of O
lymphedema O
development O
and O
decreasing O
physical O
activity O
( O
PA O
) O
, O
as O
well O
as O
decreasing O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
. O
The O
aim O
of O
the O
study O
was O
to O
compare O
the O
level O
of O
PA O
and O
HRQOL O
in O
women O
after O
breast O
cancer O
surgery O
using O
light O
arm O
compression O
with O
women O
not O
using O
compression O
1 O
year O
after O
oncological O
treatment O
. O
Forty B-total-participants
- I-total-participants
five I-total-participants
women O
were O
preoperatively O
randomly O
assigned O
to O
a O
compression O
group O
( O
CG O
, O
n O
= O
23 B-intervention-participants
) O
or O
to O
no B-control
compression I-control
group I-control
( O
NCG O
, O
n O
= O
22 B-control-participants
) O
. O
Arm O
volumes O
were O
measured O
before O
surgery O
and O
12 O
months O
thereafter O
. O
The O
CG O
received O
circular O
- O
knit O
sleeves O
in O
compression O
class O
1 O
for O
daily O
wearing O
in O
the O
postoperative O
period O
up O
to O
1 O
year O
. O
Both O
groups O
underwent O
a O
standardized O
physical O
exercise O
program O
. O
PA O
with O
the O
short O
version O
of O
International O
Physical O
Activity O
Questionnaire O
( O
IPAQ O
) O
, O
compliance O
, O
and O
HRQOL O
by O
EORTC O
QLQ O
- O
C O
30 O
and O
QLQ O
- O
BR O
23 O
questionnaires O
was O
assessed O
in O
both O
groups O
1 O
year O
after O
surgery O
. O
After O
1 O
year O
observation O
the O
CG O
showed O
significantly O
lower O
mean O
affected O
arm B-outcome
volume I-outcome
compared O
to O
NCG O
. O
The O
total B-outcome
PA I-outcome
( O
calculated O
as O
the O
sum O
of O
vigorous O
moderate O
exercises O
and O
walking O
) O
was O
markedly O
higher O
within O
the O
CG O
, O
with O
no O
difference O
in O
particular O
IPAQ O
items O
. O
There O
were O
no O
correlations O
between O
reported O
PA O
items O
and O
observed O
arm B-outcome
/ I-outcome
edema I-outcome
volume I-outcome
or O
body B-outcome
mass I-outcome
index I-outcome
changes I-outcome
. O
The O
QLQ O
- O
BR O
23 O
revealed O
only O
better O
sexual B-outcome
functioning I-outcome
( O
p O
= O
0.014 O
) O
and O
greater O
upset B-outcome
by I-outcome
hair I-outcome
loss I-outcome
in O
NCG O
( O
p O
= O
0.01 O
) O
. O
The O
available O
data O
indicate O
that O
wearing O
compression O
sleeves O
neither O
interfere O
with O
the O
level O
of O
PA O
nor O
decrease O
quality O
of O
life O
1 O
year O
after O
breast O
cancer O
surgery O
. O

A O
pilot O
study O
of O
minocycline B-intervention
for O
the O
prevention O
of O
paclitaxel B-condition
- I-condition
associated I-condition
neuropathy I-condition
: O
ACCRU O
study O
RU O
221408 O
I O
. O
Paclitaxel O
is O
associated O
with O
both O
an O
acute O
pain O
syndrome O
( O
P O
- O
APS O
) O
and O
chronic O
chemotherapy O
- O
induced O
peripheral O
neuropathy O
( O
CIPN O
) O
. O
Given O
that O
extensive O
animal O
data O
suggest O
that O
minocycline O
may O
prevent O
chemotherapy O
- O
induced O
neurotoxicity O
, O
the O
purpose O
of O
this O
pilot O
study O
was O
to O
investigate O
the O
efficacy O
of O
minocycline O
for O
the O
prevention O
of O
CIPN O
and O
the O
P O
- O
APS O
. O
Patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
were O
enrolled O
prior O
to O
initiating O
neoadjuvant O
or O
adjuvant O
weekly O
paclitaxel O
for O
12 O
weeks O
and O
were O
randomized O
to O
receive O
minocycline O
200 O
mg O
on O
day O
1 O
followed O
by O
100 O
mg O
twice O
daily O
or O
a O
matching O
placebo B-control
. O
Patients O
completed O
( O
1 O
) O
an O
acute O
pain O
syndrome O
questionnaire O
daily O
during O
chemotherapy O
to O
measure O
P O
- O
APS O
and O
( O
2 O
) O
the O
EORTC O
QLQ O
- O
CIPN O
20 O
questionnaire O
at O
baseline O
, O
prior O
to O
each O
dose O
of O
paclitaxel O
, O
and O
monthly O
for O
6 O
months O
post O
treatment O
, O
to O
measure O
CIPN O
. O
Forty B-total-participants
- I-total-participants
seven I-total-participants
patients O
were O
randomized O
. O
There O
were O
no O
remarkable O
differences O
noted O
between O
the O
minocycline O
and O
placebo O
groups O
for O
the O
overall O
sensory O
neuropathy O
score O
of O
the O
EORTC O
QLQ O
- O
CIPN O
20 O
or O
its O
individual O
components O
, O
which O
evaluate O
tingling O
, O
numbness O
and O
shooting O
/ O
burning O
pain O
in O
hands O
and O
feet O
. O
However O
, O
patients O
taking O
minocycline O
had O
a O
significant O
reduction O
in O
the O
daily O
average B-outcome
pain I-outcome
score I-outcome
attributed O
to O
P O
- O
APS O
( O
p O
= O
0.02 O
) O
. O
Not O
only O
were O
no B-outcome
increased I-outcome
toxicities I-outcome
reported O
with O
minocycline O
, O
but O
there O
was O
a O
significant O
reduction O
in O
fatigue B-outcome
( O
p O
= O
0.02 O
) O
. O
Results O
of O
this O
pilot O
study O
do O
not O
support O
the O
use O
of O
minocycline O
to O
prevent O
CIPN O
, O
but O
suggest O
that O
it O
may O
reduce O
P B-outcome-measure
- I-outcome-measure
APS I-outcome-measure
and O
decrease O
fatigue B-outcome-measure
; O
further O
study O
of O
the O
impact O
of O
this O
agent O
on O
those O
endpoints O
may O
be O
warranted O
. O

A O
randomised O
controlled O
trial O
of O
support B-intervention
group I-intervention
intervention I-intervention
after O
breast O
cancer O
treatment O
: O
results O
on O
anxiety B-condition
and I-condition
depression I-condition
. O
Previous O
studies O
have O
demonstrated O
that O
between O
20 O
and O
30 O
% O
of O
women O
treated O
for O
breast O
cancer O
have O
measurable O
signs O
of O
anxiety O
and O
depression O
compared O
with O
6 O
% O
in O
a O
population O
of O
healthy O
women O
. O
Depression O
has O
been O
proposed O
as O
a O
predictive O
factor O
for O
recurrence O
and O
survival O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
if O
psychosocial O
support O
intervention O
could O
influence O
anxiety O
and O
depression O
during O
the O
first O
year O
after O
diagnosis O
. O
Newly B-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
were O
randomised O
between O
April O
2002 O
and O
November O
2007 O
and O
stratified O
by O
adjuvant O
chemotherapy O
. O
Of O
382 B-total-participants
eligible O
patients O
, O
191 B-intervention-participants
+ O
191 B-control-participants
patients O
were O
randomised O
to O
intervention O
group O
or O
control B-control
group I-control
, O
respectively O
. O
Control O
patients O
were O
subjected O
to O
standard B-control
follow I-control
- I-control
up I-control
routines I-control
. O
The O
Intervention O
group O
had O
support O
intervention O
at O
the O
Foundation O
LustgÃ¥rden O
MÃ¤lardalen O
. O
The O
rehabilitation O
lasted O
one O
week O
on O
a O
residential O
basis O
followed O
by O
four O
days O
of O
follow O
- O
up O
two O
months O
later O
. O
We O
used O
the O
Swedish O
version O
of O
the O
HAD O
scale O
with O
a O
cut O
- O
off O
value O
greater O
than O
10 O
for O
clinical B-outcome
symptoms I-outcome
of I-outcome
depression I-outcome
and I-outcome
anxiety I-outcome
. O
Support O
group O
intervention O
lowered O
anxiety B-outcome
over I-outcome
time I-outcome
( O
p O
< O
0.001 O
) O
but O
depression B-outcome
was O
unaffected O
( O
p O
= O
0.610 O
) O
. O
This O
prospective O
randomised O
trial O
of O
support O
group O
intervention O
in O
a O
large O
homogenous O
group O
of O
breast O
cancer O
women O
showed O
a O
statistically O
significant O
effect O
on O
lowering O
anxiety O
over O
time O
. O
No O
statistically O
significant O
effect O
of O
intervention O
could O
be O
seen O
on O
depression O
. O

Outcomes O
of O
Japanese B-ethinicity
breast O
cancer O
patients O
treated O
with O
pre O
- O
operative O
and O
post O
- O
operative O
anastrozole B-intervention
or O
tamoxifen B-control
. O
The O
present O
study O
examined O
long O
- O
term O
efficacy O
outcomes O
in O
a O
subgroup O
of O
postmenopausal O
, O
estrogen O
receptor O
- O
positive O
Japanese O
breast O
cancer O
patients O
from O
the O
Pre O
- O
Operative O
" O
Arimidex O
" O
Compared O
with O
Tamoxifen O
trial O
, O
following O
pre O
- O
operative O
( O
3 O
months O
) O
and O
post O
- O
operative O
( O
5 O
years O
) O
adjuvant O
treatment O
with O
either O
anastrozole O
or O
tamoxifen O
. O
Patients B-eligibility
with I-eligibility
large I-eligibility
, I-eligibility
potentially I-eligibility
operable I-eligibility
, I-eligibility
locally I-eligibility
- I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
receive O
anastrozole O
( O
1 O
mg O
/ O
day O
) O
plus O
tamoxifen O
placebo O
or O
tamoxifen O
( O
20 O
mg O
/ O
day O
) O
plus O
anastrozole O
placebo O
pre O
- O
operatively O
. O
After O
surgery O
at O
3 O
months O
, O
patients O
continued O
on O
the O
same O
study O
medication O
as O
adjuvant O
therapy O
for O
up O
to O
5 O
years O
or O
until O
recurrence O
, O
intolerable O
toxicity O
or O
withdrawal O
of O
patient O
consent O
. O
Recurrence O
- O
free O
survival O
and O
overall O
survival O
were O
measured O
from O
the O
date O
of O
randomization O
to O
the O
date O
of O
recurrence O
or O
death O
, O
whichever O
occurred O
first O
. O
Patients O
were O
monitored O
for O
adverse O
events O
throughout O
the O
study O
period O
and O
up O
to O
30 O
days O
following O
administration O
of O
the O
last O
study O
medication O
. O
During O
post O
- O
operative O
adjuvant O
therapy O
, O
4 B-iv-bin-abs
/ O
48 B-intervention-participants
( O
8 B-iv-bin-percent
% I-iv-bin-percent
) O
anastrozole O
and O
25 B-cv-bin-abs
/ O
49 B-control-participants
( O
51 B-cv-bin-percent
% I-cv-bin-percent
) O
tamoxifen O
patients O
experienced O
recurrence B-outcome
. O
There O
was O
a O
significant O
difference O
in O
recurrence B-outcome
- I-outcome
free I-outcome
survival I-outcome
between O
the O
two O
groups O
( O
hazard O
ratio O
0.14 O
; O
95 O
% O
confidence O
interval O
0.05 O
- O
0.41 O
; O
P O
= O
0.0003 O
) O
. O
There O
was O
a O
significant O
increase O
in O
overall B-outcome
survival I-outcome
with O
anastrozole O
( O
0.21 O
; O
0.05 O
- O
0.96 O
; O
P O
= O
0.0436 O
) O
and O
there O
were O
2 B-iv-bin-abs
/ O
48 B-intervention-participants
( O
4 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
10 B-cv-bin-abs
/ O
49 B-control-participants
( O
20 B-cv-bin-percent
% I-cv-bin-percent
) O
deaths B-outcome
with O
anastrozole O
and O
tamoxifen O
, O
respectively O
. O
Most O
patients O
responding O
to O
pre O
- O
operative O
therapy O
remained O
recurrence B-outcome
- I-outcome
free I-outcome
. O
Sequential O
pre O
- O
operative O
/ O
post O
- O
operative O
treatment O
with O
anastrozole O
resulted O
in O
lower O
recurrence O
and O
death O
rates O
, O
compared O
with O
tamoxifen O
. O

Effect O
of O
tamoxifen B-intervention
on O
venous B-condition
thromboembolic I-condition
events I-condition
in O
a O
breast O
cancer O
prevention O
trial O
. O
Tamoxifen O
, O
a O
selective O
estrogen O
- O
receptor O
modulator O
, O
increases O
venous O
thromboembolic O
events O
( O
VTE O
) O
, O
but O
the O
factors O
explaining O
this O
risk O
are O
unclear O
. O
Atherosclerosis O
may O
induce O
VTE O
, O
or O
the O
2 O
conditions O
may O
share O
common O
risk O
factors O
. O
We O
assessed O
the O
effect O
of O
tamoxifen O
on O
VTE O
in O
a O
breast O
cancer O
prevention O
trial O
and O
studied O
its O
association O
with O
risk O
factors O
for O
VTE O
. O
The O
incidence O
of O
VTE O
was O
studied O
in O
5408 B-total-participants
hysterectomized B-eligibility
women I-eligibility
randomly O
assigned O
to O
tamoxifen O
20 O
mg O
/ O
d O
or O
placebo B-control
for O
5 O
years O
. O
There O
were O
28 B-cv-bin-abs
VTEs B-outcome
on O
placebo O
and O
44 B-iv-bin-abs
on O
tamoxifen O
therapy O
( O
hazard O
ratio O
[ O
HR]= O
1.63 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.02 O
to O
2.63 O
) O
, O
80 O
% O
of O
which O
were O
superficial O
phlebitis O
, O
accounting O
for O
all O
of O
the O
excess O
due O
to O
tamoxifen O
within O
18 O
months O
from O
randomization O
. O
Compared O
with O
placebo O
, O
the O
risk B-outcome
of I-outcome
VTE I-outcome
on O
tamoxifen O
was O
higher O
in O
women O
aged O
55 O
years O
or O
older O
, O
women O
with O
a O
body O
mass O
index O
> O
or O
= O
25 O
kg O
/ O
m O
2 O
, O
elevated O
blood O
pressure O
, O
total O
cholesterol O
> O
or O
= O
250 O
mg O
/ O
dL O
, O
current O
smoking O
, O
and O
a O
family O
history O
of O
coronary O
heart O
disease O
( O
CHD O
) O
. O
Of O
the O
685 O
women O
with O
a O
CHD O
risk O
score O
> O
or O
= O
5 O
who O
entered O
the O
trial O
, O
1 B-cv-bin-abs
in O
the O
placebo O
arm O
and O
13 B-iv-bin-abs
in O
the O
tamoxifen O
arm O
developed B-outcome
VTE I-outcome
( O
log O
- O
rank O
P= O
0.0013 O
) O
. O
In O
multivariate O
regression O
analysis O
, O
age O
> O
or O
= O
60 O
years O
, O
height O
> O
or O
= O
165 O
cm O
, O
and O
diastolic O
blood O
pressure O
> O
or O
= O
90 O
mm O
Hg O
had O
independent O
detrimental O
effects O
on O
VTE O
risk O
during O
tamoxifen O
therapy O
, O
whereas O
transdermal O
estrogen O
therapy O
concomitant O
with O
tamoxifen O
was O
not O
associated O
with O
any O
excess O
of O
VTE O
( O
HR= O
0.64 O
; O
95 O
% O
CI O
, O
0.23 O
to O
1.82 O
) O
. O
Women O
with O
conventional O
risk O
factors O
for O
atherosclerosis O
have O
a O
higher O
risk O
of O
VTE O
during O
tamoxifen O
therapy O
. O
This O
information O
should O
be O
incorporated O
into O
counseling O
women O
on O
its O
risk O
- O
benefit O
ratio O
, O
particularly O
in O
the O
prevention O
setting O
. O

A O
pilot O
randomized O
clinical O
study O
of O
the O
additive O
treatment O
effect O
of O
photodynamic B-intervention
therapy I-intervention
in O
breast O
cancer O
patients O
with O
chest O
wall O
recurrence O
. O
This O
study O
investigated O
the O
additive O
effect O
of O
photodynamic O
therapy O
( O
PDT O
) O
plus O
traditional O
radiotherapy O
( O
RT O
) O
for O
patients O
with O
breast O
cancer O
and O
chest O
wall O
recurrence O
. O
A O
total O
of O
40 B-total-participants
patients B-eligibility
with I-eligibility
recurrent I-eligibility
breast I-eligibility
cancer I-eligibility
were O
prospectively O
randomized O
to O
receive O
RT B-control
alone I-control
( O
group O
A O
, O
n= O
20 B-control-participants
) O
or O
PDT O
and O
RT O
in O
combination O
( O
group O
B O
, O
n= O
20 B-intervention-participants
) O
. O
Traditional O
RT O
at O
a O
dose O
of O
50 O
Gy O
was O
delivered O
in O
25 O
fractions O
with O
or O
without O
exposure O
to O
5 O
-aminolevulinic O
acid O
and O
red O
light O
as O
PDT O
. O
The O
response B-outcome
rates I-outcome
were O
not O
statistically O
different O
between O
the O
groups O
, O
but O
more O
patients O
achieved O
a O
complete O
response O
( O
CR O
) O
in O
group O
B O
( O
50 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
in O
group O
A O
( O
20 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
The O
median B-outcome
time I-outcome
to I-outcome
CR I-outcome
in O
group O
B O
was O
significantly O
shorter O
than O
that O
in O
group O
A O
( O
109.6 B-iv-cont-median
days I-iv-cont-median
vs. O
175.2 B-cv-cont-median
days I-cv-cont-median
, O
p= O
0.001 O
) O
. O
Adverse B-outcome
event I-outcome
profiles I-outcome
were O
not O
different O
between O
the O
groups O
. O
An O
additive O
antitumor O
effect O
is O
demonstrated O
with O
additional O
PDT O
to O
RT O
. O
This O
combination O
therapy O
might O
reduce O
the O
duration O
of O
exposure O
to O
RT O
, O
but O
further O
investigation O
is O
warranted O
. O

The O
Effect O
of O
Abemaciclib B-intervention
Plus I-intervention
Fulvestrant I-intervention
on O
Overall O
Survival O
in O
Hormone O
Receptor O
- O
Positive O
, O
ERBB O
2 O
- O
Negative O
Breast O
Cancer O
That O
Progressed O
on O
Endocrine O
Therapy O
- O
MONARCH O
2 O
: O
A O
Randomized O
Clinical O
Trial O
. O
Statistically O
significant O
overall O
survival O
( O
OS O
) O
benefits O
of O
CDK O
4 O
and O
CDK O
6 O
inhibitors O
in O
combination O
with O
fulvestrant O
for O
hormone O
receptor O
( O
HR O
) O
-positive O
, O
ERBB O
2 O
( O
formerly O
HER O
2 O
) O
-negative O
advanced O
breast O
cancer O
( O
ABC O
) O
in O
patients O
regardless O
of O
menopausal O
status O
after O
prior O
endocrine O
therapy O
( O
ET O
) O
has O
not O
yet O
been O
demonstrated O
. O
To O
compare O
the O
effect O
of O
abemaciclib O
plus O
fulvestrant O
vs O
placebo O
plus O
fulvestrant O
on O
OS O
at O
the O
prespecified O
interim O
of O
MONARCH O
2 O
( O
338 O
events O
) O
in O
patients O
with O
HR O
- O
positive O
, O
ERBB O
2 O
- O
negative O
advanced O
breast O
cancer O
that O
progressed O
during O
prior O
ET O
. O
MONARCH O
2 O
was O
a O
global O
, O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
phase O
3 O
trial O
of O
abemaciclib O
plus O
fulvestrant O
vs O
placebo O
plus O
fulvestrant O
for O
treatment O
of O
premenopausal O
or O
perimenopausal O
women O
( O
with O
ovarian O
suppression O
) O
and O
postmenopausal O
women O
with O
HR O
- O
positive O
, O
ERBB O
2 O
- O
negative O
ABC O
that O
progressed O
during O
ET O
. O
Patients O
were O
enrolled O
between O
August O
7 O
, O
2014 O
, O
and O
December O
29 O
, O
2015 O
. O
Analyses O
for O
this O
report O
were O
conducted O
at O
the O
time O
of O
database O
lock O
on O
June O
20 O
, O
2019 O
. O
Patients O
were O
randomized O
2 O
:1 O
to O
receive O
abemaciclib O
or O
placebo O
, O
150 O
mg O
, O
every O
12 O
hours O
on O
a O
continuous O
schedule O
plus O
fulvestrant O
, O
500 O
mg O
, O
per O
label O
. O
Randomization O
was O
stratified O
based O
on O
site O
of O
metastasis O
( O
visceral O
, O
bone O
only O
, O
or O
other O
) O
and O
resistance O
to O
prior O
ET O
( O
primary O
vs O
secondary O
) O
. O
The O
primary O
end O
point O
was O
investigator O
- O
assessed O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Overall B-outcome-measure
survival I-outcome-measure
was O
a O
gated O
key O
secondary O
end O
point O
. O
The O
boundary O
P O
value O
for O
the O
interim O
analysis O
was O
. O
02 O
. O
Of O
669 B-total-participants
women O
enrolled O
, O
446 B-intervention-participants
( O
median O
[ O
range O
] O
age O
, O
59 O
[ O
32 O
- O
91 O
] O
years O
) O
were O
randomized O
to O
the O
abemaciclib O
plus O
fulvestrant O
arm O
and O
223 B-control-participants
( O
median O
[ O
range O
] O
age O
, O
62 O
[ O
32 O
- O
87 O
] O
years O
) O
were O
randomized O
to O
the O
placebo B-control
plus I-control
fulvestrant I-control
arm O
. O
At O
the O
prespecified O
interim O
, O
338 O
deaths B-outcome
( O
77 O
% O
of O
the O
planned O
441 O
at O
the O
final O
analysis O
) O
were O
observed O
in O
the O
intent O
- O
to O
- O
treat O
population O
, O
with O
a O
median B-outcome
OS I-outcome
of O
46.7 B-iv-cont-median
â€‰ I-iv-cont-median
months I-iv-cont-median
for O
abemaciclib O
plus O
fulvestrant O
and O
37.3 B-cv-cont-median
months I-cv-cont-median
for O
placebo O
plus O
fulvestrant O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.757 O
; O
95 O
% O
CI O
, O
0.606 O
- O
0.945 O
; O
P O
= O
. O
01 O
) O
. O
Improvement O
in O
OS O
was O
consistent O
across O
all O
stratification O
factors O
. O
Among O
stratification O
factors O
, O
more B-outcome
pronounced I-outcome
effects I-outcome
were O
observed O
in O
patients B-outcome
with I-outcome
visceral I-outcome
disease I-outcome
( O
HR O
, O
0.675 O
; O
95 O
% O
CI O
, O
0.511 O
- O
0.891 O
) O
and O
primary B-outcome
resistance I-outcome
to I-outcome
prior I-outcome
ET I-outcome
( O
HR O
, O
0.686 O
; O
95 O
% O
CI O
, O
0.451 O
- O
1.043 O
) O
. O
Time B-outcome
to I-outcome
second I-outcome
disease I-outcome
progression I-outcome
( O
median O
, O
23.1 B-iv-cont-median
months I-iv-cont-median
vs O
20.6 B-cv-cont-median
months I-cv-cont-median
) O
, O
time B-outcome
to I-outcome
chemotherapy I-outcome
( O
median O
, O
50.2 B-iv-cont-median
months I-iv-cont-median
vs O
22.1 B-cv-cont-median
months I-cv-cont-median
) O
, O
and O
chemotherapy B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
median O
, O
25.5 B-iv-cont-median
months I-iv-cont-median
vs O
18.2 B-cv-cont-median
months I-cv-cont-median
) O
were O
also O
statistically O
significantly O
improved O
in O
the O
abemaciclib O
arm O
vs O
placebo O
arm O
. O
No O
new O
safety B-outcome
signals I-outcome
were O
observed O
for O
abemaciclib O
. O
Treatment O
with O
abemaciclib O
plus O
fulvestrant O
resulted O
in O
a O
statistically O
significant O
and O
clinically O
meaningful O
median B-outcome
OS I-outcome
improvement O
of O
9.4 O
months O
for O
patients O
with O
HR O
- O
positive O
, O
ERBB O
2 O
- O
negative O
ABC O
who O
progressed O
after O
prior O
ET O
regardless O
of O
menopausal O
status O
. O
Abemaciclib O
substantially O
delayed O
the O
receipt O
of O
subsequent O
chemotherapy O
. O
ClinicalTrials O
. O
gov O
identifier O
: O
NCT O
02107703 O
. O

A O
phase O
II O
breast O
cancer O
chemoprevention O
trial O
of O
oral O
alpha B-intervention
- I-intervention
difluoromethylornithine I-intervention
: O
breast O
tissue O
, O
imaging O
, O
and O
serum O
and O
urine O
biomarkers O
. O
A O
double O
- O
blind O
randomized O
Phase O
II O
chemoprevention O
trial O
of O
alpha O
- O
difluoromethylornithine O
( O
DFMO O
) O
was O
conducted O
in O
a O
group O
of O
women B-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
for I-eligibility
development I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
. O
DFMO O
is O
an O
irreversible O
inhibitor O
of O
ornithine O
decarboxylase O
, O
the O
limiting O
enzyme O
of O
polyamine O
synthesis O
that O
is O
often O
up O
- O
regulated O
in O
breast O
cancer O
. O
Study O
entrants O
were O
required O
to O
have O
random O
periareolar O
fine O
- O
needle O
aspiration O
cytology O
prior O
to O
entry O
that O
exhibited O
hyperplasia O
or O
hyperplasia O
with O
atypia O
, O
as O
well O
as O
a O
mammogram O
and O
clinical O
breast O
exam O
judged O
as O
not O
suspicious O
for O
breast O
cancer O
and O
no O
clinical O
hearing O
loss O
. O
Subjects O
were O
randomized O
to O
6 O
months O
of O
oral O
DFMO O
( O
0.5 O
g O
/ O
m O
( O
2 O
) O
/ O
day O
) O
or O
placebo B-control
, O
followed O
by O
repeat O
fine O
- O
needle O
aspiration O
and O
biomarker O
assessment O
. O
The O
main O
study O
end O
point O
was O
an O
improvement B-outcome-measure
in I-outcome-measure
cytologic I-outcome-measure
pattern I-outcome-measure
. O
Of O
119 B-total-participants
subjects O
entered O
, O
96 O
% O
completed O
the O
study O
and O
were O
evaluable O
for O
the O
main O
study O
end O
point O
. O
A O
modest O
reduction O
( O
28 O
% O
) O
in O
average O
total B-outcome
urine I-outcome
polyamines I-outcome
was O
obtained O
in O
the O
DFMO O
group O
, O
but O
there O
was O
no O
reduction B-outcome
in I-outcome
the I-outcome
spermidine I-outcome
: I-outcome
spermine I-outcome
ratio I-outcome
. O
There O
was O
no O
difference O
in O
cytologic B-outcome
improvement I-outcome
between O
DFMO O
and O
placebo O
. O
Likewise O
, O
there O
was O
no O
difference O
between O
DFMO O
and O
placebo O
for O
the O
secondary O
end O
points O
of O
breast B-outcome
molecular I-outcome
marker I-outcome
changes I-outcome
( O
immunocytochemical O
expression O
of O
proliferating O
cell O
nuclear O
antigen O
, O
p O
53 O
, O
and O
epidermal O
growth O
factor O
receptor O
) O
, O
mammographic B-outcome
breast I-outcome
density I-outcome
, O
serum B-outcome
insulin I-outcome
- I-outcome
like I-outcome
growth I-outcome
factor I-outcome
I I-outcome
: O
insulin O
- O
like O
growth O
factor O
binding O
protein O
3 O
ratio O
, O
adverse B-outcome
events I-outcome
, O
quality B-outcome
of I-outcome
life I-outcome
indices I-outcome
, O
or O
subsequent B-outcome
cancer I-outcome
development I-outcome
. O
DFMO O
at O
a O
dose O
level O
of O
0.5 O
g O
/ O
m O
( O
2 O
) O
/ O
day O
administered O
for O
6 O
months O
does O
not O
modulate O
breast O
risk O
biomarkers O
tested O
in O
this O
study O
. O

Acupuncture B-intervention
for O
breast O
cancer O
- O
related O
lymphedema O
: O
a O
randomized O
controlled O
trial O
. O
Approximately O
20 O
% O
of O
breast O
cancer O
survivors O
develop O
breast O
cancer O
- O
related O
lymphedema O
( O
BCRL O
) O
, O
and O
current O
therapies O
are O
limited O
. O
We O
compared O
acupuncture O
( O
AC O
) O
to O
usual B-control
care I-control
wait I-control
- I-control
list I-control
control I-control
( I-control
WL I-control
) I-control
for O
treatment O
of O
persistent O
BCRL O
. O
Women B-eligibility
with I-eligibility
moderate I-eligibility
BCRL I-eligibility
lasting I-eligibility
greater I-eligibility
than I-eligibility
six I-eligibility
months I-eligibility
were O
randomized O
to O
AC O
or O
WL O
. O
AC O
included O
twice O
weekly O
manual O
acupuncture O
over O
six O
weeks O
. O
We O
evaluated O
the O
difference O
in O
circumference O
and O
bioimpedance O
between O
affected O
and O
unaffected O
arms O
. O
Responders O
were O
defined O
as O
having O
a O
decrease O
in O
arm O
circumference O
difference O
greater O
than O
30 O
% O
from O
baseline O
. O
We O
used O
analysis O
of O
covariance O
for O
circumference O
and O
bioimpedance O
measurements O
and O
Fisher O
's O
exact O
to O
determine O
the O
proportion O
of O
responders O
. O
Among O
82 B-total-participants
patients O
, O
73 B-total-participants
( O
89 O
% O
) O
were O
evaluable O
for O
the O
primary O
endpoint O
( O
36 B-intervention-participants
in O
AC O
, O
37 B-control-participants
in O
WL O
) O
. O
79 O
( O
96 O
% O
) O
patients O
received O
lymphedema O
treatment O
before O
enrolling O
in O
our O
study O
; O
67 O
( O
82 O
% O
) O
underwent O
ongoing O
treatment O
during O
the O
trial O
. O
We O
found O
no O
significant O
difference O
between O
groups O
for O
arm B-outcome
circumference I-outcome
difference I-outcome
( O
0.38 O
cm O
greater O
reduction O
in O
AC O
vs. O
WL O
, O
95 O
% O
CI O
- O
0.12 O
to O
0.89 O
, O
p O
= O
0.14 O
) O
or O
bioimpedance B-outcome
difference I-outcome
( O
1.06 O
greater O
reduction O
in O
AC O
vs. O
WL O
, O
95 O
% O
CI O
- O
5.72 O
to O
7.85 O
, O
p O
= O
0.8 O
) O
. O
There O
was O
also O
no O
difference O
in O
the O
proportion B-outcome
of I-outcome
responders I-outcome
: O
17 B-iv-bin-percent
% I-iv-bin-percent
AC O
versus O
11 B-cv-bin-percent
% I-cv-bin-percent
WL O
( O
6 O
% O
difference O
, O
95 O
% O
CI O
- O
10 O
to O
22 O
% O
, O
p O
= O
0.5 O
) O
. O
No O
severe O
adverse B-outcome
events I-outcome
were O
reported O
. O
Our O
acupuncture O
protocol O
appeared O
to O
be O
safe B-outcome
and I-outcome
well I-outcome
tolerated I-outcome
. O
However O
, O
it O
did O
not O
significantly O
reduce O
BCRL O
in O
pretreated O
patients O
receiving O
concurrent O
lymphedema O
treatment O
. O
This O
regimen O
does O
not O
improve O
upon O
conventional O
lymphedema O
treatment O
for O
breast O
cancer O
survivors O
with O
persistent O
BCRL O
. O

Prevention O
of O
post B-condition
- I-condition
mastectomy I-condition
neuropathic I-condition
pain I-condition
with O
memantine B-intervention
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
N O
- O
methyl O
- O
D O
- O
aspartate O
receptor O
antagonists O
are O
potential O
therapies O
for O
neuropathic O
pain O
, O
and O
memantine O
has O
a O
good O
tolerance O
profile O
. O
A O
preclinical O
study O
recently O
reported O
that O
presurgery O
memantine O
may O
prevent O
neuropathic O
pain O
development O
and O
cognition O
dysfunction O
. O
Considering O
the O
high O
prevalence O
of O
breast O
cancer O
and O
of O
post O
- O
mastectomy O
neuropathic O
pain O
, O
a O
clinical O
trial O
is O
carried O
out O
to O
evaluate O
if O
memantine O
may O
prevent O
neuropathic O
pain O
development O
and O
maintain O
cognitive O
function O
and O
quality O
of O
life O
in O
cancer O
patients O
. O
A O
randomized O
clinical O
trial O
( O
NCT O
01536314 O
) O
includes O
40 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
mastectomy I-eligibility
at O
the O
Oncology O
Hospital O
, O
Clermont B-location
- I-location
Ferrand I-location
, I-location
France I-location
. O
Memantine O
( O
5 O
to O
20 O
mg O
/ O
day O
; O
n O
= O
20 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
20 B-control-participants
) O
is O
administered O
for O
4 O
weeks O
starting O
2 O
weeks O
before O
surgery O
. O
Intensity O
of O
pain O
, O
cognitive O
function O
, O
quality O
of O
life O
and O
of O
sleep O
, O
anxiety O
and O
depression O
are O
evaluated O
with O
questionnaires O
. O
The O
primary O
endpoint O
is O
pain B-outcome-measure
intensity I-outcome-measure
on O
a O
0 O
to O
10 O
) O
numerical O
scale O
at O
3 O
months O
post O
- O
mastectomy O
. O
Data O
analysis O
is O
performed O
using O
mixed O
models O
and O
the O
tests O
are O
two O
- O
sided O
, O
with O
a O
type O
I O
error O
set O
at O
Î± O
= O
0.05 O
. O
The O
hypothesis O
of O
this O
translational O
approach O
is O
to O
confirm O
in O
patients O
the O
beneficial O
prophylactic O
effect O
of O
memantine O
observed O
in O
animals O
. O
Such O
a O
protective O
action O
of O
memantine O
against O
neuropathic O
pain O
and O
cognitive O
dysfunction O
would O
greatly O
improve O
the O
quality O
of O
life O
of O
cancer O
patients O
. O
ClinicalTrials.gov O
: O
NCT O
01536314 O
on O
16 O
February O
2012 O
. O

Breast B-intervention
ductal I-intervention
lavage I-intervention
for O
biomarker O
assessment O
in O
high O
risk O
women O
: O
rationale O
, O
design O
and O
methodology O
of O
a O
randomized O
phase O
II O
clinical O
trial O
with O
nimesulide O
, O
simvastatin O
and O
placebo O
. O
Despite O
positive O
results O
from O
large O
phase O
III O
clinical O
trials O
proved O
that O
it O
is O
possible O
to O
prevent O
estrogen O
- O
responsive O
breast O
cancers O
with O
selective O
estrogen O
receptor O
modulators O
and O
aromatase O
inhibitors O
, O
no O
significant O
results O
have O
been O
reached O
so O
far O
to O
prevent O
hormone O
non O
- O
responsive O
tumors O
. O
The O
Ductal O
Lavage O
( O
DL O
) O
procedure O
offers O
a O
minimally O
invasive O
method O
to O
obtain O
breast O
epithelial O
cells O
from O
the O
ductal O
system O
for O
cytopathologic O
analysis O
. O
Several O
studies O
with O
long O
- O
term O
follow O
- O
up O
have O
shown O
that O
women O
with O
atypical O
hyperplasia O
have O
an O
elevated O
risk O
of O
developing O
breast O
cancer O
. O
The O
objective O
of O
the O
proposed O
trial O
is O
to O
assess O
the O
efficacy O
and O
safety O
of O
a O
daily O
administration O
of O
nimesulide O
or O
simvastatin O
in O
women O
at O
higher O
risk O
for O
breast O
cancer O
, O
focused O
particularly O
on O
hormone O
non O
- O
responsive O
tumor O
risk O
. O
The O
primary O
endpoint O
is O
the O
change B-outcome-measure
in I-outcome-measure
prevalence I-outcome-measure
of I-outcome-measure
atypical I-outcome-measure
cells I-outcome-measure
and I-outcome-measure
cell I-outcome-measure
proliferation I-outcome-measure
( O
measured O
by O
Ki O
67 O
) O
in O
DL O
or O
fine O
needle O
aspirate O
samples O
, O
after O
12 O
months O
of O
treatment O
and O
12 O
months O
after O
treatment O
cessation O
. O
METHODS O
- O
DESIGN O
: O
From O
2005 O
to O
2011 O
, O
150 B-total-participants
women B-eligibility
with I-eligibility
a I-eligibility
history I-eligibility
of I-eligibility
estrogen I-eligibility
receptor I-eligibility
negative I-eligibility
ductal I-eligibility
intraepithelial I-eligibility
neoplasia I-eligibility
or I-eligibility
lobular I-eligibility
intraepithelial I-eligibility
neoplasia I-eligibility
or I-eligibility
atypical I-eligibility
hyperplasia I-eligibility
, I-eligibility
or I-eligibility
unaffected I-eligibility
subjects I-eligibility
carrying I-eligibility
a I-eligibility
mutation I-eligibility
of I-eligibility
BRCA I-eligibility
1 I-eligibility
or I-eligibility
with I-eligibility
a I-eligibility
probability I-eligibility
of I-eligibility
mutation I-eligibility
> I-eligibility
10 I-eligibility
% I-eligibility
( I-eligibility
according I-eligibility
to I-eligibility
BRCAPRO I-eligibility
) I-eligibility
were O
randomized O
to O
receive O
nimesulide O
100 O
mg O
/ O
day O
versus O
simvastatin O
20 O
mg O
/ O
day O
versus O
placebo B-control
for O
one O
year O
followed O
by O
a O
second O
year O
of O
follow O
- O
up O
. O
This O
is O
the O
first O
randomized O
placebo O
controlled O
trial O
to O
evaluate O
the O
role O
of O
DL O
to O
study O
surrogate O
endpoints O
biomarkers O
and O
the O
effects O
of O
these O
drugs O
on O
breast O
carcinogenesis O
. O
In O
2007 O
the O
European O
Medicines O
Agency O
limited O
the O
use O
of O
systemic O
formulations O
of O
nimesulide O
to O
15 O
days O
. O
According O
to O
the O
European O
Institute O
of O
Oncology O
Ethics O
Committee O
communication O
, O
we O
are O
now O
performing O
an O
even O
more O
careful O
monitoring O
of O
the O
study O
participants O
. O
Preliminary O
results O
showed O
that O
DL B-outcome
is I-outcome
a I-outcome
feasible I-outcome
procedure I-outcome
, O
the O
treatment B-outcome
is I-outcome
well I-outcome
tolerated I-outcome
and O
the O
safety O
blood O
tests O
do O
not O
show O
any O
significant O
liver B-outcome
toxicity I-outcome
. O
There O
is O
an O
urgent O
need O
to O
confirm O
in O
the O
clinical O
setting O
the O
potential O
efficacy O
of O
other O
compounds O
in O
contrasting O
hormone O
non O
- O
responsive O
breast O
cancer O
. O
This O
paper O
is O
focused O
on O
the O
methodology O
and O
operational O
aspects O
of O
the O
clinical O
trial O
. O
( O
ClinicalTrials.gov O
Identifier O
: O
NCT O
01500577 O
) O
. O

The O
Prosigna B-intervention
gene I-intervention
expression I-intervention
assay I-intervention
and O
responsiveness O
to O
adjuvant O
cyclophosphamide O
- O
based O
chemotherapy O
in O
premenopausal B-eligibility
high I-eligibility
- I-eligibility
risk I-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
. O
The O
PAM O
50 O
- O
based O
( O
Prosigna O
) O
risk O
of O
recurrence O
( O
ROR O
) O
score O
and O
intrinsic O
subtypes O
are O
prognostic O
for O
women O
with O
high O
- O
risk O
breast O
cancer O
. O
We O
investigate O
the O
predictive O
ability O
of O
Prosigna O
regarding O
the O
effectiveness O
of O
cyclophosphamide O
- O
based O
adjuvant O
chemotherapy O
in O
premenopausal O
patients O
with O
high O
- O
risk O
breast O
cancer O
. O
Prosigna O
assays O
were O
performed O
on O
the O
NanoString O
platform O
in O
tumors O
from O
participants O
in O
Danish B-ethinicity
Breast O
Cancer O
Group O
( O
DBCG O
) O
77 O
B O
, O
a O
four O
- O
arm O
trial O
that O
randomized O
premenopausal B-eligibility
women I-eligibility
with I-eligibility
high I-eligibility
- I-eligibility
risk I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
to O
no B-control
systemic I-control
treatment I-control
, I-control
levamisole O
, O
oral O
cyclophosphamide O
( O
C O
) O
or O
cyclophosphamide O
, O
methotrexate O
and O
fluorouracil O
( O
CMF O
) O
. O
In O
total O
, O
this O
retrospective O
analysis O
included O
460 B-total-participants
women O
( O
40 O
% O
of O
the O
1146 O
randomized O
patients O
) O
. O
The O
continuous O
Prosigna O
ROR O
score O
was O
prognostic O
in O
the O
no O
systemic O
treatment O
group O
( O
unadjusted O
P O
< O
0.001 O
for O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
, O
P O
= O
0.001 O
for O
overall B-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
) O
. O
No O
statistically O
significant O
interaction O
of O
continuous O
ROR O
score O
and O
treatment O
on O
DFS B-outcome
and I-outcome
OS I-outcome
was O
found O
. O
A O
highly O
significant O
association O
was O
observed O
between O
intrinsic O
subtypes O
and O
C O
/ O
CMF O
treatment O
for O
DFS O
( O
Pinteraction O
= O
0.003 O
unadjusted O
, O
P O
= O
0.001 O
adjusted O
) O
and O
OS O
( O
Pinteraction O
= O
0.04 O
) O
. O
In O
the O
adjusted O
analysis O
treatment O
with O
C O
/ O
CMF O
was O
associated O
with O
a O
reduced O
risk O
of O
DFS B-outcome
events I-outcome
in O
patients O
with O
basal B-outcome
- I-outcome
like I-outcome
( O
hazard O
ratio O
( O
HR O
) O
0.14 O
; O
95 O
% O
CI O
0.06 O
; O
0.32 O
) O
and O
luminal B-outcome
B I-outcome
( O
HR O
0.48 O
; O
95 O
% O
CI O
0.27 O
; O
0.84 O
) O
subtypes O
but O
not O
in O
patients O
with O
Human B-outcome
epidermal I-outcome
growth I-outcome
factor I-outcome
receptor I-outcome
- I-outcome
enriched I-outcome
( O
HR O
1.05 O
; O
95 O
% O
CI O
0.56 O
; O
1.95 O
) O
or O
luminal B-outcome
A I-outcome
( O
HR O
0.61 O
; O
95 O
% O
CI O
0.32 O
; O
1.16 O
) O
subtypes O
. O
The O
Prosigna O
ROR O
score O
and O
intrinsic O
subtypes O
were O
prognostic O
in O
high O
- O
risk O
premenopausal O
patients O
with O
breast O
cancer O
, O
and O
intrinsic O
subtypes O
identify O
high O
- O
risk O
patients O
with O
or O
without O
major O
benefit O
from O
adjuvant O
C O
/ O
CMF O
treatment O
. O

The O
Effect O
of O
Counseling B-intervention
on I-intervention
Breast I-intervention
Cancer I-intervention
Awareness I-intervention
in O
Rural O
Iranian B-ethinicity
Women O
: O
a O
Randomized O
Controlled O
Clinical O
Trial O
. O
In O
a O
community O
such O
as O
Iran O
where O
late O
presentation O
is O
predominant O
and O
the O
majority O
of O
breast O
cancer O
patients O
are O
diagnosed O
at O
advanced O
stages O
of O
the O
disease O
, O
there O
is O
an O
urgent O
need O
for O
improving O
the O
level O
of O
awareness O
about O
breast O
cancer O
and O
early O
detection O
measures O
. O
Given O
that O
rural O
residents O
are O
at O
higher O
risk O
for O
late O
diagnosis O
of O
breast O
cancer O
because O
they O
have O
less O
education O
, O
income O
, O
and O
access O
to O
advanced O
screening O
technologies O
, O
this O
study O
was O
conducted O
to O
determine O
the O
effect O
of O
counseling O
on O
breast O
cancer O
awareness O
of O
rural O
Iranian O
women O
. O
This O
randomized O
clinical O
trial O
was O
conducted O
on O
60 B-total-participants
rural B-eligibility
women I-eligibility
from O
the O
Abish B-location
Ahmad I-location
area O
in O
northwestern B-location
Iran I-location
in O
2017 O
. O
The O
randomized O
cluster O
method O
was O
used O
for O
sampling O
. O
From O
20 O
rural O
health O
houses O
and O
centers O
, O
about O
one O
third O
were O
selected O
randomly O
. O
From O
the O
six O
selected O
clusters O
, O
three O
were O
randomly O
allocated O
as O
the O
control O
group O
and O
three O
as O
the O
intervention O
group O
. O
Using O
convenience O
sampling O
, O
30 B-control-participants
women O
between O
the O
ages O
of O
40 O
and O
69 O
were O
selected O
from O
the O
control B-control
group I-control
and O
30 B-intervention-participants
from O
the O
intervention O
group O
. O
The O
intervention O
group O
attended O
six O
group O
counseling O
sessions O
. O
Data O
was O
gathered O
using O
a O
demographic O
and O
obstetrical O
information O
questionnaire O
and O
breast O
cancer O
awareness O
measures O
. O
The O
chi O
- O
square O
, O
independent O
t O
test O
and O
ANCOVA O
by O
controlling O
for O
the O
baseline O
scores O
were O
used O
to O
analyze O
the O
data O
. O
After O
counseling O
, O
the O
mean B-outcome
knowledge I-outcome
about I-outcome
breast I-outcome
cancer I-outcome
score I-outcome
was O
significantly O
higher O
in O
the O
intervention O
group O
than O
in O
the O
control O
group O
( O
adjusted O
mean O
difference O
, O
17.02 O
; O
confidence O
interval O
( O
CI O
) O
95 O
% O
, O
15.44 O
to O
18.59 O
; O
p O
< O
0.001 O
) O
. O
The O
mean O
barriers B-outcome
to I-outcome
breast I-outcome
cancer I-outcome
screening I-outcome
score I-outcome
showed O
a O
significant O
decrease O
in O
the O
intervention O
group O
compared O
to O
the O
control O
group O
( O
AMD O
, O
- O
1.74 O
; O
95 O
% O
CI O
- O
3.12 O
to O
- O
0.36 O
, O
p O
< O
0.001 O
) O
. O
After O
intervention O
, O
the O
frequency B-outcome
of I-outcome
breast I-outcome
self I-outcome
- I-outcome
exam I-outcome
showed O
a O
significant O
difference O
between O
groups O
( O
p O
< O
0.001 O
) O
; O
but O
for O
confidence O
about O
noticing O
breast O
changes O
, O
no O
significant O
difference O
was O
observed O
between O
groups O
( O
p O
= O
0.08 O
) O
. O
Group O
counseling O
had O
a O
significant O
effect O
on O
enhancing O
breast O
cancer O
awareness O
of O
rural O
Iranian O
women O
, O
except O
for O
confidence O
about O
noticing O
breast O
changes O
. O

A O
protocol O
for O
a O
multicentre O
, O
parallel O
- O
group O
, O
pragmatic O
randomised O
controlled O
trial O
to O
evaluate O
the O
NEVERMIND O
system O
in O
preventing O
and O
treating O
depression B-condition
in O
patients O
with O
severe O
somatic O
conditions O
. O
Depressive O
symptoms O
are O
common O
in O
individuals O
suffering O
from O
severe O
somatic O
conditions O
. O
There O
is O
a O
lack O
of O
interventions O
and O
evidence O
- O
based O
interventions O
aiming O
to O
reduce O
depressive O
symptoms O
in O
patients O
with O
severe O
somatic O
conditions O
. O
The O
aim O
of O
the O
NEVERMIND O
project O
is O
to O
address O
these O
issues O
and O
provide O
evidence O
by O
testing O
the O
NEVERMIND O
system O
, O
designed O
to O
reduce O
and O
prevent O
depressive O
symptoms O
in O
comparison O
to O
treatment O
as O
usual O
. O
The O
NEVERMIND O
study O
is O
a O
parallel O
- O
groups O
, O
pragmatic O
randomised O
controlled O
trial O
to O
assess O
the O
effectiveness O
of O
the O
NEVERMIND O
system O
in O
reducing O
depressive O
symptoms O
among O
individuals O
with O
severe O
somatic O
conditions O
. O
The O
NEVERMIND O
system O
comprises O
a O
smart O
shirt O
and O
a O
user O
interface O
, O
in O
the O
form O
of O
a O
mobile O
application O
. O
The O
system O
is O
a O
real B-intervention
- I-intervention
time I-intervention
decision I-intervention
support I-intervention
system I-intervention
, O
aiming O
to O
predict O
the O
severity O
and O
onset O
of O
depressive O
symptoms O
by O
modelling O
the O
well O
- O
being O
condition O
of O
patients O
based O
on O
physiological O
data O
, O
body O
movement O
, O
and O
the O
recurrence O
of O
social O
interactions O
. O
The O
study O
includes O
330 B-total-participants
patients B-eligibility
who I-eligibility
have I-eligibility
a I-eligibility
diagnosis I-eligibility
of I-eligibility
myocardial I-eligibility
infarction I-eligibility
, I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
prostate I-eligibility
cancer I-eligibility
, I-eligibility
kidney I-eligibility
failure I-eligibility
, I-eligibility
or I-eligibility
lower I-eligibility
limb I-eligibility
amputation I-eligibility
. O
Participants O
are O
randomised O
in O
blocks O
of O
ten O
to O
either O
the O
NEVERMIND O
intervention O
or O
treatment B-control
as I-control
usual I-control
as I-control
the I-control
control I-control
group I-control
. O
Clinical O
interviews O
and O
structured O
questionnaires O
are O
administered O
at O
baseline O
, O
at O
12 O
weeks O
, O
and O
24 O
weeks O
to O
assess O
whether O
the O
NEVERMIND O
system O
is O
superior O
to O
treatment O
as O
usual O
. O
The O
endpoint O
of O
primary O
interest O
is O
Beck B-outcome-measure
Depression I-outcome-measure
Inventory I-outcome-measure
II I-outcome-measure
( I-outcome-measure
BDI I-outcome-measure
- I-outcome-measure
II I-outcome-measure
) I-outcome-measure
at I-outcome-measure
12 I-outcome-measure
â€‰ I-outcome-measure
weeks I-outcome-measure
defined O
as O
( O
i O
) O
the O
severity O
of O
depressive O
symptoms O
as O
measured O
by O
the O
BDI O
- O
II O
. O
Secondary O
outcomes O
include O
prevention B-outcome-measure
of I-outcome-measure
the I-outcome-measure
onset I-outcome-measure
of I-outcome-measure
depressive I-outcome-measure
symptoms I-outcome-measure
, O
changes B-outcome
in I-outcome
quality I-outcome
of I-outcome
life I-outcome
, O
perceived B-outcome-measure
stigma I-outcome-measure
, O
and O
self B-outcome-measure
- I-outcome-measure
efficacy I-outcome-measure
. O
There O
is O
a O
lack O
of O
evidence O
- O
based O
interventions O
aiming O
to O
reduce O
and O
prevent O
depressive B-outcome
symptoms I-outcome
in O
patients O
with O
severe O
somatic O
conditions O
. O
If O
the O
NEVERMIND O
system O
is O
effective O
, O
it O
will O
provide O
healthcare O
systems O
with O
a O
novel O
and O
innovative O
method O
to O
attend O
to O
depressive O
symptoms O
in O
patients O
with O
severe O
somatic O
conditions O
. O
DRKS O
00013391 O
. O
Registered O
23 O
November O
2017 O
. O

Efficacy O
of O
short B-intervention
- I-intervention
term I-intervention
psychodynamic I-intervention
psychotherapy I-intervention
( I-intervention
STPP I-intervention
) I-intervention
with O
depressed O
breast O
cancer O
patients O
: O
results O
of O
a O
randomized O
controlled O
multicenter O
trial O
. O
There O
is O
a O
lack O
of O
trials O
of O
psychodynamic O
treatments O
of O
depression O
in O
breast O
cancer O
patients O
. O
The O
purpose O
of O
this O
trial O
was O
to O
determine O
the O
efficacy O
of O
short O
- O
term O
psychodynamic O
psychotherapy O
( O
STPP O
) O
in O
non O
- O
metastatic O
breast O
cancer O
patients O
diagnosed O
with O
depression O
, O
one O
of O
the O
most O
frequent O
mental O
comorbidities O
of O
breast O
cancer O
. O
In O
a O
multicenter O
prospective O
trial O
, O
157 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
comorbid I-eligibility
depression I-eligibility
were O
randomized O
to O
either O
individual O
STPP O
( O
intervention O
group O
, O
N= O
78 B-intervention-participants
) O
or O
' B-control
treatment I-control
as I-control
usual I-control
' I-control
( O
control O
group O
, O
TAU O
, O
N= O
79 B-control-participants
) O
. O
As O
our O
primary O
outcome O
measure O
, O
we O
hypothesized O
a O
higher O
rate B-outcome-measure
of I-outcome-measure
remission I-outcome-measure
defined O
as O
no O
diagnosis O
of O
depression O
( O
Structured O
Clinical O
Interview O
for O
DSM O
- O
IV O
) O
and O
reduction O
in O
depression O
score O
by O
at O
least O
2 O
points O
( O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
HADS O
- O
D O
) O
in O
STPP O
versus O
TAU O
at O
treatment O
termination O
. O
Secondary O
outcomes O
mainly O
refer O
to O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
( I-outcome-measure
QoL I-outcome-measure
) I-outcome-measure
. O
In O
the O
intention O
to O
treat O
( O
ITT O
) O
analysis O
, O
44 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
STPP O
group O
achieved O
highly O
significantly O
more O
remission B-outcome
than O
TAU O
( O
23 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
STPP B-outcome
treatment I-outcome
( O
OR= O
7.64 O
; O
P O
< O
0.001 O
) O
was O
the O
strongest O
predictor O
for O
remission O
post O
- O
treatment O
; O
time B-outcome
was O
also O
significant O
( O
OR= O
0.96 O
; O
P O
< O
0.05 O
) O
. O
A O
high O
effect O
favoring O
STPP O
( O
d= O
0.82 O
) O
was O
observed O
for O
the O
HADS B-outcome
- I-outcome
D I-outcome
score I-outcome
post I-outcome
- I-outcome
treatment I-outcome
( O
secondary O
outcome O
) O
. O
Regarding O
further O
secondary O
outcomes O
( O
QoL B-outcome
) O
, O
analyses O
of O
covariance O
yielded O
main O
effects O
for O
group O
( O
favoring O
STPP O
with O
an O
effect O
size O
of O
at O
least O
d= O
0.5 O
) O
for O
global O
QoL O
, O
role O
, O
emotional O
and O
social O
functioning O
, O
pain O
, O
treatment O
side O
- O
effects O
, O
breast O
symptoms O
and O
upset O
by O
hair O
loss O
. O
STPP O
is O
an O
effective O
treatment O
of O
a O
broad O
range O
of O
depressive O
conditions O
in O
breast O
cancer O
patients O
improving O
depression O
and O
functional O
QoL O
. O
Findings O
are O
limited O
by O
the O
drop O
- O
out O
rate O
( O
âˆ¼ O
1 O
/ O
3 O
) O
and O
delayed O
post O
- O
treatment O
assessments O
. O
Future O
trials O
may O
consider O
stepped O
- O
care O
approaches O
, O
tailored O
to O
patients O
' O
needs O
and O
requirements O
in O
the O
acute O
treatment O
phase O
. O

The O
effect O
of O
an O
aerobic B-intervention
exercise I-intervention
bout O
24 O
h O
prior O
to O
each O
doxorubicin O
treatment O
for O
breast O
cancer O
on O
markers O
of O
cardiotoxicity B-condition
and O
treatment O
symptoms O
: O
a O
RCT O
. O
In O
rodents O
, O
a O
single O
exercise O
bout O
performed O
24 O
h O
prior O
to O
a O
single O
doxorubicin O
treatment O
provides O
cardio O
- O
protection O
. O
This O
study O
investigated O
whether O
performing O
this O
intervention O
prior O
to O
every O
doxorubicin O
treatment O
for O
breast O
cancer O
reduced O
subclinical O
cardiotoxicity O
and O
treatment O
symptoms O
. O
Twenty B-total-participants
- I-total-participants
four I-total-participants
women B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
perform O
a O
30 O
-min O
, O
vigorous O
- O
intensity O
treadmill O
bout O
24 O
h O
prior O
to O
each O
of O
four O
doxorubicin O
- O
containing O
chemotherapy O
treatments O
or O
to O
usual B-control
care I-control
. O
Established O
echocardiographic O
and O
circulating O
biomarkers O
of O
subclinical O
cardiotoxicity O
, O
as O
well O
as O
blood O
pressure O
and O
body O
weight O
were O
measured O
before O
the O
first O
and O
7 O
- O
14 O
days O
after O
the O
last O
treatment O
. O
The O
Rotterdam O
symptom O
checklist O
was O
used O
to O
assess O
patient O
- O
reported O
symptoms O
. O
The O
exercise O
and O
usual O
care O
groups O
did O
not O
differ O
in O
the O
doxorubicin B-outcome
- I-outcome
related I-outcome
change I-outcome
in I-outcome
longitudinal I-outcome
strain I-outcome
, I-outcome
twist I-outcome
, I-outcome
or I-outcome
cardiac I-outcome
troponin I-outcome
. O
However O
, O
the O
four O
total O
exercise O
bouts O
prevented O
changes B-outcome
in I-outcome
hemodynamics I-outcome
( O
increased O
cardiac O
output O
, O
resting O
heart O
rate O
, O
decreased O
systemic O
vascular O
resistance O
, O
p O
< O
0.01 O
) O
and O
reduced O
body B-outcome
weight I-outcome
gain I-outcome
, O
prevalence B-outcome
of I-outcome
depressed I-outcome
mood I-outcome
, O
sore B-outcome
muscles I-outcome
, O
and O
low B-outcome
back I-outcome
pain I-outcome
after O
the O
last O
treatment O
( O
p O
< O
0.05 O
) O
relative O
to O
the O
usual O
care O
group O
. O
No B-outcome
adverse I-outcome
events I-outcome
occurred O
. O
An O
exercise O
bout O
performed O
24 O
h O
prior O
to O
every O
doxorubicin O
treatment O
did O
not O
have O
an O
effect O
on O
markers O
of O
subclinical O
cardiotoxicity O
, O
but O
had O
a O
positive O
systemic O
effect O
on O
hemodynamics O
, O
musculoskeletal O
symptoms O
, O
mood O
, O
and O
body O
weight O
in O
women O
with O
breast O
cancer O
. O
A O
single O
exercise O
bout O
prior O
to O
chemotherapy O
treatments O
may O
be O
a O
simple O
clinical O
modality O
to O
reduce O
symptoms O
and O
weight O
gain O
among O
women O
with O
breast O
cancer O
. O

Effect O
of O
Rosuvastatin B-intervention
in O
Preventing O
Chemotherapy B-condition
- I-condition
Induced I-condition
Cardiotoxicity I-condition
in O
Women O
With O
Breast O
Cancer O
: O
A O
Randomized O
, O
Single O
- O
Blind O
, O
Placebo O
- O
Controlled O
Trial O
. O
Chemotherapy O
- O
induced O
cardiotoxicity O
is O
a O
major O
and O
leading O
cause O
of O
death O
in O
breast O
cancer O
survivors O
. O
It O
can O
present O
decades O
after O
chemotherapy O
and O
can O
manifest O
in O
different O
ways O
; O
some O
chemotherapeutic O
agents O
have O
a O
powerful O
dose O
- O
dependent O
relationship O
with O
cardiotoxicity O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
rosuvastatin O
on O
preventing O
chemotherapy O
- O
induced O
cardiotoxicity O
in O
patients O
with O
breast O
cancer O
. O
Our O
study O
was O
a O
randomized O
, O
single O
- O
blind O
, O
placebo O
- O
controlled O
trial O
that O
involved O
89 B-total-participants
women B-eligibility
with I-eligibility
newly I-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
scheduled I-eligibility
to I-eligibility
receive I-eligibility
chemotherapy I-eligibility
. O
Patients O
were O
randomly O
assigned O
to O
receive O
rosuvastatin O
or O
a O
placebo B-control
in O
a O
1 O
:1 O
ratio O
for O
6 O
months O
. O
Echocardiography O
, O
using O
2 O
-dimensional O
( O
2 O
D O
) O
Doppler O
, O
tissue O
Doppler O
, O
and O
speckle O
- O
tracking O
methods O
, O
was O
used O
to O
determine O
the O
absolute O
changes O
in O
the O
left O
ventricular O
systolic O
ejection O
fraction O
( O
LVEF O
) O
, O
left O
ventricular O
end O
- O
diastolic O
volume O
( O
LVEDV O
) O
, O
left O
ventricular O
end O
- O
systolic O
volume O
( O
LVESV O
) O
, O
left O
atrial O
( O
LA O
) O
diameter O
, O
transmitral O
Doppler O
early O
diastolic O
velocity O
( O
E O
wave O
) O
, O
tissue O
Doppler O
early O
diastolic O
( O
e O
' O
) O
and O
peak O
systolic O
( O
s O
' O
) O
mitral O
annular O
velocities O
, O
E O
/ O
e O
' O
ratio O
, O
and O
global O
longitudinal O
systolic O
strain O
. O
The O
LVEF B-outcome
was O
significantly O
reduced O
in O
the O
placebo O
group O
at O
the O
end O
of O
the O
study O
when O
compared O
with O
the O
baseline O
value O
. O
However O
, O
there O
was O
no O
significant O
difference O
in O
the O
LVEF B-outcome
in O
the O
intervention O
group O
( O
intergroup O
P O
= O
. O
012 O
) O
. O
Furthermore O
, O
compared O
with O
the O
intervention O
group O
at O
the O
end O
of O
the O
study O
, O
there O
was O
a O
significant O
increase O
in O
the O
4 B-outcome
- I-outcome
and I-outcome
2 I-outcome
-chamber I-outcome
LVESV I-outcome
, I-outcome
LA I-outcome
diameter I-outcome
, I-outcome
and I-outcome
E I-outcome
/ I-outcome
e I-outcome
' I-outcome
ratio I-outcome
in O
the O
placebo O
group O
( O
intergroup O
P O
= O
. O
019 O
, O
P O
= O
. O
024 O
, O
P O
< O
. O
001 O
, O
and O
P O
= O
. O
021 O
, O
respectively O
) O
and O
a O
significant O
decrease O
in O
the O
e B-outcome
' I-outcome
and I-outcome
s I-outcome
' I-outcome
velocities I-outcome
in O
the O
placebo O
group O
( O
intergroup O
P O
< O
. O
001 O
and O
P O
< O
. O
006 O
, O
respectively O
) O
. O
The O
present O
study O
showed O
that O
the O
prophylactic O
use O
of O
rosuvastatin O
may O
prevent O
the O
development O
of O
chemotherapy O
- O
induced O
cardiotoxicity O
. O

A O
randomized O
, O
double O
- O
blinded O
placebo O
- O
controlled O
clinical O
trial O
of O
the O
routine O
use O
of O
preoperative B-intervention
antibiotic I-intervention
prophylaxis I-intervention
in O
modified O
radical O
mastectomy O
. O
The O
effectiveness O
of O
antibiotic O
prophylaxis O
for O
prevention O
of O
surgical B-condition
site I-condition
infection I-condition
( I-condition
SSI I-condition
) I-condition
following O
specific O
types O
of O
breast O
cancer O
surgery O
remains O
uncertain O
. O
This O
study O
assessed O
the O
effectiveness O
of O
prophylaxis O
in O
modified O
radical O
mastectomy O
( O
MRM O
) O
. O
Women B-eligibility
undergoing I-eligibility
MRM I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
were O
recruited O
. O
Women O
were O
excluded O
who O
had O
diabetes O
mellitus O
, O
severe O
malnutrition O
or O
known O
allergy O
to O
cephalosporins O
; O
were O
receiving O
corticosteroid O
therapy O
or O
were O
treated O
with O
antibiotics O
within O
one O
week O
prior O
to O
surgery O
; O
were O
scheduled O
for O
simultaneous O
breast O
reconstruction O
or O
bilateral O
oophorectomy O
; O
had O
existing O
local O
infection O
. O
Participants O
were O
randomized O
to O
receive O
either O
intravenous B-intervention
cefazolin I-intervention
1 O
g O
or O
placebo B-control
within O
30 O
min O
prior O
to O
skin O
incision O
. O
Standard O
skin O
preparation O
and O
operative O
technique O
for O
MRM O
were O
carried O
out O
. O
Wounds O
were O
assessed O
for O
SSI O
and O
other O
complications O
weekly O
for O
30 O
days O
. O
A O
total O
of O
254 B-total-participants
women O
were O
recruited O
. O
Age O
, O
clinical O
stage O
, O
prior O
chemotherapy O
, O
and O
operative O
time O
were O
similar O
for O
antibiotic O
and O
placebo O
groups O
. O
The O
overall B-outcome
incidence I-outcome
of I-outcome
SSI I-outcome
was O
14.2 O
% O
. O
There O
were O
no O
significant O
differences O
in O
the O
infection B-outcome
rate I-outcome
over O
the O
30 O
-day O
follow O
- O
up O
period O
between O
the O
placebo O
and O
antibiotic O
groups O
( O
15 B-cv-bin-percent
% I-cv-bin-percent
vs O
13.4 B-iv-bin-percent
% I-iv-bin-percent
; O
p O
= O
0.719 O
) O
or O
at O
each O
week O
. O
The O
majority O
of O
SSI O
were O
either O
cellulitis O
or O
superficial O
infection O
for O
both O
groups O
. O
There O
were O
no O
significant O
differences O
between O
groups O
in O
treatments O
required O
for O
SSI B-outcome
, O
incidence B-outcome
of I-outcome
hematoma I-outcome
or O
seroma B-outcome
. O
The O
findings O
of O
this O
study O
, O
alone O
and O
when O
meta O
- O
analyzed O
with O
data O
from O
studies O
in O
similar O
surgical O
populations O
, O
do O
not O
support O
the O
use O
of O
antibiotic O
prophylaxis O
in O
MRM O
. O

Adherence O
to O
a O
long O
- O
term O
progressive B-intervention
resistance I-intervention
training I-intervention
program I-intervention
, O
combining O
supervised O
and O
home O
- O
based O
exercise O
for O
breast O
cancer O
patients O
during O
adjuvant O
treatment O
. O
Background O
: O
The O
purpose O
of O
the O
study O
was O
to O
examine O
adherence O
and O
identify O
patient- O
and O
treatment O
- O
related O
factors O
associated O
with O
adherence O
to O
a O
20 O
-week O
combined O
supervised O
and O
home O
- O
based O
progressive O
resistance O
training O
program O
in O
women O
treated O
for O
breast O
cancer O
. O
Methodology O
: O
The O
study O
population O
consisted O
of O
the O
intervention O
group O
in O
a O
randomized O
clinical O
trial O
examining O
the O
effect O
of O
resistance O
exercise O
on O
lymphoedema B-condition
prevention O
( O
n O
= O
82 B-total-participants
) O
. O
The O
full O
program O
lasted O
50 O
weeks O
, O
with O
an O
initial O
20 O
weeks O
combined O
supervised O
and O
home O
- O
based O
exercise O
followed O
by O
30 O
weeks O
self O
- O
administered O
exercise O
. O
Information O
about O
attendance O
rates O
( O
supervised O
exercise O
) O
and O
exercise B-control
dairies I-control
( O
home O
- O
based O
exercise O
) O
in O
the O
first O
20 O
weeks O
was O
available O
for O
74 O
and O
62 O
participants O
, O
respectively O
. O
Adherence O
was O
measured O
as O
numbers O
of O
exercise O
sessions O
performed O
divided O
by O
expected O
number O
of O
exercise O
sessions O
with O
> O
2 O
/ O
3 O
categorized O
as O
high O
adherence O
. O
Age O
- O
adjusted O
odds O
ratios O
( O
OR O
) O
were O
used O
to O
assess O
the O
associations O
between O
patient- O
and O
treatment O
- O
related O
factors O
with O
adherence O
. O
Results O
: O
The O
number O
of O
participants O
with O
high O
adherence B-outcome
to I-outcome
supervised I-outcome
exercise I-outcome
decreased O
in O
the O
late O
period O
( O
from O
week O
11 O
onward O
) O
compared O
to O
the O
early O
period O
( O
65 O
% O
vs. O
48 O
% O
) O
whereas O
the O
proportion O
of O
participants O
with O
high O
adherence B-outcome
to I-outcome
home I-outcome
- I-outcome
based I-outcome
exercise I-outcome
remained O
close O
to O
55 O
% O
. O
The O
most O
prominent O
factor O
associated O
with O
high O
adherence B-outcome
to I-outcome
supervised I-outcome
exercise I-outcome
was O
neoadjuvant O
chemotherapy O
[ O
OR O
7.09 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
1.12 O
- O
44.62 O
] O
. O
For O
home O
- O
based O
exercise O
, O
lower O
adherence B-outcome
was O
seen O
in B-outcome
obese I-outcome
participants I-outcome
( O
OR O
0.16 O
; O
95 O
% O
CI O
, O
0.04 O
- O
0.65 O
) O
and O
in B-outcome
participants I-outcome
with I-outcome
average I-outcome
or I-outcome
below I-outcome
average I-outcome
lower I-outcome
body I-outcome
muscle I-outcome
strength I-outcome
at O
baseline O
( O
OR O
0.12 O
; O
95 O
% O
CI O
, O
0.03 O
- O
0.46 O
) O
. O
Conclusion O
: O
The O
results O
of O
this O
study O
offer O
valuable O
information O
on O
factors O
associated O
with O
adherence O
to O
a O
program O
of O
supervised O
and O
home O
- O
based O
exercise O
. O
Interventions O
may O
be O
adapted O
to O
ensure O
higher O
adherence O
rates O
through O
supportive O
efforts O
targeted O
to O
women O
who O
are O
obese O
, O
have O
low O
muscle O
strength O
and O
who O
receive O
no O
or O
adjuvant O
chemotherapy O
( O
as O
opposed O
to O
neoadjuvant O
chemotherapy O
) O
during O
exercise O
. O

High O
Ki O
67 O
predicts O
unfavourable O
outcomes O
in O
early O
breast O
cancer O
patients O
with O
a O
clinically O
clear O
axilla O
who O
do O
not O
receive O
axillary B-intervention
dissection I-intervention
or O
axillary B-control
radiotherapy I-control
. O
Axillary O
dissection O
is O
increasingly O
forgone O
in O
early O
breast O
cancer O
patients O
with O
a O
clinically O
negative O
axilla O
. O
The O
GRISO O
053 O
randomised O
trial O
recruited O
435 B-total-participants
patients O
of O
age O
over B-age
45 I-age
years I-age
, O
tumour B-eligibility
â‰¤ I-eligibility
1.4 I-eligibility
cm I-eligibility
and I-eligibility
clinically I-eligibility
negative I-eligibility
axilla I-eligibility
, O
to O
assess O
the O
importance O
of O
axillary O
radiotherapy O
versus O
no O
axillary O
radiotherapy O
in O
patients O
not O
given O
axillary O
dissection O
. O
In O
the O
present O
study O
on O
a O
subgroup O
GRISO O
cases O
our O
aim O
was O
to O
assess O
the O
prognostic O
importance O
of O
tumour O
biological O
factors O
after O
more O
than O
10 O
years O
of O
follow O
- O
up O
. O
We O
retrospectively O
assessed O
biological O
factors O
in O
a O
subgroup O
of O
285 O
GRISO O
cases O
( O
145 B-control-participants
given O
axillary O
radiotherapy O
; O
140 B-intervention-participants
not O
given O
axillary O
radiotherapy O
) O
with O
complete O
biologic O
, O
therapeutic O
and O
follow O
- O
up O
information O
, O
using O
multivariable O
Cox O
proportional O
hazards O
regression O
modelling O
. O
Only O
10 B-outcome
-year I-outcome
cumulative I-outcome
incidence I-outcome
of I-outcome
distant I-outcome
metastasis I-outcome
was O
lower O
in O
the O
axillary O
radiotherapy O
( O
1 B-cv-bin-percent
% I-cv-bin-percent
) O
than O
no O
axillary O
radiotherapy O
arm O
( O
7 B-iv-bin-percent
% I-iv-bin-percent
) O
( O
p= O
0.037 O
) O
. O
Irrespective O
of O
study O
arm O
, O
hormone O
receptor O
positivity O
had O
significantly O
favourable O
effects O
on O
10 B-outcome
-year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
and O
overall B-outcome
survival I-outcome
. O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER O
2 O
) O
-positive O
and O
triple O
- O
negative O
subtypes O
were O
associated O
with O
lower O
10 B-outcome
-year I-outcome
DFS I-outcome
( O
60 O
% O
and O
76 O
% O
, O
respectively O
) O
than O
luminal O
A O
( O
96 O
% O
) O
and O
B O
( O
91 O
% O
) O
( O
p= O
0.001 O
) O
. O
Ten B-outcome
- I-outcome
year I-outcome
DFS I-outcome
for O
high O
( O
â‰¥ O
14 O
% O
) O
Ki O
67 O
cancers O
was O
lower O
than O
for O
low O
Ki O
67 O
cancers O
( O
p= O
0.027 O
) O
; O
however O
, O
this O
effect O
was O
mainly O
confined O
to O
the O
no O
axillary O
radiotherapy O
arm O
. O
For O
patients O
with O
clinically O
node O
- O
negative O
small O
breast O
cancer O
not O
given O
axillary O
dissection O
, O
10 O
-year O
DFS O
is O
worsened O
by O
HER O
2 O
positivity O
, O
triple O
- O
negative O
phenotype O
and O
high O
Ki O
67 O
. O
Axillary O
radiotherapy O
counteracts O
the O
negative O
prognostic O
effect O
of O
high O
Ki O
67 O
in O
patients O
not O
receiving O
axillary O
dissection O
. O

Fatty O
acid O
profiles O
in O
erythrocyte O
membranes O
following O
the O
Mediterranean B-intervention
diet I-intervention
- O
data O
from O
a O
multicenter O
lifestyle O
intervention O
study O
in O
women O
with O
hereditary O
breast O
cancer O
( O
LIBRE O
) O
. O
Evidence O
- O
based O
concepts O
to O
prevent O
breast O
cancer O
in O
women O
with O
BRCA O
1 O
/ O
2 O
mutations O
are O
limited O
. O
Adherence O
to O
a O
Mediterranean O
diet O
( O
MedD O
) O
has O
been O
associated O
with O
a O
lower O
risk O
for O
breast O
cancer O
, O
possibly O
due O
to O
a O
favorable O
fatty O
acid O
( O
FA O
) O
intake O
. O
Here O
, O
we O
studied O
in O
an O
at O
- O
risk O
population O
the O
effect O
of O
a O
lifestyle O
intervention O
that O
included O
the O
MedD O
on O
FA O
composition O
in O
red O
blood O
cell O
membranes O
( O
RBCM O
) O
. O
Data O
derived O
from O
the O
German B-location
multicenter O
trial O
LIBRE O
, O
from O
which O
68 B-total-participants
women O
were O
randomized O
into O
an O
intervention O
group O
( O
IG O
) O
trained O
for O
MedD O
and O
increased O
physical O
activity O
for O
12 O
months O
, O
and O
a O
usual B-control
care I-control
control I-control
group I-control
( O
CG O
) O
. O
Adherence O
to O
the O
diet O
was O
assessed O
after O
3 O
and O
12 O
months O
using O
the O
validated O
Mediterranean O
Diet O
Adherence O
Screener O
( O
MEDAS O
) O
and O
a O
food O
frequency O
questionnaire O
. O
RBCM O
FA O
were O
analyzed O
by O
gas O
chromatography O
with O
mass O
spectrometry O
. O
The O
MEDAS O
was O
increased O
in O
both O
groups O
after O
3 O
months O
( O
IG O
: O
P O
< O
0.001 O
; O
CG O
: O
P O
= O
0.004 O
) O
, O
and O
remained O
increased O
only O
in O
the O
IG O
after O
12 O
months O
( O
P O
< O
0.001 O
) O
. O
The O
food O
frequency O
questionnaire O
revealed O
an O
increased O
intake B-outcome
of I-outcome
omega- I-outcome
3 I-outcome
( I-outcome
n- I-outcome
3 I-outcome
) I-outcome
FA I-outcome
at I-outcome
month I-outcome
3 I-outcome
and I-outcome
month I-outcome
12 I-outcome
in O
the O
IG O
( O
both O
P O
< O
0.01 O
) O
, O
but O
not O
in O
the O
CG O
, O
in O
which O
intake O
of O
energy O
, O
protein O
and O
saturated O
FA O
decreased O
. O
In O
both O
groups O
n- B-outcome
6 I-outcome
FA I-outcome
in I-outcome
the I-outcome
RBCM I-outcome
decreased O
( O
P O
< O
0.001 O
) O
, O
while O
n- B-outcome
9 I-outcome
FA I-outcome
increased O
( O
P O
< O
0.001 O
) O
and O
n- B-outcome
3 I-outcome
FA I-outcome
were O
unchanged O
. O
Women O
with O
higher O
consumption O
of O
fish O
had O
higher O
amounts O
of O
n- B-outcome
3 I-outcome
fatty I-outcome
acids I-outcome
in I-outcome
the I-outcome
RBCM I-outcome
. O
The O
MEDAS O
was O
inversely O
correlated O
with O
n- O
6 O
fatty O
acids O
. O
The O
RBCM O
FA O
composition O
was O
associated O
with O
dietetic O
parameters O
related O
to O
the O
MedD O
. O
Adherence O
to O
the O
MedD O
resulted O
in O
an O
altered O
, O
likely O
favorable O
FA O
composition O
. O
Our O
data O
suggest O
selected O
FA O
as O
biomarkers O
to O
monitor O
compliance O
to O
a O
dietetic O
intervention O
such O
as O
the O
MedD O
. O
The O
trial O
is O
registered O
at O
ClinicalTrials.gov O
( O
reference O
: O
NCT O
02087592 O
) O
. O

Radiation O
- O
related O
quality O
of O
life O
parameters O
after O
targeted B-intervention
intraoperative I-intervention
radiotherapy I-intervention
versus O
whole B-control
breast I-control
radiotherapy I-control
in O
patients O
with O
breast O
cancer O
: O
results O
from O
the O
randomized O
phase O
III O
trial O
TARGIT O
- O
A O
. O
Intraoperative O
radiotherapy O
( O
IORT O
) O
is O
a O
new O
treatment O
approach O
for O
early O
stage O
breast O
cancer O
. O
This O
study O
reports O
on O
the O
effects O
of O
IORT O
on O
radiation O
- O
related O
quality O
of O
life O
( O
QoL O
) O
parameters O
. O
Two B-total-participants
hundred I-total-participants
and I-total-participants
thirty I-total-participants
women B-eligibility
with I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
( O
age O
, O
31 B-age
to I-age
84 I-age
years I-age
) O
were O
entered O
into O
the O
study O
. O
A O
single O
- O
center O
subgroup O
of O
87 B-total-participants
women O
from O
the O
two O
arms O
of O
the O
randomized O
phase O
III O
trial O
TARGIT O
- O
A O
( O
TARGeted O
Intra O
- O
operative O
radioTherapy O
versus O
whole O
breast O
radiotherapy O
for O
breast O
cancer O
) O
was O
analyzed O
. O
Furthermore O
, O
results O
were O
compared O
to O
non O
- O
randomized O
control O
groups O
: O
n O
= O
90 B-intervention-participants
receiving O
IORT O
as O
a O
tumor O
bed O
boost O
followed O
by O
external O
beam O
whole O
breast O
radiotherapy O
( O
EBRT O
) O
outside O
of O
TARGIT O
- O
A O
( O
IORT O
- O
boost O
) O
, O
and O
n O
= O
53 B-control-participants
treated O
with O
EBRT O
followed O
by O
an O
external O
- O
beam O
boost O
( O
EBRT O
- O
boost O
) O
. O
QoL O
was O
collected O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaires O
C O
30 O
( O
QLQ O
- O
C O
30 O
) O
and O
BR O
23 O
( O
QLQ O
- O
BR O
23 O
) O
. O
The O
mean B-outcome
follow I-outcome
- I-outcome
up I-outcome
period I-outcome
in O
the O
TARGIT O
- O
A O
groups O
was O
32 B-iv-cont-mean
versus O
39 B-cv-cont-mean
months I-cv-cont-mean
in O
the O
non O
- O
randomized O
control O
groups O
. O
Patients O
receiving O
IORT O
alone O
reported O
less O
general O
pain B-outcome
( O
21.3 B-iv-cont-mean
points I-iv-cont-mean
) O
, O
breast B-outcome
( O
7.0 B-iv-cont-mean
points I-iv-cont-mean
) O
and O
arm B-outcome
( O
15.1 B-iv-cont-mean
points I-iv-cont-mean
) O
symptoms O
, O
and O
better O
role B-outcome
functioning I-outcome
( O
78.7 B-iv-cont-mean
points I-iv-cont-mean
) O
as O
patients O
receiving O
EBRT O
( O
40.9 B-cv-cont-mean
; O
19.0 B-cv-cont-mean
; O
32.8 B-cv-cont-mean
; O
and O
60.5 B-cv-cont-mean
points I-cv-cont-mean
, O
respectively O
, O
P O
< O
0.01 O
) O
. O
Patients O
receiving O
IORT O
alone O
also O
had O
fewer O
breast B-outcome
symptoms I-outcome
than O
TARGIT O
- O
A O
patients O
receiving O
IORT O
followed O
by O
EBRT O
for O
high O
risk O
features O
on O
final O
pathology O
( O
IORT O
- O
EBRT O
; O
7.0 B-iv-cont-mean
versus O
29.7 B-cv-cont-mean
points I-cv-cont-mean
, O
P O
< O
0.01 O
) O
. O
There O
were O
no O
significant O
differences O
between O
TARGIT O
- O
A O
patients O
receiving O
IORT O
- O
EBRT O
compared O
to O
non O
- O
randomized O
IORT O
- O
boost O
or O
EBRT O
- O
boost O
patients O
and O
patients O
receiving O
EBRT O
without O
a O
boost O
. O
In O
the O
randomized O
setting O
, O
important O
radiation O
- O
related O
QoL O
parameters O
after O
IORT O
were O
superior O
to O
EBRT O
. O
Non O
- O
randomized O
comparisons O
showed O
equivalent O
parameters O
in O
the O
IORT O
- O
EBRT O
group O
and O
the O
control O
groups O
. O

Managing O
the O
risk O
of O
invasive O
breast O
cancer O
in O
women O
at O
risk O
for O
breast O
cancer O
and O
osteoporosis O
: O
the O
role O
of O
raloxifene B-intervention
. O
Raloxifene O
hydrochloride O
is O
a O
selective O
estrogen O
receptor O
modulator O
( O
SERM O
) O
that O
has O
antiestrogenic O
effects O
on O
breast O
and O
endometrial O
tissue O
and O
estrogenic O
effects O
on O
bone O
, O
lipid O
metabolism O
, O
and O
blood O
clotting O
. O
Raloxifene O
significantly O
improves O
serum O
lipids O
and O
serum O
markers O
of O
cardiovascular O
disease O
risk O
, O
but O
it O
has O
no O
significant O
effect O
on O
the O
risk O
of O
primary O
coronary O
events O
. O
A O
meta O
- O
analysis O
of O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trials O
of O
raloxifene O
for O
osteoporosis O
showed O
the O
odds O
of O
fracture B-outcome
risk I-outcome
were O
0.60 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.49 O
- O
0.74 O
) O
for O
raloxifene O
60 O
mg O
/ O
day O
compared O
with O
placebo B-control
. O
During O
8 O
years O
of O
follow O
- O
up O
in O
an O
osteoporosis O
trial O
, O
the O
raloxifene O
group O
had O
a O
76 B-iv-bin-percent
% I-iv-bin-percent
reduction O
in O
the O
incidence B-outcome
of I-outcome
invasive I-outcome
ER I-outcome
- I-outcome
positive I-outcome
breast I-outcome
cancer I-outcome
compared O
with O
the O
placebo O
group O
. O
In O
the O
STAR O
trial O
, O
the O
incidence B-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
was O
4.30 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
- O
years O
with O
raloxifene O
and O
4.41 B-cv-bin-abs
per O
1000 B-control-participants
with O
tamoxifen O
; O
RR O
= O
1.02 O
; O
95 O
% O
CI O
, O
0.82 O
- O
1.28 O
. O
The O
effect O
of O
raloxifene O
on O
invasive O
breast O
cancer O
was O
, O
therefore O
, O
equivalent O
to O
that O
of O
tamoxifen O
with O
more O
favorable O
rates O
of O
adverse O
effects O
including O
uterine B-outcome
malignancy I-outcome
and O
clotting B-outcome
events I-outcome
. O
Millions O
of O
postmenopausal O
women O
could O
derive O
net O
benefit O
from O
raloxifene O
through O
reduced O
rates O
of O
fracture O
and O
invasive O
breast O
cancer O
. O

Efficacy O
and O
tolerability O
of O
aprepitant B-intervention
for O
the O
prevention O
of O
chemotherapy B-condition
- I-condition
induced I-condition
nausea I-condition
and I-condition
vomiting I-condition
in O
patients O
with O
breast O
cancer O
after O
moderately O
emetogenic O
chemotherapy O
. O
This O
is O
the O
first O
study O
in O
which O
the O
NK O
( O
1 O
) O
-receptor O
antagonist O
, O
aprepitant O
( O
APR O
) O
, O
was O
evaluated O
for O
the O
prevention O
of O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
with O
moderately O
emetogenic O
chemotherapy O
. O
Eligible O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
were I-eligibility
naive I-eligibility
to I-eligibility
emetogenic I-eligibility
chemotherapy I-eligibility
and I-eligibility
treated I-eligibility
with I-eligibility
cyclophosphamide I-eligibility
+ I-eligibility
/- I-eligibility
doxorubicin I-eligibility
or I-eligibility
epirubicin I-eligibility
. O
Patients O
were O
randomly O
assigned O
to O
either O
an O
aprepitant O
regimen O
( O
day O
1 O
, O
APR O
125 O
mg O
, O
ondansetron O
( O
OND O
) O
8 O
mg O
, O
and O
dexamethasone O
12 O
mg O
before O
chemotherapy O
and O
OND O
8 O
mg O
8 O
hours O
later O
; O
days O
2 O
through O
3 O
, O
APR O
80 O
qd O
) O
[ O
DOSAGE O
ERROR O
CORRECTED O
] O
or O
a O
control B-control
regimen I-control
( O
day O
1 O
, O
OND O
8 O
mg O
and O
dexamethasone O
20 O
mg O
before O
chemotherapy O
and O
OND O
8 O
mg O
8 O
hours O
later O
; O
days O
2 O
through O
3 O
, O
OND O
8 O
mg O
bid O
) O
. O
Data O
on O
nausea O
, O
vomiting O
, O
and O
use O
of O
rescue O
medication O
were O
collected O
with O
a O
self O
- O
report O
diary O
. O
The O
primary O
efficacy O
end O
point O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
complete I-outcome-measure
response I-outcome-measure
, O
defined O
as O
no O
vomiting O
and O
no O
use O
of O
rescue O
therapy O
, O
during O
120 O
hours O
after O
initiation O
of O
chemotherapy O
in O
cycle O
1 O
. O
The O
secondary O
end O
point O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
an I-outcome-measure
average I-outcome-measure
item I-outcome-measure
score I-outcome-measure
higher I-outcome-measure
than I-outcome-measure
6 I-outcome-measure
of I-outcome-measure
7 I-outcome-measure
on I-outcome-measure
the I-outcome-measure
Functional I-outcome-measure
Living I-outcome-measure
Index I-outcome-measure
- I-outcome-measure
Emesis I-outcome-measure
questionnaire I-outcome-measure
. O
Of O
866 B-total-participants
patients O
randomized O
, O
857 B-total-participants
patients O
( O
99 O
% O
) O
were O
assessable O
. O
Overall O
complete B-outcome
response I-outcome
was O
greater O
with O
the O
aprepitant O
regimen O
than O
with O
the O
control O
regimen O
( O
50.8 B-iv-bin-percent
% I-iv-bin-percent
v O
42.5 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
. O
015 O
) O
. O
More O
patients O
in O
the O
aprepitant O
group O
reported O
minimal O
or O
no O
impact B-outcome
of I-outcome
CINV I-outcome
on I-outcome
daily I-outcome
life I-outcome
( O
63.5 B-iv-bin-percent
% I-iv-bin-percent
v O
55.6 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
. O
019 O
) O
. O
Both O
treatments O
were O
generally O
well B-outcome
tolerated I-outcome
. O
The O
aprepitant O
regimen O
was O
more O
effective O
than O
the O
control O
regimen O
for O
prevention O
of O
CINV O
in O
patients O
receiving O
both O
an O
anthracycline O
and O
cyclophosphamide O
. O

An O
exercise B-intervention
trial I-intervention
targeting O
African B-ethinicity
- I-ethinicity
American I-ethinicity
women O
with O
metabolic O
syndrome O
and O
at O
high O
risk O
for O
breast O
cancer O
: O
Rationale O
, O
design O
, O
and O
methods O
. O
Metabolic O
syndrome O
and O
obesity O
are O
known O
risk O
factors O
for O
breast O
cancers O
. O
Exercise O
interventions O
can O
potentially O
modify O
circulating O
biomarkers O
of O
breast O
cancer O
risk O
but O
evidence O
in O
African O
- O
Americans O
and O
women O
with O
metabolic O
syndrome O
is O
lacking O
. O
The O
Focused O
Intervention O
on O
Exercise O
to O
Reduce O
CancEr O
( O
FIERCE O
) O
trial O
is O
a O
prospective O
, O
6 O
-month O
, O
3 O
-arm O
, O
randomized O
controlled O
trial O
to O
examine O
the O
effect O
of O
exercise O
on O
obesity O
, O
metabolic O
syndrome O
components O
, O
and O
breast O
cancer O
biomarkers O
among O
African B-eligibility
- I-eligibility
American I-eligibility
women I-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Two B-total-participants
hundred I-total-participants
- I-total-participants
forty I-total-participants
inactive B-eligibility
women I-eligibility
with I-eligibility
metabolic I-eligibility
syndrome I-eligibility
and I-eligibility
absolute I-eligibility
risk I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
â‰¥ I-eligibility
1.40 I-eligibility
will O
be O
randomized O
to O
one O
of O
the O
three O
trial O
arms O
: O
1 O
) O
a O
supervised O
, O
facility O
- O
based O
exercise O
arm O
; O
2 O
) O
a O
home O
- O
based O
exercise O
arm O
; O
and O
3 O
) O
a O
control B-control
group I-control
that O
maintains O
physical O
activity O
levels O
through O
the O
course O
of O
the O
trial O
. O
Assessments O
will O
be O
conducted O
at O
baseline O
, O
3 O
months O
, O
and O
6 O
months O
. O
The O
primary O
outcome O
variables O
are O
anthropometric B-outcome-measure
indicators I-outcome-measure
of I-outcome-measure
obesity I-outcome-measure
, O
metabolic B-outcome-measure
syndrome I-outcome-measure
components I-outcome-measure
, O
and O
inflammatory B-outcome-measure
, I-outcome-measure
insulin B-outcome-measure
- I-outcome-measure
pathway I-outcome-measure
, O
and O
hormonal B-outcome-measure
biomarkers I-outcome-measure
of I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
risk I-outcome-measure
. O
The O
FIERCE O
trial O
will O
provide O
evidence O
on O
whether O
a O
short O
- O
term O
exercise O
intervention O
might O
be O
effective O
in O
reducing O
breast O
cancer O
risk O
among O
African O
- O
American O
women O
with O
comorbidities O
and O
high O
breast O
cancer O
risk O
-- O
a O
group O
traditionally O
under O
- O
represented O
in O
non O
- O
therapeutic O
breast O
cancer O
trials O
. O
NCT O
02103140 O
. O

No O
differences O
between O
Calendula B-intervention
cream I-intervention
and O
aqueous B-control
cream I-control
in O
the O
prevention O
of O
acute B-condition
radiation I-condition
skin I-condition
reactions I-condition
-- O
results O
from O
a O
randomised O
blinded O
trial O
. O
The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula B-intervention
Weleda I-intervention
cream I-intervention
vs. O
Essex B-intervention
cream I-intervention
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O
The O
primary O
endpoint O
was O
the O
difference B-outcome-measure
in I-outcome-measure
proportion I-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
ARSR I-outcome-measure
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group O
/ O
The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG O
/ O
EORTC O
scale O
) O
at O
follow O
- O
up O
. O
The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
; O
Quality B-outcome-measure
of I-outcome-measure
Life I-outcome-measure
Questionnaire I-outcome-measure
( O
QLQ O
- O
C O
30 O
) O
, O
Sleep B-outcome-measure
disturbances I-outcome-measure
( O
MOS O
- O
sleep O
questionnaire O
) O
and O
symptoms B-outcome-measure
from I-outcome-measure
the I-outcome-measure
irradiated I-outcome-measure
area I-outcome-measure
( O
visual O
analogue O
scale O
) O
. O
Patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O
A O
total O
of O
420 B-total-participants
patients O
were O
randomised O
and O
411 B-total-participants
were O
analysed O
. O
With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient O
- O
related O
factors O
. O
The O
incidence B-outcome
of I-outcome
severe I-outcome
ARSR I-outcome
( O
RTOG O
/ O
EORTC O
grade O
â‰¤ O
2 O
) O
at O
the O
follow O
- O
up O
visit O
was O
23 B-iv-bin-percent
% I-iv-bin-percent
( O
n O
= O
45 B-intervention-participants
) O
in O
the O
Calendula O
group O
and O
19 B-cv-bin-percent
% I-cv-bin-percent
( O
n O
= O
38 B-control-participants
) O
in O
the O
Essex O
group O
. O
We O
found O
no O
difference O
in O
severe B-outcome
ARSR I-outcome
between O
the O
groups O
at O
any O
point O
of O
assessment O
. O
The O
patients O
reported O
low O
levels B-outcome
of I-outcome
skin I-outcome
related I-outcome
symptoms I-outcome
and O
no O
statistically O
significant O
differences O
between O
the O
groups O
were O
found O
. O
No O
differences O
in O
ARSR O
between O
patients O
randomised O
to O
Calendula O
or O
Essex O
cream O
was O
found O
. O
ARSR O
seem O
to O
be O
a O
relatively O
limited O
problem O
, O
probably O
more O
influenced O
by O
treatment O
related O
factors O
than O
by O
choice O
of O
skin O
care O
products O
in O
this O
patient O
group O
. O

A O
Nonrandomized O
, O
Phase O
II O
Study O
of O
Sequential B-intervention
Irinotecan I-intervention
and I-intervention
Flavopiridol I-intervention
in O
Patients O
With O
Advanced O
Hepatocellular O
Carcinoma O
. O
Flavopiridol O
, O
a O
Cdk O
inhibitor O
, O
potentiates O
irinotecan O
- O
induced O
apoptosis O
. O
In O
a O
phase O
I O
trial O
of O
sequential O
irinotecan O
and O
flavopiridol O
, O
2 O
patients O
with O
advanced O
hepatocellular O
carcinoma O
( O
HCC O
) O
had O
stable O
disease O
( O
SD O
) O
for O
â‰¥ O
14 O
months O
. O
We O
thus O
studied O
the O
sequential O
combination O
of O
irinotecan O
and O
flavopiridol O
in O
patients O
with O
HCC O
. O
Patients B-eligibility
with I-eligibility
advanced I-eligibility
HCC I-eligibility
naÃ¯ve I-eligibility
to I-eligibility
systemic I-eligibility
therapy I-eligibility
, O
Child O
- O
Pugh O
â‰¤B O
8 O
, O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
â‰¥ O
70 O
% O
received O
100 O
mg O
/ O
m O
( O
2 O
) O
irinotecan O
followed O
7 O
hours O
later O
by O
flavopiridol O
60 O
mg O
/ O
m O
( O
2 O
) O
weekly O
for O
4 O
of O
6 O
weeks O
. O
The O
primary O
end O
point O
was O
an O
improvement B-outcome-measure
in I-outcome-measure
progression I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
at I-outcome-measure
4 I-outcome-measure
months I-outcome-measure
( I-outcome-measure
PFS- I-outcome-measure
4 I-outcome-measure
) I-outcome-measure
from O
33 O
% O
to O
54 O
% O
, O
using O
a O
Simon O
's O
two O
- O
stage O
design O
. O
Tumors O
were O
stained O
for O
p O
53 O
. O
Only O
16 B-total-participants
patients O
in O
the O
first O
stage O
were O
enrolled O
: O
median O
age O
, O
64 B-age
years I-age
; O
median O
KPS O
, O
80 O
% O
; O
Child O
- O
Pugh O
A O
, O
87.5 O
% O
; O
and O
stage O
III O
/ O
IV O
, O
25 O
% O
/ O
75 O
% O
. O
The O
primary O
end O
point O
was O
not O
met O
; O
PFS- B-outcome
4 I-outcome
was O
20 O
% O
, O
leading O
to O
early O
termination O
of O
the O
study O
. O
Ten O
patients O
were O
evaluable O
for O
response O
: O
1 B-iv-bin-abs
had O
SD B-outcome
> I-outcome
1 I-outcome
year O
and O
9 B-iv-bin-abs
had O
disease B-outcome
progression I-outcome
. O
Grade B-outcome
3 I-outcome
fatigue I-outcome
, O
dehydration B-outcome
, O
diarrhea B-outcome
, O
neutropenia B-outcome
with I-outcome
or I-outcome
without I-outcome
fever I-outcome
, O
lymphopenia B-outcome
, O
anemia B-outcome
, O
hyperbilirubinemia B-outcome
, O
and O
transaminitis B-outcome
occurred O
in O
â‰¥ O
10 O
% O
of O
the O
patients O
. O
Of O
the O
9 B-total-participants
patients O
who O
progressed O
, O
5 B-iv-bin-abs
had O
mutant B-outcome
p I-outcome
53 I-outcome
and O
4 B-iv-bin-abs
had O
wild B-outcome
- I-outcome
type I-outcome
p I-outcome
53 I-outcome
. O
The O
patient O
with O
stable O
disease O
had O
wild O
- O
type O
p O
53 O
. O
Sequential O
irinotecan O
and O
flavopiridol O
are O
ineffective O
and O
poorly O
tolerated O
in O
patients O
with O
advanced O
HCC O
. O
Despite O
our O
limited O
assessments O
, O
it O
is O
possible O
that O
the O
presence O
of O
wild O
- O
type O
p O
53 O
is O
necessary O
but O
not O
sufficient O
to O
predict O
response O
in O
HCC O
. O

Inulin B-intervention
Supplementation I-intervention
Reduces O
Systolic B-condition
Blood I-condition
Pressure I-condition
in O
Women O
with O
Breast O
Cancer O
Undergoing O
Neoadjuvant O
Chemotherapy O
. O
Breast O
cancer O
is O
the O
most O
frequently O
diagnosed O
malignancy O
in O
women O
, O
and O
comorbidities O
like O
hypertension O
and O
obesity O
diminish O
their O
quality O
of O
life O
and O
negatively O
affect O
their O
response O
to O
chemotherapy O
. O
Furthermore O
, O
inulin O
supplementation O
is O
associated O
with O
the O
reduction O
of O
cardiovascular O
diseases O
( O
CVD O
) O
risk O
. O
To O
determine O
whether O
inulin O
supplementation O
prevents O
the O
elevation O
of O
blood O
pressure O
in O
women O
with O
breast O
cancer O
undergoing O
neoadjuvant O
therapy O
with O
cyclophosphamide O
and O
doxorubicin O
. O
This O
was O
a O
randomized O
, O
double O
- O
blind O
placebo O
controlled O
trial O
which O
included O
women B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
neoadjuvant I-eligibility
therapy I-eligibility
( O
n= O
38 B-total-participants
) O
. O
Patients O
were O
randomly O
assigned O
to O
participate O
in O
two O
different O
groups O
to O
receive O
either O
15 O
g O
of O
inulin O
or O
15 O
g O
of O
placebo B-control
( I-control
maltodextrin I-control
) I-control
for O
21 O
days O
. O
Body O
composition O
and O
blood O
pressure O
were O
evaluated O
before O
and O
after O
the O
supplementation O
period O
. O
Women O
in O
the O
inulin O
group O
showed O
a O
lower O
systolic B-outcome
blood I-outcome
pressure I-outcome
( I-outcome
SBP I-outcome
) I-outcome
after O
the O
supplementation O
( O
- O
4.21 O
mmHg O
, O
p O
< O
0.001 O
) O
. O
However O
, O
SBP O
increased O
in O
the O
placebo O
supplemented O
group O
. O
Diastolic B-outcome
blood I-outcome
pressure I-outcome
( I-outcome
DBP I-outcome
) I-outcome
nonsignificantly O
decreased O
in O
the O
inulin O
group O
. O
Inulin O
supplementation O
also O
increased O
BMI B-outcome
( O
p O
< O
0.001 O
) O
but O
reduced O
BFP B-outcome
( O
p= O
0.288 O
) O
. O
Furthermore O
, O
confounding O
variables O
, O
such O
as O
BMI O
, O
baseline O
fasting O
glucose O
, O
age O
, O
menopause O
status O
, O
vomiting O
, O
constipation O
, O
and O
chronic O
medication O
did O
not O
have O
a O
statistical O
influence O
over O
the O
inulin O
effect O
on O
SBP O
. O
Inulin O
supplementation O
reduces O
SBP O
and O
prevents O
increases O
in O
DBP O
in O
women O
with O
breast O
cancer O
. O
This O
could O
be O
an O
innovative O
nutraceutical O
approach O
to O
prevent O
hypertension O
present O
in O
women O
with O
this O
type O
of O
cancer O
at O
an O
early O
stage O
and O
may O
improve O
the O
quality O
of O
life O
of O
the O
patients O
and O
their O
prognostic O
development O
through O
chemotherapy O
. O
This O
trial O
is O
registered O
with O
ACTRN O
12616001532493 O
. O

Randomized O
phase O
II O
trial O
of O
cyclophosphamide B-intervention
and I-intervention
the I-intervention
oral I-intervention
poly I-intervention
( I-intervention
ADP I-intervention
- I-intervention
ribose I-intervention
) I-intervention
polymerase I-intervention
inhibitor I-intervention
veliparib I-intervention
in O
patients O
with O
recurrent O
, O
advanced O
triple O
- O
negative O
breast O
cancer O
. O
Background O
In O
tumors O
carrying O
BRCA O
mutations O
, O
DNA O
damage O
caused O
by O
standard O
cytotoxic O
chemotherapy O
can O
be O
potentiated O
by O
poly O
[ O
ADP O
- O
ribose O
] O
polymerase O
( O
PARP O
) O
inhibitors O
, O
leading O
to O
increased O
cell O
death O
through O
synthetic O
lethality O
. O
Individuals O
carrying O
mutations O
in O
BRCA O
have O
an O
increased O
incidence O
of O
triple O
negative O
breast O
cancer O
( O
TNBC O
) O
. O
In O
order O
to O
assess O
the O
role O
of O
PARP O
inhibition O
in O
the O
treatment O
of O
TNBC O
, O
we O
conducted O
a O
randomized O
phase O
II O
trial O
of O
the O
combination O
of O
veliparib O
, O
a O
small O
molecule O
PARP O
inhibitor O
, O
with O
the O
cytotoxic O
agent O
cyclophosphamide O
versus O
cyclophosphamide O
alone O
in O
patients O
with O
refractory O
TNBC O
. O
Methods O
Adult B-eligibility
patients I-eligibility
with I-eligibility
TNBC I-eligibility
were O
randomized O
to O
receive O
oral O
cyclophosphamide O
50 O
mg O
once O
daily O
with O
or O
without O
oral O
veliparib O
at O
60 O
mg O
daily O
in O
21 O
-day O
cycles O
. O
Patients O
on O
the O
cyclophosphamide O
arm O
could O
crossover O
to O
the O
combination O
arm O
at O
disease O
progression O
. O
Results O
Forty B-total-participants
- I-total-participants
five I-total-participants
patients O
were O
enrolled O
; O
18 B-control-participants
received O
cyclophosphamide B-control
alone I-control
and O
21 B-intervention-participants
received O
the O
combination O
as O
their O
initial O
treatment O
regimen O
. O
Lymphopenia B-outcome
was O
the O
most O
common O
grade O
3 O
/ O
4 O
toxicity O
noted O
in O
both O
arms O
. O
One B-cv-bin-abs
patient O
in O
the O
cyclophosphamide O
alone O
arm O
, O
and O
2 B-iv-bin-abs
in O
the O
combination O
arm O
had O
objective B-outcome
responses I-outcome
. O
Response B-outcome
rates I-outcome
and O
median B-outcome
progression I-outcome
free I-outcome
survival I-outcome
did O
not O
significantly O
differ O
between O
both O
treatment O
arms O
. O
Conclusion O
The O
addition O
of O
veliparib O
to O
cyclophosphamide O
, O
at O
the O
dose O
and O
schedule O
evaluated O
, O
did O
not O
improve O
the O
response O
rate O
over O
cyclophosphamide O
treatment O
alone O
in O
patients O
with O
heavily O
pre O
- O
treated O
triple O
- O
negative O
breast O
cancer O
. O

Efficacy O
of O
gabapentin B-intervention
for O
the O
prevention O
of O
paclitaxel B-condition
induced I-condition
peripheral I-condition
neuropathy I-condition
: O
A O
randomized O
placebo O
controlled O
clinical O
trial O
. O
Neuropathy O
is O
a O
dose O
limiting O
side O
effect O
of O
taxanes O
which O
may O
impact O
the O
quality O
of O
life O
and O
treatment O
outcomes O
. O
This O
randomized O
placebo O
- O
controlled O
double O
- O
blinded O
clinical O
trial O
was O
carried O
out O
to O
assess O
the O
efficacy O
of O
gabapentin O
in O
preventing O
chemotherapy O
induced O
neuropathy O
. O
Women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
into O
two O
groups O
of O
paclitaxel O
chemotherapy O
with O
gabapentin O
300 O
mg O
/ O
three O
times O
a O
day O
orally O
or O
placebo B-control
for O
2 O
weeks O
started O
at O
day O
1 O
of O
each O
paclitaxel O
cycle O
. O
Two O
groups O
were O
compared O
based O
on O
the O
relative O
frequency O
of O
neuropathy O
and O
change O
in O
nerve O
conducting O
velocity O
( O
NCV O
) O
. O
Twenty B-intervention-participants
women O
were O
assigned O
to O
each O
study O
arm O
. O
The O
majority O
of O
the O
neuropathy B-outcome
in O
gabapentin O
group O
was O
grade O
1 O
in O
all O
of O
the O
four O
cycles O
with O
no O
event O
of O
â‰¥grade O
3 O
neuropathy O
in O
this O
group O
. O
Compared O
to O
the O
placebo O
, O
the O
rate B-outcome
of I-outcome
2 I-outcome
nd I-outcome
and I-outcome
3 I-outcome
rd I-outcome
grade I-outcome
neuropathy I-outcome
was O
significantly O
lower O
in O
the O
gabapentin O
group O
( O
P O
= O
0.000 O
) O
. O
The O
change B-outcome
in I-outcome
NCV I-outcome
after O
four O
cycles O
of O
paclitaxel O
was O
significantly O
lower O
in O
the O
gabapentin O
group O
compared O
to O
the O
placebo O
group O
( O
17.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
61.0 B-cv-bin-percent
% I-cv-bin-percent
decline B-outcome
in I-outcome
NCV I-outcome
for I-outcome
sural I-outcome
and O
21.9 B-iv-bin-percent
% I-iv-bin-percent
vs O
62.5 B-cv-bin-percent
% I-cv-bin-percent
declines B-outcome
in I-outcome
NCV I-outcome
for I-outcome
peroneal I-outcome
nerve I-outcome
) O
. O
Gabapentin O
given O
with O
paclitaxel O
is O
effective O
in O
the O
prevention O
of O
intermediate O
and O
high O
grade O
neuropathies O
both O
objectively O
and O
subjectively O
. O

Predictive O
factors O
of O
pathologic O
complete O
response O
and O
clinical O
tumor O
progression O
after O
preoperative B-intervention
chemotherapy I-intervention
in O
patients B-eligibility
with I-eligibility
stage I-eligibility
II I-eligibility
and I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
. O
This O
study O
aimed O
to O
define O
predictive O
factors O
of O
pathologic O
complete O
response O
( O
pCR O
) O
and O
disease O
progression O
in O
stage B-eligibility
II I-eligibility
and I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
. O
Three B-total-participants
hundred I-total-participants
thirty I-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
included O
in O
the O
study O
. O
Patients O
had O
received O
preoperative O
chemotherapy O
as O
follows O
: O
101 B-intervention-participants
had O
doxorubicin O
plus O
cyclophosphamide O
( O
AC O
) O
; O
91 B-intervention-participants
had O
doxorubicin O
plus O
docetaxel O
; O
103 B-intervention-participants
had O
docetaxel O
plus O
capecitabine O
; O
and O
43 B-intervention-participants
had O
paclitaxel O
plus O
gemcitabine O
. O
A O
pCR O
was O
defined O
as O
the O
absence O
of O
residual O
invasive O
carcinoma O
in O
the O
breast O
. O
The O
majority O
of O
patients O
( O
73 O
% O
) O
were O
premenopausal O
with O
a O
median O
age O
of O
44 B-age
( I-age
range I-age
, I-age
21 I-age
- I-age
76 I-age
) I-age
years I-age
. O
Fifty O
- O
four O
patients O
( O
16 O
% O
) O
achieved B-outcome
pCR I-outcome
and O
were O
distributed O
among O
the O
4 O
breast O
cancer O
subtypes O
as O
follows O
: O
10 O
% O
of O
patients O
with O
-ER O
or O
PR+ O
/ O
HER O
2 O
- O
, O
13 O
% O
with O
ER O
or O
PR+ O
/ O
HER O
2 O
+ O
, O
33 O
% O
with O
ER- O
/ O
PR- O
/ O
HER O
2 O
+ O
, O
and O
19 O
% O
with O
ER- O
/ O
PR- O
/ O
HER O
2 O
- O
( O
p O
= O
0.001 O
) O
. O
Taxane O
- O
containing O
regimen O
( O
p O
= O
0.042 O
) O
and O
Breast O
cancer O
subtype O
( O
p O
= O
0.005 O
) O
were O
significant O
predictive O
variables O
for O
pCR B-outcome
. O
On O
the O
other O
hand O
, O
significantly O
more O
patients O
who O
received O
non O
- O
taxane O
- O
containing O
regimen O
( O
AC O
) O
experienced O
no B-outcome
response I-outcome
( O
p O
= O
0.001 O
) O
or O
progression B-outcome
( O
p O
= O
0.006 O
) O
. O
Patients O
with O
ER- O
/ O
PR- O
/ O
HER O
2 O
+ O
tumors O
and O
those O
who O
received O
taxane O
- O
containing O
regimen O
achieved O
a O
higher O
pCR O
rate O
, O
while O
significantly O
more O
patients O
developed O
tumor O
progression O
by O
preoperative O
non O
- O
taxane O
- O
containing O
regimen O
( O
AC O
) O
compared O
to O
those O
who O
received O
taxane O
- O
containing O
chemotherapy O
. O

A O
phase O
- O
III O
prevention O
trial O
of O
low O
- O
dose O
tamoxifen B-intervention
in O
postmenopausal O
hormone O
replacement O
therapy O
users O
: O
the O
HOT O
study O
. O
Postmenopausal O
hormone O
replacement O
therapy O
( O
HRT O
) O
relieves O
menopausal O
symptoms O
and O
may O
decrease O
mortality O
in O
recently O
postmenopausal O
women O
, O
but O
increases O
breast O
cancer O
risk O
. O
Low O
- O
dose O
tamoxifen O
has O
shown O
retained O
activity O
in O
phase O
- O
II O
studies O
. O
We O
conducted O
a O
phase O
- O
III O
trial O
in O
1884 B-total-participants
recently O
postmenopausal O
women O
on O
HRT O
who O
were O
randomly O
assigned O
to O
either O
tamoxifen O
, O
5 O
mg O
/ O
day O
, O
or O
placebo B-control
for O
5 O
years O
. O
The O
primary O
end O
point O
was O
breast B-outcome-measure
cancer I-outcome-measure
incidence I-outcome-measure
. O
After O
6.2 O
Â± O
1.9 O
years O
mean O
follow O
- O
up O
, O
there O
were O
24 B-cv-bin-abs
breast B-outcome
cancers I-outcome
on O
placebo O
and O
19 B-iv-bin-abs
on O
tamoxifen O
( O
risk O
ratio O
, O
RR O
, O
0.80 O
; O
95 O
% O
CI O
0.44 O
- O
1.46 O
) O
. O
Tamoxifen O
showed O
favorable O
trends B-outcome
in I-outcome
luminal I-outcome
- I-outcome
A I-outcome
tumors I-outcome
( O
RR O
, O
0.32 O
; O
95 O
% O
CI O
0.12 O
- O
0.86 O
) O
, O
in O
HRT O
users O
< O
5 O
years O
( O
RR O
, O
0.35 O
; O
95 O
% O
CI O
0.15 O
- O
0.82 O
) O
and O
in O
women O
completing O
at O
least O
12 O
months O
of O
treatment O
( O
RR O
, O
0.49 O
; O
95 O
% O
CI O
0.23 O
- O
1.02 O
) O
. O
Serious O
adverse O
events O
did O
not O
differ O
between O
placebo O
and O
tamoxifen O
, O
including O
, O
respectively O
, O
coronary B-outcome
heart I-outcome
syndrome I-outcome
( O
6 B-cv-bin-abs
versus O
4 B-iv-bin-abs
) O
, O
cerebrovascular B-outcome
events I-outcome
( O
2 B-cv-bin-abs
versus O
5 B-iv-bin-abs
) O
, O
VTE B-outcome
( O
2 B-cv-bin-abs
versus O
5 B-iv-bin-abs
) O
and O
uterine B-outcome
cancers I-outcome
( O
3 B-cv-bin-abs
versus O
1 B-iv-bin-abs
) O
. O
Vasomotor B-outcome
symptoms I-outcome
were O
50 B-iv-bin-percent
% I-iv-bin-percent
more O
frequent O
on O
tamoxifen O
. O
The O
addition O
of O
low O
- O
dose O
tamoxifen O
to O
HRT O
did O
not O
significantly O
reduce O
breast O
cancer O
risk O
and O
increased O
climacteric O
symptoms O
in O
recently O
postmenopausal O
women O
. O
However O
, O
we O
noted O
beneficial O
trends O
in O
some O
subgroups O
which O
may O
deserve O
a O
larger O
study O
. O

Evaluation O
of O
lecithinized B-intervention
human I-intervention
recombinant I-intervention
super I-intervention
oxide I-intervention
dismutase I-intervention
as O
cardioprotectant O
in O
anthracycline O
- O
treated O
breast O
cancer O
patients O
. O
Anthracycline O
- O
induced O
cardiotoxicity O
is O
( O
partly O
) O
mediated O
by O
free O
radical O
overload O
. O
A O
randomized O
study O
was O
performed O
in O
breast O
cancer O
patients O
to O
investigate O
whether O
free O
radical O
scavenger O
super O
oxide O
dismutase O
( O
SOD O
) O
protects O
against O
anthracycline B-condition
- I-condition
induced I-condition
cardiotoxicity I-condition
as O
measured O
by O
changes O
in O
echo O
, O
electrocardiography O
and O
an O
array O
of O
biomarkers O
. O
Eighty B-total-participants
female B-eligibility
, I-eligibility
chemotherapy I-eligibility
- I-eligibility
naÃ¯ve I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
( O
median O
age O
49 O
, O
range O
24 B-age
- I-age
67 I-age
years I-age
) O
scheduled O
for O
four O
or O
five O
courses O
of O
adjuvant O
3 O
weekly O
doxorubicin O
plus O
cyclophosphamide O
( O
AC O
) O
chemotherapy O
, O
were O
randomly O
assigned O
to O
receive O
80 O
mg O
PC O
- O
SOD O
( O
human O
recombinant O
SOD O
bound O
to O
lecithin O
) O
or O
placebo B-control
, O
administered O
intravenously O
( O
i.v O
. O
) O
immediately O
prior O
to O
each O
AC O
course O
. O
The O
primary O
end O
point O
was O
protection B-outcome-measure
against I-outcome-measure
cardiac I-outcome-measure
damage I-outcome-measure
evaluated O
using O
echocardiography O
, O
QT O
assessments O
and O
a O
set O
of O
biochemical O
markers O
for O
myocardial O
function O
, O
oxidative O
stress O
and O
inflammation O
. O
Assessments O
were O
performed O
before O
and O
during O
each O
course O
of O
chemotherapy O
, O
and O
at O
1 O
, O
4 O
and O
9 O
months O
after O
completion O
of O
the O
chemotherapy O
regimen O
. O
In O
all O
patients O
cardiac O
effects O
such O
as O
increases O
in O
NT B-outcome
- I-outcome
proBNP I-outcome
concentration I-outcome
and I-outcome
prolongation I-outcome
of I-outcome
the I-outcome
QTc I-outcome
interval I-outcome
were O
noticed O
. O
There O
were O
no O
differences O
between O
the O
PC O
- O
SOD O
and O
placebo O
- O
treated O
patients O
in O
systolic B-outcome
or I-outcome
diastolic I-outcome
cardiac I-outcome
function I-outcome
or O
for O
any O
other O
of O
the O
biomarkers O
used O
to O
assess O
the O
cardiac O
effects O
of O
anthracyclines O
. O
PC O
- O
SOD O
at O
a O
dose O
of O
80 O
mg O
i.v O
. O
is O
not O
cardioprotective O
in O
patients O
with O
breast O
carcinoma O
treated O
with O
anthracyclines O
. O

The O
clinical O
relevance O
of O
axillary B-intervention
reverse I-intervention
mapping I-intervention
( I-intervention
ARM I-intervention
) I-intervention
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
Axillary O
lymph O
node O
dissection O
( O
ALND O
) O
in O
patients O
with O
breast O
cancer O
has O
the O
potential O
to O
induce O
side O
- O
effects O
, O
including O
upper O
- O
limb O
lymphedema O
. O
Axillary O
reverse O
mapping O
( O
ARM O
) O
is O
a O
technique O
that O
enables O
discrimination O
of O
the O
lymphatic O
drainage O
of O
the O
breast O
from O
that O
of O
the O
upper O
limb O
in O
the O
axillary O
lymph O
node O
( O
LN O
) O
basin O
. O
If O
lymphedema O
is O
caused O
by O
removing O
these O
lymphatics O
and O
nodes O
in O
the O
upper O
limb O
, O
the O
possibility O
of O
identifying O
these O
lymphatics O
would O
enable O
surgeons O
to O
preserve O
them O
. O
The O
aim O
of O
this O
study O
is O
to O
determine O
the O
clinical O
relevance O
of O
selective O
axillary O
LN O
and O
lymphatic O
preservation O
by O
means O
of O
ARM O
. O
To O
minimize O
the O
risk O
of O
overlooking O
tumor O
- O
positive O
ARM O
nodes O
and O
the O
associated O
risk O
of O
undertreatment O
, O
we O
will O
only O
include O
patients O
with O
a O
tumor O
- O
positive O
sentinel O
lymph O
node O
( O
SLN O
) O
. O
Patients O
who O
are O
candidates O
for O
ALND O
because O
of O
a O
proven O
positive O
axillary O
LN O
at O
clinical O
examination O
can O
be O
included O
in O
a O
registration O
study O
. O
The O
study O
will O
enroll O
280 B-total-participants
patients B-eligibility
diagnosed I-eligibility
with I-eligibility
SLN I-eligibility
biopsy I-eligibility
- I-eligibility
proven I-eligibility
metastasis I-eligibility
of I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
an I-eligibility
indication I-eligibility
for I-eligibility
a I-eligibility
completion I-eligibility
ALND I-eligibility
. O
Patients O
will O
be O
randomized O
to O
undergo O
standard B-control
ALND I-control
or O
an O
ALND O
in O
which O
the O
ARM O
nodes O
and O
their O
corresponding O
lymphatics O
will O
be O
left O
in O
situ O
. O
Primary O
outcome O
is O
the O
presence B-outcome-measure
of I-outcome-measure
axillary I-outcome-measure
surgery I-outcome-measure
- I-outcome-measure
related I-outcome-measure
lymphedema I-outcome-measure
at O
6 O
, O
12 O
, O
and O
24 O
months O
post O
- O
operatively O
, O
measured O
by O
the O
water O
- O
displacement O
method O
. O
Secondary O
outcome O
measures O
include O
pain B-outcome-measure
, O
paresthesia B-outcome-measure
, O
numbness B-outcome-measure
, O
and O
loss B-outcome-measure
of I-outcome-measure
shoulder I-outcome-measure
mobility I-outcome-measure
, O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
and O
axillary B-outcome-measure
recurrence I-outcome-measure
risk I-outcome-measure
. O
The O
benefit O
of O
ALND O
in O
patients O
with O
a O
positive O
SLN O
is O
a O
subject O
of O
debate O
. O
For O
many O
patients O
, O
an O
ALND O
will O
remain O
the O
treatment O
of O
choice O
. O
This O
multicenter O
randomized O
trial O
will O
provide O
evidence O
of O
whether O
or O
not O
axillary O
LN O
preservation O
by O
means O
of O
ARM O
decreases O
the O
side O
- O
effects O
of O
an O
ALND O
. O
Enrolment O
of O
patients O
will O
start O
in O
April O
2013 O
in O
five O
breast O
- O
cancer O
centers O
in O
the O
Netherlands B-location
, O
and O
is O
expected O
to O
conclude O
by O
April O
2016 O
. O
TC O
3698 O
. O

Prevention O
of O
cardiac B-condition
dysfunction I-condition
during O
adjuvant O
breast O
cancer O
therapy O
( O
PRADA O
) O
: O
a O
2 O
Ã— O
2 O
factorial O
, O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
clinical O
trial O
of O
candesartan B-intervention
and I-intervention
metoprolol I-intervention
. O
Contemporary O
adjuvant O
treatment O
for O
early O
breast O
cancer O
is O
associated O
with O
improved O
survival O
but O
at O
the O
cost O
of O
increased O
risk O
of O
cardiotoxicity O
and O
cardiac O
dysfunction O
. O
We O
tested O
the O
hypothesis O
that O
concomitant O
therapy O
with O
the O
angiotensin O
receptor O
blocker O
candesartan O
or O
the O
Î² O
- O
blocker O
metoprolol O
will O
alleviate O
the O
decline O
in O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
associated O
with O
adjuvant O
, O
anthracycline O
- O
containing O
regimens O
with O
or O
without O
trastuzumab O
and O
radiation O
. O
In O
a O
2 O
Ã— O
2 O
factorial O
, O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
trial O
, O
we O
assigned O
130 B-total-participants
adult B-eligibility
women I-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
no I-eligibility
serious I-eligibility
co I-eligibility
- I-eligibility
morbidity I-eligibility
to O
the O
angiotensin O
receptor O
blocker O
candesartan O
cilexetil O
, O
the O
Î² O
- O
blocker O
metoprolol O
succinate O
, O
or O
matching O
placebos B-control
in O
parallel O
with O
adjuvant O
anticancer O
therapy O
. O
The O
primary O
outcome O
measure O
was O
change B-outcome-measure
in I-outcome-measure
LVEF I-outcome-measure
by O
cardiac O
magnetic O
resonance O
imaging O
. O
A O
priori O
, O
a O
change O
of O
5 O
percentage O
points O
was O
considered O
clinically O
important O
. O
There O
was O
no B-outcome
interaction I-outcome
between I-outcome
candesartan I-outcome
and I-outcome
metoprolol I-outcome
treatments I-outcome
( O
P O
= O
0.530 O
) O
. O
The O
overall O
decline O
in O
LVEF B-outcome
was O
2.6 B-cv-cont-mean
( O
95 O
% O
CI O
1.5 O
, O
3.8 O
) O
percentage O
points O
in O
the O
placebo O
group O
and O
0.8 B-iv-cont-mean
( O
95 O
% O
CI O
- O
0.4 O
, O
1.9 O
) O
in O
the O
candesartan O
group O
in O
the O
intention O
- O
to O
- O
treat O
analysis O
( O
P O
- O
value O
for O
between O
- O
group O
difference O
: O
0.026 O
) O
. O
No O
effect O
of O
metoprolol O
on O
the O
overall O
decline O
in O
LVEF B-outcome
was O
observed O
. O
In O
patients O
treated O
for O
early O
breast O
cancer O
with O
adjuvant O
anthracycline O
- O
containing O
regimens O
with O
or O
without O
trastuzumab O
and O
radiation O
, O
concomitant O
treatment O
with O
candesartan O
provides O
protection O
against O
early O
decline O
in O
global O
left O
ventricular O
function O
. O

Prevention O
of O
postmenopausal O
osteoporosis B-condition
in O
Chinese B-ethinicity
women O
: O
a O
5 O
-year O
, O
double O
- O
blind O
, O
randomized O
, O
parallel O
placebo O
- O
controlled O
study O
. O
To O
observe O
the O
effectiveness O
and O
safety O
of O
menopause O
- O
related O
hormone O
therapy O
( O
MHT O
) O
to O
prevent O
bone O
loss O
in O
Chinese O
women O
during O
the O
menopausal O
transition O
and O
early O
menopause O
, O
as O
well O
as O
to O
evaluate O
the O
effects O
of O
5 O
-year O
MHT O
on O
overall O
health O
to O
add O
Level O
I O
evidence O
for O
the O
prevention O
of O
osteoporosis O
using O
MHT O
. O
This O
clinical O
study O
was O
a O
prospective O
, O
double O
- O
blind O
, O
randomized O
, O
parallel O
placebo O
- O
controlled O
study O
. O
Chinese B-eligibility
women I-eligibility
in I-eligibility
the I-eligibility
menopausal I-eligibility
transition I-eligibility
and I-eligibility
early I-eligibility
menopause I-eligibility
were O
randomly O
allocated O
to O
the O
MHT B-intervention
group I-intervention
or O
the O
placebo B-control
group I-control
. O
All O
subjects O
received O
a O
5 O
-year O
intervention O
. O
The O
effectiveness O
of O
MHT O
for O
bone O
mineral O
density O
( O
BMD O
) O
and O
bone O
metabolism O
and O
the O
safety O
of O
MHT O
in O
relation O
to O
glycolipid O
metabolism O
, O
breast O
cancer O
, O
and O
cardiovascular O
disease O
were O
studied O
. O
In O
the O
MHT O
group O
, O
women O
in O
both O
transition O
and O
early O
menopause O
showed O
a O
significant O
increase O
in O
lumbar B-outcome
and I-outcome
femoral I-outcome
neck I-outcome
BMD I-outcome
after O
the O
1 O
st O
year O
of O
therapy O
; O
BMD O
tended O
to O
decrease O
in O
the O
3 O
rd O
year O
but O
ultimately O
was O
sustained O
at O
stable O
levels O
that O
were O
near O
the O
baseline O
levels O
. O
In O
the O
placebo O
group O
, O
BMD B-outcome
decreased O
at O
both O
sites O
. O
Metabolism B-outcome
indexes I-outcome
and I-outcome
breast I-outcome
ultrasound I-outcome
examination I-outcome
findings O
did O
not O
differ O
significantly O
between O
the O
MHT O
and O
placebo O
groups O
. O
Three O
cases O
of O
breast B-outcome
cancer I-outcome
and O
three O
cases O
of O
cardiovascular B-outcome
disease I-outcome
were O
diagnosed O
during O
follow O
- O
up O
. O
One B-iv-bin-abs
breast B-outcome
cancer I-outcome
case O
and O
two B-iv-bin-abs
cardiovascular B-outcome
disease I-outcome
cases I-outcome
occurred O
in O
the O
MHT O
group O
. O
Five O
- O
year O
sequential O
therapy O
with O
estrogen O
and O
progesterone O
can O
increase O
or O
maintain O
the O
BMD O
of O
women O
in O
their O
menopausal O
transition O
and O
early O
menopause O
. O
This O
regimen O
had O
no O
negative O
effect O
on O
glycolipid O
metabolism O
and O
did O
not O
increase O
the O
risk O
of O
breast O
cancer O
or O
cardiovascular O
events O
. O

Guided B-intervention
paravertebral I-intervention
blocks I-intervention
with O
versus O
without B-control
clonidine I-control
for O
women O
undergoing O
breast O
surgery O
: O
a O
prospective O
double O
- O
blinded O
randomized O
study O
. O
Paravertebral O
blocks O
( O
PVBs O
) O
have O
been O
introduced O
as O
an O
alternative O
to O
general O
anesthesia O
for O
breast O
cancer O
surgeries O
. O
The O
addition O
of O
clonidine O
as O
an O
adjuvant O
in O
PVBs O
may O
enhance O
quality O
and O
duration O
of O
analgesia O
and O
significantly O
reduce O
the O
consumption O
of O
analgesics O
after O
breast O
surgery O
. O
In O
this O
prospective O
randomized O
double O
- O
blind O
study O
, O
we O
assessed O
the O
significance O
of O
adding O
clonidine O
to O
the O
anesthetic O
mixture O
for O
women B-eligibility
undergoing I-eligibility
mastectomy I-eligibility
. O
Sixty B-total-participants
patients O
were O
randomized O
equally O
into O
2 O
groups O
, O
both O
of O
which O
received O
PVB O
block O
, O
either O
with O
or O
without O
clonidine O
. O
Analgesic O
consumption O
was O
noted O
up O
to O
2 O
weeks O
after O
the O
operation O
. O
A O
visual O
analog O
scale O
was O
used O
to O
assess O
pain O
postoperatively O
during O
the O
hospital O
stay O
, O
and O
a O
numeric O
rating O
scale O
was O
used O
when O
patients O
were O
discharged O
. O
Analgesic B-outcome
consumption I-outcome
was O
significantly O
lower O
in O
the O
clonidine O
group O
48 O
hours O
postoperatively O
with O
95 O
% O
confidence O
interval O
( O
CI O
) O
for O
the O
difference O
( O
- O
69.5 O
% O
to O
- O
6.6 O
% O
) O
. O
Pain B-outcome
scores I-outcome
at O
rest O
showed O
significant O
reduction O
in O
the O
clonidine O
group O
during O
the O
period O
from O
24 O
to O
72 O
hours O
postoperatively O
with O
95 O
% O
CI O
for O
the O
ratios O
of O
2 O
means O
( O
1.09 O
- O
3.61 O
) O
, O
( O
2.04 O
- O
9.04 O
) O
, O
and O
( O
2.54 O
- O
16.55 O
) O
, O
respectively O
, O
with O
shoulder B-outcome
movement I-outcome
at O
24 O
, O
48 O
, O
and O
72 O
hours O
postoperatively O
95 O
% O
CI O
for O
the O
ratio O
of O
2 O
means O
( O
1.10 O
- O
3.15 O
) O
, O
( O
1.32 O
- O
6.38 O
) O
, O
and O
( O
1.33 O
- O
8.42 O
) O
, O
respectively O
. O
The O
time B-outcome
needed I-outcome
to I-outcome
resume I-outcome
daily I-outcome
activity I-outcome
was O
shorter O
in O
the O
clonidine O
group O
compared O
with O
the O
control O
group O
with O
95 O
% O
CI O
for O
the O
ratio O
of O
2 O
means O
( O
1.14 O
- O
1.62 O
) O
. O
The O
addition O
of O
clonidine O
enhanced O
the O
analgesic O
efficacy O
of O
PVB O
up O
to O
3 O
days O
postoperatively O
for O
patients O
undergoing O
breast O
surgery O
. O

Tamoxifen B-intervention
for O
prevention O
of O
breast O
cancer O
: O
extended O
long O
- O
term O
follow O
- O
up O
of O
the O
IBIS O
- O
I O
breast O
cancer O
prevention O
trial O
. O
Four O
previously O
published O
randomised O
clinical O
trials O
have O
shown O
that O
tamoxifen O
can O
reduce O
the O
risk O
of O
breast O
cancer O
in O
healthy O
women O
at O
increased O
risk O
of O
breast O
cancer O
in O
the O
first O
10 O
years O
of O
follow O
- O
up O
. O
We O
report O
the O
long O
- O
term O
follow O
- O
up O
of O
the O
IBIS O
- O
I O
trial O
, O
in O
which O
the O
participants O
and O
investigators O
remain O
largely O
masked O
to O
treatment O
allocation O
. O
In O
the O
IBIS O
- O
I O
randomised O
controlled O
trial O
, O
premenopausal B-eligibility
and I-eligibility
postmenopausal I-eligibility
women I-eligibility
35 B-age
- I-age
70 I-age
years I-age
of O
age O
deemed B-eligibility
to I-eligibility
be I-eligibility
at I-eligibility
an I-eligibility
increased I-eligibility
risk I-eligibility
of I-eligibility
developing I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
( O
1 O
:1 O
) O
to O
receive O
oral O
tamoxifen O
20 O
mg O
daily O
or O
matching O
placebo B-control
for O
5 O
years O
. O
Patients O
were O
randomly O
assigned O
to O
the O
two O
treatment O
groups O
by O
telephone O
or O
fax O
according O
to O
a O
block O
randomisation O
schedule O
( O
permuted O
block O
sizes O
of O
six O
or O
ten O
) O
. O
Patients O
and O
investigators O
were O
masked O
to O
treatment O
assignment O
by O
use O
of O
central O
randomisation O
and O
coded O
drug O
supply O
. O
The O
primary O
endpoint O
was O
the O
occurrence B-outcome-measure
of I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
( I-outcome-measure
invasive I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
and I-outcome-measure
ductal I-outcome-measure
carcinoma I-outcome-measure
in I-outcome-measure
situ I-outcome-measure
) I-outcome-measure
, O
analysed O
by O
intention O
to O
treat O
. O
Cox O
proportional O
hazard O
models O
were O
used O
to O
assess O
breast O
cancer O
occurrence O
and O
mortality O
. O
The O
trial O
is O
closed O
to O
recruitment O
and O
active O
treatment O
is O
completed O
, O
but O
long O
- O
term O
follow O
- O
up O
is O
ongoing O
. O
This O
trial O
is O
registered O
with O
controlledtrials.com O
, O
number O
ISRCTN O
91879928 O
. O
Between O
April O
14 O
, O
1992 O
, O
and O
March O
30 O
, O
2001 O
, O
7154 B-total-participants
eligible O
women O
recruited O
from O
genetics O
clinics O
and O
breast O
care O
clinics O
in O
eight O
countries O
were O
enrolled O
into O
the O
IBIS O
- O
I O
trial O
and O
were O
randomly O
allocated O
to O
the O
two O
treatment O
groups O
: O
3579 B-intervention-participants
to O
tamoxifen O
and O
3575 B-control-participants
to O
placebo O
. O
After O
a O
median O
follow O
up O
of O
16.0 O
years O
( O
IQR O
14.1 O
- O
17.6 O
) O
, O
601 O
breast B-outcome
cancers I-outcome
have O
been O
reported O
( O
251 B-iv-bin-abs
[ O
7.0 B-iv-bin-percent
% I-iv-bin-percent
] O
in O
3579 B-intervention-participants
patients O
in O
the O
tamoxifen O
group O
vs O
350 B-cv-bin-abs
[ O
9.8 B-cv-bin-percent
% I-cv-bin-percent
] O
in O
3575 B-control-participants
women O
in O
the O
placebo O
group O
; O
hazard O
ratio O
[ O
HR O
] O
0.71 O
[ O
95 O
% O
CI O
0.60 O
- O
0.83 O
] O
, O
p O
< O
0.0001 O
) O
. O
The O
risk B-outcome
of I-outcome
developing I-outcome
breast I-outcome
cancer I-outcome
was O
similar O
between O
years B-outcome
0 I-outcome
- I-outcome
10 I-outcome
( O
226 B-cv-bin-abs
[ O
6.3 B-cv-bin-percent
% I-cv-bin-percent
] O
in O
3575 B-control-participants
women O
in O
the O
placebo O
group O
vs O
163 B-iv-bin-abs
[ O
4.6 B-iv-bin-percent
% I-iv-bin-percent
] O
in O
3579 B-intervention-participants
women O
in O
the O
tamoxifen O
group O
; O
hazard O
ratio O
[ O
HR O
] O
0.72 O
[ O
95 O
% O
CI O
0.59 O
- O
0.88 O
] O
, O
p= O
0.001 O
) O
and O
after B-outcome
10 I-outcome
years I-outcome
( O
124 B-cv-bin-abs
[ O
3.8 B-cv-bin-percent
% I-cv-bin-percent
] O
in O
3295 B-control-participants
women O
vs O
88 B-iv-bin-abs
[ O
2.6 B-iv-bin-percent
% I-iv-bin-percent
] O
in O
3343 B-intervention-participants
, O
respectively O
; O
HR O
0.69 O
[ O
0.53 O
- O
0.91 O
] O
, O
p= O
0.009 O
) O
. O
The O
greatest O
reduction O
in O
risk O
was O
seen O
in O
invasive B-outcome
oestrogen I-outcome
receptor I-outcome
- I-outcome
positive I-outcome
breast I-outcome
cancer I-outcome
( O
HR O
0.66 O
[ O
95 O
% O
CI O
0.54 O
- O
0.81 O
] O
, O
p O
< O
0.0001 O
) O
and O
ductal B-outcome
carcinoma I-outcome
in I-outcome
situ I-outcome
( O
0.65 O
[ O
0.43 O
- O
1.00 O
] O
, O
p= O
0.05 O
) O
, O
but O
no O
effect O
was O
noted O
for O
invasive B-outcome
oestrogen I-outcome
receptor I-outcome
- I-outcome
negative I-outcome
breast I-outcome
cancer I-outcome
( O
HR O
1.05 O
[ O
95 O
% O
CI O
0.71 O
- O
1.57 O
] O
, O
p= O
0.8 O
) O
. O
These O
results O
show O
that O
tamoxifen O
offers O
a O
very O
long O
period O
of O
protection O
after O
treatment O
cessation O
, O
and O
thus O
substantially O
improves O
the O
benefit O
- O
to O
- O
harm O
ratio O
of O
the O
drug O
for O
breast O
cancer O
prevention O
. O
Cancer O
Research O
UK O
( O
UK O
) O
and O
the O
National O
Health O
and O
Medical O
Research O
Council O
( O
Australia O
) O
. O

A O
Comparison O
of O
Fentanyl B-intervention
and I-intervention
Flurbiprofen I-intervention
Axetil I-intervention
on O
Serum O
VEGF O
- O
C O
, O
TNF O
- O
Î± O
, O
and O
IL- O
1 O
ÃŸ O
Concentrations O
in O
Women O
Undergoing O
Surgery O
for O
Breast O
Cancer O
. O
Vascular O
endothelial O
growth O
factor O
- O
C O
( O
VEGF O
- O
C O
) O
, O
tumor O
necrosis O
factor O
- O
Î± O
( O
TNF O
- O
Î± O
) O
, O
and O
interleukin- O
1 O
ÃŸ O
( O
IL- O
1 O
ÃŸ O
) O
have O
been O
shown O
to O
be O
associated O
with O
the O
recurrence O
and O
metastasis O
of O
breast O
cancer O
after O
surgery O
. O
This O
study O
tested O
the O
hypothesis O
that O
patients O
undergoing O
surgery O
for O
breast O
cancer O
, O
who O
received O
postoperative O
analgesia O
with O
flurbiprofen O
axetil O
combined O
with O
small O
doses O
of O
fentanyl O
( O
FA O
) O
, O
exhibited O
reduced O
levels O
of O
VEGF O
- O
C O
, O
TNF O
- O
Î± O
, O
and O
IL- O
1 O
ÃŸ O
compared O
with O
those O
patients O
receiving O
fentanyl O
alone O
( O
F O
) O
. O
Forty B-total-participants
- O
women B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
a I-eligibility
modified I-eligibility
radical I-eligibility
mastectomy I-eligibility
were O
randomized O
to O
receive O
postoperative O
analgesia O
with O
flurbiprofen O
axetil O
combined O
with O
fentanyl O
or O
fentanyl B-control
alone I-control
. O
Venous O
blood O
was O
sampled O
before O
anesthesia O
, O
at O
the O
end O
of O
surgery O
, O
and O
at O
48 O
hours O
after O
surgery O
, O
and O
the O
serum O
was O
analyzed O
. O
The O
primary O
endpoint O
was O
changes B-outcome-measure
in I-outcome-measure
the I-outcome-measure
VEGF I-outcome-measure
- I-outcome-measure
C I-outcome-measure
concentrations I-outcome-measure
in I-outcome-measure
serum I-outcome-measure
. O
Group O
FA O
patients O
reported O
similar O
analgesic B-outcome
effects I-outcome
as O
group O
F O
patients O
at O
2 O
, O
24 O
, O
and O
48 O
hours O
. O
At O
48 O
hours O
, O
mean B-outcome
postoperative I-outcome
concentrations I-outcome
of I-outcome
VEGF I-outcome
- I-outcome
C I-outcome
in O
group O
F O
patients O
were O
higher O
than O
in O
group O
FA O
patients O
, O
730.9 B-iv-cont-mean
versus O
. O
354.1 B-cv-cont-mean
pg I-cv-cont-mean
/ I-cv-cont-mean
mL I-cv-cont-mean
( O
P O
= O
0.003 O
) O
, O
respectively O
. O
The O
mean B-outcome
postoperative I-outcome
concentrations I-outcome
of I-outcome
TNF I-outcome
- I-outcome
Î± I-outcome
in O
group O
F O
patients O
were O
also O
higher O
compared O
with O
group O
FA O
patients O
27.1 B-iv-cont-mean
vs. O
15.8 B-cv-cont-mean
pg I-cv-cont-mean
/ I-cv-cont-mean
mL I-cv-cont-mean
( O
P O
= O
0.005 O
) O
. O
Finally O
, O
the O
mean B-outcome
postoperative I-outcome
concentrations I-outcome
of I-outcome
IL- I-outcome
1 I-outcome
ÃŸ I-outcome
in O
group O
F O
were O
also O
significantly O
higher O
than O
in O
group O
FA O
497.5 B-iv-cont-mean
vs. O
197.7 B-cv-cont-mean
pg I-cv-cont-mean
/ I-cv-cont-mean
mL I-cv-cont-mean
( O
P O
= O
0.001 O
) O
. O
In O
patients O
undergoing O
a O
mastectomy O
, O
postoperative O
analgesia O
with O
flurbiprofen O
axetil O
, O
combined O
with O
fentanyl O
, O
were O
associated O
with O
decreases O
in O
serum O
concentrations O
of O
VEGF O
- O
C O
, O
TNF O
- O
Î± O
, O
and O
IL- O
1 O
ÃŸ O
compared O
with O
patients O
receiving O
doses O
of O
only O
fentanyl O
. O

A O
randomized O
phase O
II O
study O
evaluating O
pyridoxine B-intervention
for O
the O
prevention O
of O
hand B-condition
- I-condition
foot I-condition
syndrome I-condition
associated O
with O
capecitabine O
therapy O
for O
advanced O
or O
metastatic O
breast O
cancer O
. O
Pyridoxine O
, O
an O
activated O
form O
of O
vitamin O
B O
6 O
used O
to O
treat O
allergic O
dermatitis O
, O
may O
prevent O
capecitabine O
- O
associated O
hand O
- O
foot O
syndrome O
( O
HFS O
) O
, O
although O
evidence O
of O
the O
benefit O
of O
prophylactic O
pyridoxine O
is O
lacking O
. O
The O
aim O
of O
this O
open O
- O
label O
, O
multicenter O
, O
randomized O
phase O
II O
study O
was O
to O
determine O
whether O
prophylactic O
pyridoxine O
could O
delay O
the O
onset O
of O
capecitabine O
- O
induced O
HFS O
in O
patients B-eligibility
with I-eligibility
advanced I-eligibility
or I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
received O
either O
concomitant O
pyridoxine O
( O
60 O
mg O
per O
day O
; O
pyridoxine O
group O
) O
, O
or O
no B-control
pyridoxine I-control
but O
treatment O
with O
capecitabine O
- O
containing O
regimens O
( O
no O
pyridoxine O
group O
) O
. O
Study O
treatment O
was O
administered O
until O
the O
development O
of O
grade O
2 O
or O
worse O
HFS O
or O
disease O
progression O
. O
The O
primary O
endpoint O
was O
the O
time B-outcome-measure
to I-outcome-measure
onset I-outcome-measure
of I-outcome-measure
grade I-outcome-measure
2 I-outcome-measure
or I-outcome-measure
worse I-outcome-measure
HFS I-outcome-measure
from O
the O
start O
of O
protocol O
treatment O
. O
A O
total O
of O
135 B-total-participants
patients O
were O
randomized O
to O
the O
pyridoxine O
( O
n O
= O
67 B-intervention-participants
) O
or O
no O
pyridoxine O
( O
n O
= O
68 B-control-participants
) O
groups O
. O
Grade B-outcome
2 I-outcome
or I-outcome
worse I-outcome
HFS I-outcome
developed O
in O
19 B-iv-bin-abs
of O
66 B-intervention-participants
patients O
( O
28.8 B-iv-bin-percent
% I-iv-bin-percent
) O
versus O
21 B-cv-bin-abs
of O
67 B-control-participants
patients O
( O
31.3 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
pyridoxine O
and O
no O
pyridoxine O
groups O
, O
respectively O
. O
The O
median B-outcome
time I-outcome
to I-outcome
onset I-outcome
of I-outcome
grade I-outcome
2 I-outcome
or I-outcome
worse I-outcome
HFS I-outcome
was O
13.6 B-iv-cont-median
and O
10.6 B-cv-cont-median
months I-cv-cont-median
in O
the O
pyridoxine O
and O
no O
pyridoxine O
groups O
, O
respectively O
[ O
hazard O
ratio O
= O
0.75 O
( O
80 O
% O
confidence O
interval O
0.50 O
- O
1.13 O
) O
, O
one O
- O
sided O
P O
= O
0.18 O
] O
. O
Prophylactic O
pyridoxine O
was O
not O
shown O
to O
have O
an O
effect O
on O
the O
onset O
of O
capecitabine O
- O
associated O
HFS O
in O
this O
study O
. O

The O
Influence O
of O
Spiritual B-intervention
Framing I-intervention
on O
African B-ethinicity
American I-ethinicity
Women O
's O
Mammography O
Intentions O
: O
A O
Randomized O
Trial O
. O
Spiritual O
framing O
of O
breast O
cancer O
communication O
may O
provide O
a O
useful O
strategy O
for O
addressing O
disparate O
rates O
of O
breast O
cancer O
mortality O
among O
African O
American O
women O
. O
The O
efficacy O
of O
a O
spiritually O
framed O
breast O
cancer O
screening O
( O
BCS O
) O
message O
was O
compared O
with O
that O
of O
a O
traditional B-control
BCS I-control
message I-control
. O
Specifically O
, O
200 B-total-participants
African B-eligibility
American I-eligibility
women I-eligibility
were O
randomly O
assigned O
to O
review O
either O
a O
spiritually O
framed O
or O
traditional O
BCS O
message O
and O
complete O
a O
self O
- O
administered O
survey O
, O
including O
a O
thought O
- O
listing O
form O
. O
Message O
efficacy O
was O
measured O
by O
number B-outcome-measure
of I-outcome-measure
thoughts I-outcome-measure
generated I-outcome-measure
( I-outcome-measure
elaboration I-outcome-measure
) I-outcome-measure
, O
ratio B-outcome-measure
of I-outcome-measure
positive I-outcome-measure
to I-outcome-measure
negative I-outcome-measure
thoughts I-outcome-measure
( I-outcome-measure
polarity I-outcome-measure
) I-outcome-measure
, O
and O
intention B-outcome-measure
to I-outcome-measure
obtain I-outcome-measure
and/or I-outcome-measure
recommend I-outcome-measure
a I-outcome-measure
mammogram I-outcome-measure
. O
Multiple O
linear O
regression O
and O
structural O
equation O
modeling O
were O
used O
to O
assess O
direct O
and O
indirect O
( O
mediated O
) O
associations O
among O
variables O
. O
Spiritual O
framing O
was O
positively O
associated O
with O
greater B-outcome
elaboration I-outcome
( O
Î² O
= O
. O
265 O
, O
SE O
= O
. O
36 O
, O
p O
< O
. O
001 O
) O
and O
more O
positive B-outcome
polarity I-outcome
( O
Î² O
= O
. O
237 O
, O
SE O
= O
. O
04 O
, O
p O
< O
. O
001 O
) O
. O
Spiritual O
framing O
also O
had O
a O
significant O
indirect O
effect B-outcome
on I-outcome
mammography I-outcome
intentions I-outcome
through I-outcome
polarity I-outcome
( O
standardized O
indirect O
effect O
= O
. O
057 O
, O
95 O
% O
confidence O
interval O
[ O
. O
024 O
, O
. O
106 O
] O
, O
p O
< O
. O
001 O
) O
. O
These O
results O
indicate O
that O
spiritual O
framing O
may O
improve O
the O
efficacy O
of O
BCS O
messages O
among O
African O
American O
women O
by O
eliciting O
more O
positive O
thoughts O
about O
screening O
. O
Interventions O
targeting O
African O
American O
women O
might O
consider O
the O
role O
of O
spirituality O
when O
tailoring O
messages O
to O
encourage O
regular O
mammography O
use O
. O

A O
Phase O
III O
Study O
of O
Balugrastim B-intervention
Versus O
Pegfilgrastim B-control
in O
Breast O
Cancer O
Patients O
Receiving O
Chemotherapy O
With O
Doxorubicin O
and O
Docetaxel O
. O
This O
study O
aimed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
once O
- O
per O
- O
cycle O
balugrastim O
versus O
pegfilgrastim O
for O
neutrophil O
support O
in O
breast O
cancer O
patients O
receiving O
myelosuppressive O
chemotherapy O
. O
Breast B-eligibility
cancer I-eligibility
patients I-eligibility
( O
n O
= O
256 B-total-participants
) O
were O
randomized O
to O
40 O
or O
50 O
mg O
of O
subcutaneous O
balugrastim O
or O
6 O
mg O
of O
pegfilgrastim O
â‰ˆ O
24 O
hours O
after O
chemotherapy O
( O
60 O
mg O
/ O
m O
( O
2 O
) O
doxorubicin O
and O
75 O
mg O
/ O
m O
( O
2 O
) O
docetaxel O
, O
every O
21 O
days O
for O
up O
to O
4 O
cycles O
) O
. O
The O
primary O
efficacy O
parameter O
was O
the O
duration B-outcome-measure
of I-outcome-measure
severe I-outcome-measure
neutropenia I-outcome-measure
( I-outcome-measure
DSN I-outcome-measure
) I-outcome-measure
in O
cycle O
1 O
. O
Secondary O
parameters O
included O
DSN B-outcome-measure
( I-outcome-measure
cycles I-outcome-measure
2 I-outcome-measure
- I-outcome-measure
4 I-outcome-measure
) I-outcome-measure
, O
absolute B-outcome-measure
neutrophil I-outcome-measure
count I-outcome-measure
( I-outcome-measure
ANC I-outcome-measure
) I-outcome-measure
nadir I-outcome-measure
, O
febrile B-outcome-measure
neutropenia I-outcome-measure
rates I-outcome-measure
, O
and O
time B-outcome-measure
to I-outcome-measure
ANC I-outcome-measure
recovery I-outcome-measure
( I-outcome-measure
cycles I-outcome-measure
1 I-outcome-measure
- I-outcome-measure
4 I-outcome-measure
) I-outcome-measure
. O
Safety O
, O
pharmacokinetics O
, O
and O
immunogenicity O
were O
assessed O
. O
Mean B-outcome
cycle I-outcome
1 I-outcome
DSN I-outcome
was O
1.0 B-iv-cont-mean
day I-iv-cont-mean
with O
40 O
mg O
of O
balugrastim O
, O
1.3 B-iv-cont-mean
with O
50 O
mg O
of O
balugrastim O
, O
and O
1.2 B-cv-cont-mean
with O
pegfilgrastim O
( O
upper O
limit O
of O
95 O
% O
confidence O
intervals O
for O
between O
- O
group O
DSN O
differences O
was O
< O
1.0 O
day O
for O
both O
balugrastim O
doses O
versus O
pegfilgrastim O
) O
. O
Between O
- O
group O
efficacy O
parameters O
were O
comparable O
except O
for O
time B-outcome
to I-outcome
ANC I-outcome
recovery I-outcome
in I-outcome
cycle I-outcome
1 I-outcome
( O
40 O
mg O
of O
balugrastim O
, O
2.0 B-iv-cont-mean
days I-iv-cont-mean
; O
50 O
mg O
of O
balugrastim O
, O
2.1 B-iv-cont-mean
; O
pegfilgrastim O
, O
2.6 B-cv-cont-mean
) O
. O
Median B-outcome
terminal I-outcome
elimination I-outcome
half O
- O
life O
was O
â‰ˆ O
37 B-iv-cont-median
hours I-iv-cont-median
for O
40 O
mg O
of O
balugrastim O
, O
â‰ˆ O
36 B-iv-cont-median
for O
50 O
mg O
of O
balugrastim O
, O
and O
â‰ˆ O
45 B-cv-cont-median
for O
pegfilgrastim O
. O
Antibody B-outcome
response I-outcome
to O
balugrastim O
was O
low O
and O
transient O
, O
with O
no O
neutralizing O
effect O
. O
Once O
- O
per O
- O
cycle O
balugrastim O
is O
not O
inferior O
to O
pegfilgrastim O
in O
reducing B-outcome
cycle I-outcome
1 I-outcome
DSN I-outcome
in O
breast O
cancer O
patients O
receiving O
chemotherapy O
; O
both O
drugs O
have O
comparable O
safety O
profiles O
. O
This O
paper O
provides O
efficacy O
and O
safety O
data O
for O
a O
new O
, O
once O
- O
per O
- O
cycle O
granulocyte O
colony O
- O
stimulating O
factor O
, O
balugrastim O
, O
for O
the O
prevention O
of O
chemotherapy O
- O
induced O
neutropenia O
in O
patients O
with O
breast O
cancer O
receiving O
myelosuppressive O
chemotherapy O
. O
In O
this O
phase O
III O
trial O
, O
balugrastim O
was O
shown O
to O
be O
not O
inferior O
to O
pegfilgrastim O
in O
the O
duration O
of O
severe O
neutropenia O
in O
cycle O
1 O
of O
doxorubicin O
/ O
docetaxel O
chemotherapy O
, O
and O
the O
safety O
profiles O
of O
the O
two O
agents O
were O
similar O
. O
Once O
- O
per O
- O
cycle O
balugrastim O
is O
a O
safe O
and O
effective O
alternative O
to O
pegfilgrastim O
for O
hematopoietic O
support O
in O
patients O
with O
breast O
cancer O
receiving O
myelosuppressive O
chemotherapy O
associated O
with O
a O
greater O
than O
20 O
% O
risk O
of O
developing O
febrile O
neutropenia O
. O

Biophysical O
skin O
measurements O
to O
evaluate O
the O
effectiveness O
of O
photobiomodulation B-intervention
therapy I-intervention
in O
the O
prevention O
of O
acute B-condition
radiation I-condition
dermatitis I-condition
in O
breast O
cancer O
patients O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
objectively O
the O
effectiveness O
of O
photobiomodulation O
therapy O
( O
PBMT O
) O
for O
the O
prevention O
of O
acute O
radiation O
dermatitis O
( O
ARD O
) O
by O
using O
biophysical O
skin O
measurements O
. O
A O
randomized O
, O
placebo O
- O
controlled O
trial O
with O
120 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
who I-eligibility
underwent I-eligibility
an I-eligibility
identical I-eligibility
radiotherapy I-eligibility
( I-eligibility
RT I-eligibility
) I-eligibility
regimen I-eligibility
post I-eligibility
- I-eligibility
lumpectomy I-eligibility
was O
performed O
( O
TRANSDERMIS O
trial O
) O
. O
Patients O
were O
randomized O
to O
receive O
PBM O
( O
808 O
nm O
CW O
/ O
905 O
nm O
pulsed O
, O
168 O
mW O
/ O
cm O
2 O
, O
spot O
size O
19.6 O
cm O
2 O
, O
fluence O
4 O
J O
/ O
cm O
2 O
) O
or O
placebo B-control
treatments O
from O
the O
first O
day O
of O
RT O
( O
2 O
Ã— O
/ O
week O
) O
. O
Biophysical O
skin O
measurements O
were O
collected O
to O
assess O
the O
skin O
pigmentation O
and O
barrier O
function O
. O
Measurements O
were O
collected O
at O
the O
first O
day O
of O
RT O
, O
a O
RT O
dose O
of O
40 O
Gray O
( O
Gy O
) O
, O
and O
the O
end O
of O
RT O
( O
66 O
Gy O
) O
. O
The O
incidence B-outcome
of I-outcome
moist I-outcome
desquamation I-outcome
was O
significantly O
higher O
in O
the O
control O
than O
in O
the O
PBMT O
group O
at O
the O
end O
of O
RT O
( O
30 B-cv-bin-percent
vs. O
7 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
odds O
ratio O
= O
6 O
, O
p O
= O
0.004 O
) O
. O
The O
biophysical O
skin O
measures O
showed O
that O
the O
mean O
percentage O
change O
from O
the O
baseline O
transepidermal B-outcome
water I-outcome
loss I-outcome
( I-outcome
TEWL I-outcome
) I-outcome
, O
erythema B-outcome
, O
and O
melanin B-outcome
values I-outcome
was O
significantly O
higher O
in O
the O
control O
than O
in O
the O
PBMT O
group O
at O
the O
end O
of O
RT O
( O
ps O
< O
0.05 O
) O
. O
Logistic O
regression O
analysis O
revealed O
that O
the O
risk O
on O
moist B-outcome
desquamation I-outcome
was O
significantly O
increased O
for O
patients O
with O
a O
large O
( O
> O
800 O
cc O
) O
breast O
volume O
( O
odds O
ratio O
= O
4 O
, O
p O
= O
0.017 O
) O
. O
This O
is O
the O
first O
randomized O
controlled O
trial O
demonstrating O
by O
objective O
measurements O
that O
PBMT O
is O
effective O
in O
reducing O
the O
incidence O
of O
moist O
desquamation O
in O
breast O
cancer O
patients O
undergoing O
RT O
. O
Additionally O
, O
a O
large O
breast O
volume O
is O
an O
important O
risk O
factor O
for O
the O
development O
of O
moist O
desquamation O
. O

Patterns O
of O
HER B-intervention
2 I-intervention
testing I-intervention
in O
the O
management O
of O
primary O
breast O
cancer O
. O
Women O
with O
invasive O
breast O
cancer O
should O
be O
tested O
for O
human O
epidermal O
growth O
factor O
receptor- O
2 O
( O
HER O
2 O
) O
status O
at O
the O
time O
of O
diagnosis O
. O
To O
date O
, O
no O
population O
- O
based O
patterns O
of O
use O
studies O
have O
examined O
demographic O
and O
clinicopathologic O
factors O
associated O
with O
decisions O
by O
clinicians O
to O
test O
patients O
. O
We O
reviewed O
summary O
pathology O
reports O
submitted O
to O
the O
Connecticut B-location
Tumor O
Registry O
for O
all O
Black B-intervention
/ I-intervention
African I-intervention
American I-intervention
( O
B O
/ O
AA O
) O
women O
( O
n= O
644 B-intervention-participants
) O
and O
a O
7 O
% O
random O
sample O
( O
n= O
720 B-control-participants
) O
of O
White B-control
women B-eligibility
diagnosed I-eligibility
in I-eligibility
2000 I-eligibility
- I-eligibility
2003 I-eligibility
with I-eligibility
primary I-eligibility
invasive I-eligibility
breast I-eligibility
carcinoma I-eligibility
. O
Receipt O
of O
a O
HER O
2 O
test O
( O
yes O
vs. O
no O
) O
was O
examined O
in O
relation O
to O
patient O
race O
, O
age O
, O
socioeconomic O
status O
, O
year O
of O
diagnosis O
, O
estrogen O
receptor O
( O
ER O
) O
status O
, O
tumor O
grade O
, O
lymph O
node O
status O
, O
size O
and O
stage O
at O
diagnosis O
. O
A O
greater O
proportion O
of O
tumors O
from O
B O
/ O
AA O
patients O
were O
tested B-outcome
compared O
to O
those O
of O
White O
women O
( O
69.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
61.9 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
< O
0.05 O
) O
. O
Tumors O
of O
patients O
under O
the O
age O
of O
60 O
were O
1.50 O
-times O
more O
likely O
than O
older O
women O
to O
have O
been O
tested O
, O
and O
B O
/ O
AA O
women O
were O
1.40 O
-times O
more O
likely O
than O
White O
patients O
to O
be O
tested O
. O
HER O
2 O
testing O
was O
more O
likely O
to O
be O
observed O
when O
information O
also O
was O
reported O
about O
ER B-outcome
status I-outcome
( O
OR= O
15.9 O
, O
p O
< O
0.001 O
) O
, O
tumor B-outcome
grade I-outcome
( O
OR= O
2.28 O
, O
p O
< O
0.05 O
) O
, O
tumor B-outcome
size I-outcome
( O
OR= O
2.16 O
, O
p O
< O
0.05 O
) O
, O
and O
lymph B-outcome
node I-outcome
status I-outcome
( O
OR= O
2.06 O
, O
p O
< O
0.05 O
) O
. O
Variation O
in O
which O
breast O
cancer O
patients O
received O
HER O
2 O
testing O
appears O
to O
reflect O
expectations O
about O
a O
woman O
's O
prognosis O
. O
Discrepancies O
in O
receipt O
of O
testing O
deserve O
further O
study O
as O
current O
guidelines O
call O
for O
all O
tumors O
to O
be O
assessed O
in O
order O
to O
adequately O
characterize O
prognosis O
and O
determine O
eligibility O
for O
HER O
2 O
- O
targeted O
therapy O
. O

Prevention O
of O
anastrozole B-condition
induced I-condition
bone I-condition
loss I-condition
with O
monthly O
oral O
ibandronate B-intervention
: O
Final O
5 O
year O
results O
from O
the O
ARIBON O
trial O
. O
The O
ARIBON O
trial O
is O
a O
double O
blind O
, O
randomised O
, O
placebo O
controlled O
study O
designed O
to O
evaluate O
the O
impact O
of O
ibandronate O
on O
bone O
mineral O
density O
( O
BMD O
) O
in O
women O
taking O
anastrozole O
for O
adjuvant O
treatment O
of O
breast O
cancer O
. O
131 B-total-participants
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
were O
recruited O
to O
the O
study O
. O
Of O
these O
, O
13 B-total-participants
had O
osteoporosis O
, O
50 B-total-participants
osteopenia O
and O
68 B-total-participants
normal O
BMD O
. O
Patients O
with O
osteoporosis O
at O
baseline O
were O
treated O
with O
monthly O
oral O
ibandronate O
150 O
Ã‚ O
mg O
for O
5 O
years O
; O
osteopenic O
patients O
were O
randomised O
to O
receive O
either O
ibandronate O
or O
placebo B-control
for O
two O
years O
and O
offered O
open O
label O
ibandronate O
depending O
upon O
the O
results O
of O
their O
2 O
-year O
BMD O
result O
. O
Of O
the O
20 B-intervention-participants
patients O
with O
osteopenia O
who O
were O
randomised O
to O
ibandronate O
and O
evaluable O
at O
the O
2 O
year O
visit O
, O
17 O
/ O
20 O
were O
not O
offered O
a O
bisphosphonate O
and O
the O
improvements O
in O
BMD B-outcome
accrued O
during O
the O
first O
2 O
years O
were O
lost O
both O
at O
the O
LS O
( O
- O
3.21 O
% O
) O
and O
TH O
( O
- O
5.0 O
% O
) O
. O
Of O
the O
16 B-control-participants
patients O
randomised O
to O
placebo O
8 O
/ O
16 O
with O
high O
rates O
of O
bone O
loss O
during O
years O
0 O
- O
2 O
received O
ibandronate O
over O
the O
next O
3 O
years O
with O
improvements B-outcome
in I-outcome
BMD I-outcome
of O
+ O
5.01 O
and O
+ O
1.19 O
at O
the O
LS O
and O
TH O
respectively O
. O
The O
8 B-control-participants
patients O
who O
were O
not O
offered O
a O
bisphosphonate O
experienced O
relatively O
little O
change B-outcome
in I-outcome
BMD I-outcome
throughout O
the O
5 O
years O
of O
the O
study O
( O
LS O
+ O
0.15 O
% O
, O
TH O
- O
2.72 O
% O
) O
. O
BMD B-outcome
increased I-outcome
steadily O
in O
the O
9 O
/ O
13 O
patients O
initially O
identified O
as O
having O
osteoporosis O
( O
LS O
+ O
9.65 O
% O
, O
TH O
+ O
2.72 O
% O
) O
. O
Monthly O
oral O
ibandronate O
provides O
an O
option O
to O
clinicians O
considering O
use O
of O
a O
bisphosphonate O
to O
prevent O
bone O
loss O
during O
aromatase O
inhibitor O
therapy O
. O

The O
effectiveness O
of O
a O
clinical O
and O
home O
- O
based O
physical B-intervention
activity I-intervention
program I-intervention
and I-intervention
simple I-intervention
lymphatic I-intervention
drainage I-intervention
in O
the O
prevention O
of O
breast B-condition
cancer I-condition
- I-condition
related I-condition
lymphedema I-condition
: O
A O
prospective O
randomized O
controlled O
study O
. O
To O
investigate O
the O
effectiveness O
of O
a O
clinical O
and O
home O
- O
based O
, O
nurse O
- O
led O
physical O
activity O
program O
( O
PAP O
) O
and O
simple O
lymphatic O
drainage O
( O
SLD O
) O
in O
the O
prevention O
of O
breast O
cancer O
- O
related O
lymphedema O
. O
A O
total O
of O
52 B-total-participants
breast O
cancer O
patients O
were O
randomized O
to O
either O
a O
PAP O
and O
SLD O
program O
( O
n O
= O
25 B-intervention-participants
) O
or O
a O
control B-control
group I-control
( O
n O
= O
27 B-control-participants
) O
. O
Patients O
in O
both O
groups O
were O
also O
provided O
training O
for O
lymphedema O
. O
The O
PAP O
and O
SLD O
were O
administered O
through O
home O
visits O
by O
the O
investigators O
, O
twice O
a O
week O
for O
six O
weeks O
, O
in O
the O
intervention O
group O
. O
The O
control O
group O
did O
not O
undergo O
intervention O
. O
The O
circumference O
of O
the O
upper O
extremity O
, O
symptom O
severity O
, O
and O
physical O
function O
were O
measured O
in O
both O
groups O
. O
The O
upper B-outcome
extremity I-outcome
circumference I-outcome
increased O
by O
about O
two O
times O
from O
the O
baseline O
, O
in O
the O
control O
group O
, O
especially O
in O
the O
sixth O
week O
( O
p O
< O
0.05 O
) O
. O
Lymphedema B-outcome
- I-outcome
related I-outcome
symptom I-outcome
severity I-outcome
scores I-outcome
were O
found O
to O
decrease O
significantly O
in O
the O
intervention O
group O
, O
compared O
to O
those O
at O
the O
baseline O
( O
p O
< O
0.05 O
) O
. O
It O
was O
recommended O
that O
PAP O
and O
SLD O
, O
with O
a O
follow O
- O
up O
program O
, O
be O
used O
for O
patients O
who O
planned O
to O
undergo O
breast O
cancer O
surgery O
, O
starting O
from O
before O
surgery O
and O
continuing O
until O
after O
, O
to O
prevent O
breast O
cancer O
- O
related O
lymphedema O
. O

Effects O
of O
a O
physical B-intervention
therapy I-intervention
program I-intervention
combined I-intervention
with I-intervention
manual I-intervention
lymphatic I-intervention
drainage I-intervention
on O
shoulder B-condition
function I-condition
, I-condition
quality I-condition
of I-condition
life I-condition
, I-condition
lymphedema I-condition
incidence I-condition
, I-condition
and I-condition
pain I-condition
in O
breast O
cancer O
patients O
with O
axillary O
web O
syndrome O
following O
axillary O
dissection O
. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
effects O
of O
physical O
therapy O
( O
PT O
) O
combined O
with O
manual O
lymphatic O
drainage O
( O
MLD O
) O
on O
shoulder O
function O
, O
pain O
, O
lymphedema O
, O
visible O
cords O
, O
and O
quality O
of O
life O
( O
QOL O
) O
in O
breast O
cancer O
patients O
with O
axillary O
web O
syndrome O
( O
AWS O
) O
. O
In O
this O
prospective O
, O
randomized O
trial O
, O
41 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
visible I-eligibility
and I-eligibility
palpable I-eligibility
cords I-eligibility
on I-eligibility
the I-eligibility
arm I-eligibility
and I-eligibility
axilla I-eligibility
and I-eligibility
a I-eligibility
numeric I-eligibility
rating I-eligibility
scale I-eligibility
( I-eligibility
NRS I-eligibility
) I-eligibility
pain I-eligibility
score I-eligibility
of I-eligibility
> I-eligibility
3 I-eligibility
were O
randomly O
assigned O
to O
PT B-control
( O
3 O
times O
/ O
week O
for O
4 O
weeks O
; O
n O
= O
20 B-control-participants
) O
and O
PT O
combined O
with O
MLD O
( O
5 O
times O
/ O
week O
for O
4 O
weeks O
; O
PTMLD O
; O
n O
= O
21 B-intervention-participants
) O
groups O
. O
MLD O
was O
performed O
by O
a O
physical O
therapist O
and O
the O
patients O
themselves O
during O
week O
1 O
and O
weeks O
2 O
- O
4 O
, O
respectively O
. O
Arm O
volume O
, O
shoulder O
function O
( O
muscular O
strength O
; O
active O
range O
of O
motion O
; O
and O
disabilities O
of O
the O
arm O
, O
shoulder O
, O
and O
hand O
[ O
DASH O
] O
) O
; O
QOL O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
and O
Breast O
Cancer O
- O
Specific O
QOL O
questionnaires O
) O
, O
and O
pain O
( O
NRS O
) O
were O
assessed O
at O
baseline O
and O
after O
4 O
weeks O
of O
treatment O
. O
QOL B-outcome
including I-outcome
functional I-outcome
and I-outcome
symptom I-outcome
aspects I-outcome
, O
shoulder B-outcome
flexor I-outcome
strength I-outcome
, O
DASH B-outcome
, O
and O
NRS B-outcome
scores I-outcome
were O
significantly O
improved O
in O
both O
groups O
after O
the O
4 O
-week O
intervention O
( O
P O
< O
0.05 O
) O
. O
NRS B-outcome
score I-outcome
and O
arm B-outcome
volume I-outcome
were O
significantly O
lower O
in O
the O
PTMLD O
group O
than O
in O
the O
PT O
group O
( O
P O
< O
0.05 O
) O
. O
Lymphedema B-outcome
was O
observed O
in O
the O
PT O
( O
n O
= O
6 B-cv-bin-abs
) O
, O
but O
not B-iv-bin-abs
PTMLD O
, O
group O
( O
P O
< O
0.05 O
) O
. O
PT O
improves O
shoulder O
function O
, O
pain O
, O
and O
QOL O
in O
breast O
cancer O
patients O
with O
AWS O
and O
combined O
with O
MLD O
decreases O
arm O
lymphedema O
. O

Phase O
3 O
study O
comparing O
the O
use O
of O
docetaxel B-intervention
on I-intervention
an I-intervention
every- I-intervention
3 I-intervention
- I-intervention
week I-intervention
versus O
weekly B-control
schedule I-control
in O
the O
treatment O
of O
metastatic O
breast O
cancer O
. O
Previous O
studies O
have O
evaluated O
3 O
-week O
and O
weekly O
docetaxel O
schedules O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
The O
varying O
efficacy O
results O
and O
toxicity O
profiles O
noted O
in O
these O
earlier O
studies O
led O
to O
a O
comparison O
of O
the O
schedules O
to O
determine O
which O
was O
safer O
and O
more O
efficacious O
. O
A O
phase O
3 O
clinical O
trial O
was O
conducted O
in O
patients B-eligibility
with I-eligibility
MBC I-eligibility
who O
were O
treated O
with O
docetaxel O
either O
every O
3 O
weeks O
or O
once O
weekly O
to O
determine O
and O
compare O
response O
rate O
and O
duration O
, O
time O
to O
disease O
progression O
, O
progression O
- O
free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
toxicity O
. O
Patients O
were O
randomized O
to O
receive O
docetaxel O
at O
a O
starting O
dose O
of O
either O
75 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
or O
35 O
mg O
/ O
m O
( O
2 O
) O
weekly O
for O
3 O
consecutive O
weeks O
followed O
by O
1 O
week O
of O
rest O
. O
A O
total O
of O
118 B-total-participants
patients O
underwent O
efficacy O
analysis O
; O
59 B-intervention-participants
patients O
were O
randomized O
to O
the O
every- O
3 O
- O
week O
treatment O
arm O
and O
59 B-control-participants
to O
the O
weekly O
arm O
. O
The O
response B-outcome
rate I-outcome
was O
35.6 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
] O
, O
23.6 O
- O
49.1 O
% O
) O
for O
the O
every- O
3 O
- O
week O
arm O
versus O
20.3 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
11.0 O
- O
32.8 O
% O
) O
for O
the O
weekly O
arm O
. O
There O
was O
no O
statistical O
difference O
between O
the O
every O
3 O
-week O
and O
the O
weekly O
treatment O
arms O
with O
regard O
to O
median B-outcome
PFS I-outcome
( O
5.7 B-iv-cont-median
months I-iv-cont-median
vs O
5.5 B-cv-cont-median
months I-cv-cont-median
; O
P= O
. O
46 O
) O
or O
OS B-outcome
( O
18.3 B-iv-cont-median
months I-iv-cont-median
vs O
18.6 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P= O
. O
34 O
) O
. O
There O
was O
a O
higher O
overall B-outcome
toxicity I-outcome
rate I-outcome
( O
grades O
3 O
and O
4 O
, O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
[ O
version O
2.0 O
] O
) O
in O
the O
every- O
3 O
- O
week O
treatment O
arm O
versus O
the O
weekly O
treatment O
arm O
( O
88.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
55.9 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P= O
. O
0001 O
) O
. O
Compared O
with O
patients O
who O
received O
weekly O
docetaxel O
, O
those O
who O
received O
docetaxel O
every O
3 O
weeks O
had O
a O
higher O
response O
rate O
but O
experienced O
similar O
PFS O
and O
OS O
and O
a O
more O
pronounced O
toxicity O
. O

Dexrazoxane B-intervention
protects O
breast O
cancer O
patients O
with O
diabetes O
from O
chemotherapy B-condition
- I-condition
induced I-condition
cardiotoxicity I-condition
. O
To O
evaluate O
the O
cardioprotective O
effect O
of O
dexrazoxane O
( O
DEX O
) O
on O
chemotherapy O
in O
patients O
with O
breast B-eligibility
cancer I-eligibility
with I-eligibility
concurrent I-eligibility
type I-eligibility
2 I-eligibility
diabetes I-eligibility
mellitus I-eligibility
( I-eligibility
DM I-eligibility
2 I-eligibility
) I-eligibility
. O
Eighty B-total-participants
female O
patients O
with O
breast O
cancer O
with O
DM O
2 O
were O
randomly O
assigned O
to O
receive O
chemotherapy B-control
only I-control
or O
chemotherapy O
plus O
DEX O
. O
All O
patients O
received O
80 O
mg O
/ O
m O
epirubicin O
and O
500 O
mg O
/ O
m O
cyclophosphamide O
by O
intravenous O
infusion O
every O
3 O
weeks O
for O
a O
total O
of O
6 O
cycles O
. O
The O
group O
assigned O
to O
receive O
chemotherapy O
alone O
received O
placebo O
30 O
minutes O
before O
epirubicin O
administration O
. O
The O
group O
assigned O
to O
receive O
chemotherapy O
plus O
DEX O
received O
800 O
mg O
/ O
m O
DEX O
30 O
minutes O
before O
epirubicin O
administration O
. O
Cardiac O
function O
and O
hematology O
before O
and O
after O
6 O
cycles O
of O
chemotherapy O
were O
analyzed O
. O
There O
was O
no O
difference O
in O
baseline B-outcome
systole I-outcome
or I-outcome
diastole I-outcome
function I-outcome
between O
the O
2 O
DM O
2 O
groups O
. O
Patients O
receiving O
chemotherapy O
alone O
experienced O
significantly O
greater O
reductions B-outcome
in I-outcome
Ea I-outcome
and O
significantly O
greater O
elevations B-outcome
in I-outcome
E I-outcome
/ I-outcome
Ea I-outcome
and I-outcome
Tei I-outcome
index I-outcome
in O
comparison O
with O
patients O
receiving O
chemotherapy O
plus O
DEX O
. O
After O
chemotherapy O
, O
superoxide B-outcome
dismutase I-outcome
was O
significantly O
reduced O
, O
and O
serum O
malondialdehyde O
( O
MDA O
) O
was O
significantly O
increased O
in O
patients O
with O
DM O
2 O
. O
Serum B-outcome
superoxide I-outcome
dismutase I-outcome
levels I-outcome
were O
comparable O
between O
the O
2 O
groups O
before O
and O
after O
chemotherapy O
, O
MDA O
levels O
were O
comparable O
between O
the O
2 O
groups O
before O
chemotherapy O
, O
whereas O
serum O
MDA O
was O
significantly O
higher O
after O
chemotherapy O
in O
the O
chemotherapy O
alone O
group O
in O
comparison O
with O
the O
group O
that O
received O
DEX O
. O
DEX O
protects O
against O
cardiotoxicity O
induced O
by O
chemotherapy O
in O
patients O
with O
breast O
cancer O
with O
concurrent O
DM O
2 O
. O

Internet B-intervention
- I-intervention
based I-intervention
physical I-intervention
activity I-intervention
intervention O
for O
women O
with O
a O
family O
history O
of O
breast O
cancer O
. O
Physical O
inactivity O
is O
a O
modifiable O
risk O
factor O
for O
breast O
cancer O
. O
Physical O
activity O
interventions O
that O
can O
be O
delivered O
through O
the O
Internet O
have O
the O
potential O
to O
increase O
participant O
reach O
. O
The O
efficacy O
of O
an O
Internet O
- O
based O
physical O
activity O
intervention O
was O
tested O
in O
a O
sample O
of O
women O
at O
an O
elevated O
risk O
for O
breast O
cancer O
. O
A O
total O
of O
55 B-total-participants
women B-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
1 I-eligibility
first I-eligibility
- I-eligibility
degree I-eligibility
relative I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
but I-eligibility
no I-eligibility
personal I-eligibility
history I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
) I-eligibility
were O
randomized O
to O
a O
3 O
-month O
theoretically O
grounded O
Internet O
- O
based O
physical O
activity O
intervention O
or O
an O
active B-control
control I-control
arm I-control
. O
Minutes O
of O
moderate O
to O
vigorous O
physical O
activity O
, O
psychosocial O
mediators O
of O
physical O
activity O
adoption O
and O
maintenance O
, O
as O
well O
as O
worry O
and O
perceived O
risk O
of O
developing O
breast O
cancer O
were O
assessed O
at O
baseline O
, O
3 O
-month O
, O
and O
5 O
-month O
follow O
up O
. O
Participants O
were O
on O
average O
46.2 B-age
( I-age
SD I-age
= I-age
11.4 I-age
) I-age
years I-age
old O
with O
a O
body O
mass O
index O
of O
27.3 O
( O
SD O
= O
4.8 O
) O
kg O
/ O
m O
2 O
. O
The O
intervention O
arm O
significantly O
increased O
minutes B-outcome
of I-outcome
moderate I-outcome
to I-outcome
vigorous I-outcome
physical I-outcome
activity I-outcome
compared O
to O
the O
active O
control O
arm O
at B-outcome
3 I-outcome
months I-outcome
( O
213 B-iv-cont-mean
vs. O
129 B-cv-cont-mean
min I-cv-cont-mean
/ I-cv-cont-mean
week I-cv-cont-mean
) O
and O
5 B-outcome
months I-outcome
( O
208 B-iv-cont-mean
vs. O
119 B-cv-cont-mean
min I-cv-cont-mean
/ I-cv-cont-mean
week I-cv-cont-mean
; O
both O
ps O
< O
. O
001 O
) O
. O
Regression O
models O
indicated O
that O
participants O
in O
the O
intervention O
had O
significantly O
higher O
self B-outcome
- I-outcome
efficacy I-outcome
for I-outcome
physical I-outcome
activity I-outcome
at I-outcome
3 I-outcome
months I-outcome
( O
p O
< O
. O
01 O
) O
and O
borderline O
significantly O
higher O
self B-outcome
- I-outcome
efficacy I-outcome
at I-outcome
5 I-outcome
months I-outcome
( O
p O
= O
. O
05 O
) O
. O
Baseline B-outcome
breast I-outcome
cancer I-outcome
worry I-outcome
and O
perceived B-outcome
risk I-outcome
were O
not O
associated O
with O
physical O
activity O
. O
Findings O
from O
this O
study O
suggest O
that O
an O
Internet O
- O
based O
physical O
activity O
intervention O
may O
substantially O
increase O
physical O
activity O
in O
women O
with O
a O
family O
history O
of O
breast O
cancer O
. O

A O
randomised O
controlled O
trial O
to O
evaluate O
both O
the O
role O
and O
the O
optimal B-intervention
fractionation I-intervention
of I-intervention
radiotherapy I-intervention
in O
the O
conservative O
management O
of O
early O
breast O
cancer O
. O
Postoperative O
radiotherapy O
is O
routinely O
used O
in O
early O
breast O
cancer O
employing O
either O
50 O
Gy O
in O
25 O
daily O
fractions O
( O
long O
course O
) O
or O
40 O
Gy O
in O
15 O
daily O
fractions O
( O
short O
course O
) O
. O
The O
role O
of O
radiotherapy O
and O
shorter O
fractionation O
regimens O
require O
validation O
. O
Patients B-eligibility
with I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
and I-eligibility
II I-eligibility
disease I-eligibility
were O
randomised O
to O
receive O
immediate O
radiotherapy O
or O
delayed O
salvage O
treatment O
( O
no B-control
radiotherapy I-control
) O
. O
Patients O
receiving O
radiotherapy O
were O
further O
randomised O
between O
long O
( O
50 O
Gy O
in O
25 O
daily O
fractions O
) O
or O
short O
( O
40 O
Gy O
in O
15 O
daily O
fractions O
) O
regimens O
. O
The O
primary O
outcome O
measure O
was O
time B-outcome-measure
to I-outcome-measure
first I-outcome-measure
locoregional I-outcome-measure
relapse I-outcome-measure
. O
Reported O
results O
are O
at O
a O
median O
follow O
- O
up O
of O
16.9 O
years O
( O
interquartile O
range O
15.4 O
- O
18.8 O
) O
. O
In O
total O
, O
707 B-total-participants
women O
were O
recruited O
between O
1985 O
and O
1992 O
: O
median O
age O
59 B-age
years I-age
( O
range O
28 O
- O
80 O
) O
, O
68 O
% O
postmenopausal O
, O
median O
tumour O
size O
2.0 O
cm O
( O
range O
0.12 O
- O
8.0 O
) O
; O
271 O
patients O
have O
relapsed B-outcome
: O
110 B-iv-bin-abs
radiotherapy O
, O
161 B-cv-bin-abs
no O
radiotherapy O
. O
The O
site B-outcome
of I-outcome
first I-outcome
relapse I-outcome
was I-outcome
locoregional I-outcome
158 O
( O
64 O
% O
) O
and O
distant B-outcome
87 O
( O
36 O
% O
) O
. O
There O
was O
an O
estimated O
24 B-iv-bin-percent
% I-iv-bin-percent
reduction O
in O
the O
risk B-outcome
of I-outcome
any I-outcome
competing I-outcome
event I-outcome
( I-outcome
local I-outcome
relapse I-outcome
, I-outcome
distant I-outcome
relapse I-outcome
or I-outcome
death I-outcome
) I-outcome
with O
radiotherapy O
( O
hazard O
ratio O
= O
0.76 O
; O
95 O
% O
confidence O
interval O
0.65 O
, O
0.88 O
) O
. O
The O
benefit O
of O
radiotherapy O
treatment O
for O
all O
competing O
event O
types O
was O
statistically O
significant O
( O
X O
( O
Wald O
) O
( O
2 O
) O
= O
36.04 O
, O
P O
< O
0.001 O
) O
. O
Immediate O
radiotherapy O
reduced O
the O
risk B-outcome
of I-outcome
locoregional I-outcome
relapse I-outcome
by O
62 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.38 O
; O
95 O
% O
confidence O
interval O
0.27 O
, O
0.53 O
) O
, O
consistent O
across O
prognostic O
subgroups O
. O
No O
differences O
were O
seen O
between O
either O
radiotherapy O
fractionation O
schedules O
. O
This O
study O
confirmed O
better O
locoregional O
control O
for O
patients O
with O
early O
breast O
cancer O
receiving O
radiotherapy O
. O
A O
radiotherapy O
schedule O
of O
40 O
Gy O
in O
15 O
daily O
fractions O
is O
an O
efficient O
and O
effective O
regimen O
that O
is O
at O
least O
as O
good O
as O
the O
international O
conventional O
regimen O
of O
50 O
Gy O
in O
25 O
daily O
fractions O
. O

Effects O
of O
Music B-intervention
Therapy I-intervention
on O
Anesthesia O
Requirements O
and O
Anxiety O
in O
Women O
Undergoing O
Ambulatory O
Breast O
Surgery O
for O
Cancer O
Diagnosis O
and O
Treatment O
: O
A O
Randomized O
Controlled O
Trial O
. O
To O
investigate O
the O
effect O
of O
live O
and O
recorded O
perioperative O
music O
therapy O
on O
anesthesia O
requirements O
, O
anxiety O
levels O
, O
recovery O
time O
, O
and O
patient O
satisfaction O
in O
women O
experiencing O
surgery O
for O
diagnosis O
or O
treatment O
of O
breast O
cancer O
. O
Between O
2012 O
and O
2014 O
, O
207 B-total-participants
female B-eligibility
patients I-eligibility
undergoing I-eligibility
surgery I-eligibility
for I-eligibility
potential I-eligibility
or I-eligibility
known I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
patient O
- O
selected O
live O
music O
( O
LM O
) O
preoperatively O
with O
therapist O
- O
selected O
recorded O
music O
intraoperatively O
( O
n= O
69 B-intervention-participants
) O
, O
patient O
- O
selected O
recorded O
music O
( O
RM O
) O
preoperatively O
with O
therapist O
- O
selected O
recorded O
music O
intraoperatively O
( O
n= O
70 B-intervention-participants
) O
, O
or O
usual B-control
care I-control
( I-control
UC I-control
) I-control
preoperatively O
with O
noise O
- O
blocking O
earmuffs O
intraoperatively O
( O
n= O
68 B-control-participants
) O
. O
The O
LM O
and O
the O
RM O
groups O
did O
not O
differ O
significantly O
from O
the O
UC O
group O
in O
the O
amount O
of O
propofol O
required O
to O
reach O
moderate O
sedation O
. O
Compared O
with O
the O
UC O
group O
, O
both O
the O
LM O
and O
the O
RM O
groups O
had O
greater O
reductions O
( O
P O
< O
. O
001 O
) O
in O
anxiety B-outcome
scores I-outcome
preoperatively I-outcome
( O
mean O
changes O
[ O
and O
standard O
deviation O
: O
- B-iv-cont-mean
30.9 I-iv-cont-mean
[ O
36.3 B-iv-cont-sd
] O
, O
- B-iv-cont-mean
26.8 I-iv-cont-mean
[ O
29.3 B-iv-cont-sd
] O
, O
and O
0.0 B-cv-cont-mean
[ O
22.7 B-cv-cont-sd
] O
) O
, O
respectively O
. O
The O
LM O
and O
RM O
groups O
did O
not O
differ O
from O
the O
UC O
group O
with O
respect O
to O
recovery B-outcome
time I-outcome
; O
however O
, O
the O
LM O
group O
had O
a O
shorter O
recovery O
time O
compared O
with O
the O
RM O
group O
( O
a O
difference O
of O
12.4 O
minutes O
; O
95 O
% O
CI O
, O
2.2 O
to O
22.5 O
; O
P= O
. O
018 O
) O
. O
Satisfaction B-outcome
scores I-outcome
for O
the O
LM O
and O
RM O
groups O
did O
not O
differ O
from O
those O
of O
the O
UC O
group O
. O
Including O
music O
therapy O
as O
a O
complementary O
modality O
with O
cancer O
surgery O
may O
help O
manage O
preoperative O
anxiety O
in O
a O
way O
that O
is O
safe O
, O
effective O
, O
time O
- O
efficient O
, O
and O
enjoyable O
. O

Effectiveness O
of O
nurse B-intervention
- I-intervention
led I-intervention
group I-intervention
CBT I-intervention
for O
hot B-condition
flushes I-condition
and I-condition
night I-condition
sweats I-condition
in O
women O
with O
breast O
cancer O
: O
Results O
of O
the O
MENOS O
4 O
randomised O
controlled O
trial O
. O
Troublesome O
hot O
flushes O
and O
night O
sweats O
( O
HFNS O
) O
are O
experienced O
by O
many O
women O
after O
treatment O
for O
breast O
cancer O
, O
impacting O
significantly O
on O
sleep O
and O
quality O
of O
life O
. O
Cognitive O
behavioural O
therapy O
( O
CBT O
) O
is O
known O
to O
be O
effective O
for O
the O
alleviation O
of O
HFNS O
. O
However O
, O
it O
is O
not O
known O
if O
it O
can O
effectively O
be O
delivered O
by O
specialist O
nurses O
. O
We O
investigated O
whether O
group O
CBT O
, O
delivered O
by O
breast O
care O
nurses O
( O
BCNs O
) O
, O
can O
reduce O
the O
impact O
of O
HFNS O
. O
We O
recruited O
women B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
following I-eligibility
primary I-eligibility
treatment I-eligibility
with I-eligibility
seven I-eligibility
or I-eligibility
more I-eligibility
HFNS I-eligibility
/ I-eligibility
week I-eligibility
( O
including O
4 O
/ O
10 O
or O
above O
on O
the O
HFNS O
problem O
rating O
scale O
) O
, O
from O
six O
UK B-location
hospitals O
to O
an O
open O
, O
randomised O
, O
phase O
3 O
effectiveness O
trial O
. O
Participants O
were O
randomised O
to O
Group O
CBT O
or O
usual B-control
care I-control
( I-control
UC I-control
) I-control
. O
The O
primary O
endpoint O
was O
HFNS B-outcome-measure
problem I-outcome-measure
rating I-outcome-measure
at I-outcome-measure
26 I-outcome-measure
â€‰ I-outcome-measure
weeks I-outcome-measure
after I-outcome-measure
randomisation I-outcome-measure
. O
Secondary O
outcomes O
included O
sleep B-outcome-measure
, O
depression B-outcome-measure
, O
anxiety B-outcome-measure
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
. O
Between O
2017 O
and O
2018 O
, O
130 B-total-participants
participants O
were O
recruited O
( O
CBT O
: O
63 B-intervention-participants
, O
control O
: O
67 B-control-participants
) O
. O
We O
found O
a O
46 O
% O
( O
6.9 O
- O
3.7 O
) O
reduction B-outcome
in I-outcome
the I-outcome
mean I-outcome
HFNS I-outcome
problem O
rating O
score O
from O
randomisation O
to O
26 O
weeks O
in O
the O
CBT O
arm O
and O
a O
15 O
% O
( O
6.5 O
- O
5.5 O
) O
reduction O
in O
the O
UC O
arm O
( O
adjusted O
mean O
difference O
- O
1.96 O
, O
CI O
- O
3.68 O
to O
- O
0.23 O
, O
P O
= O
. O
039 O
) O
. O
Secondary O
outcomes O
, O
including O
frequency B-outcome
of I-outcome
HFNS I-outcome
, I-outcome
sleep I-outcome
, I-outcome
anxiety I-outcome
and I-outcome
depression I-outcome
all O
improved O
significantly O
. O
Our O
results O
suggest O
that O
specialist O
nurses O
can O
be O
trained O
to O
deliver O
CBT O
effectively O
to O
alleviate O
troublesome O
menopausal O
hot O
flushes O
in O
women O
following O
breast O
cancer O
in O
the O
NHS O
setting O
. O

A O
planned O
, O
prospective O
comparison O
of O
short O
- O
term O
quality O
of O
life O
outcomes O
among O
older O
patients O
with O
breast O
cancer O
treated O
with O
standard B-intervention
chemotherapy I-intervention
in O
a O
randomized O
clinical O
trial O
vs. O
an O
observational B-control
study I-control
: O
CALGB O
# O
49907 O
and O
# O
369901 O
. O
Patients O
â‰¥ B-age
65 I-age
years I-age
old O
( O
" O
older O
" O
) O
are O
often O
not O
included O
in O
randomized O
clinical O
trials O
( O
RCT O
) O
, O
but O
when O
they O
are O
, O
care O
in O
an O
RCT O
might O
improve O
quality O
of O
life O
( O
QoL O
) O
. O
We O
conducted O
a O
prospective O
comparison O
of O
QoL O
among O
older O
women O
receiving O
standard O
chemotherapy O
from O
the O
same O
cooperative O
group O
physicians O
in O
an O
RCT O
vs. O
an O
observational O
study O
( O
" O
off O
- O
trial O
" O
) O
. O
Older B-eligibility
women I-eligibility
with I-eligibility
invasive I-eligibility
, I-eligibility
non I-eligibility
- I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
( O
n= O
150 B-intervention-participants
RCT O
; O
530 B-control-participants
off O
- O
trial O
) O
were O
included O
. O
Linear O
mixed O
- O
effects O
models O
tested O
associations O
between O
chemotherapy O
on- O
vs. O
off O
- O
trial O
and O
changes O
in O
EORTC O
( O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
) O
QoL O
scores O
over O
24 O
months O
, O
controlling O
for O
pre O
- O
treatment O
QoL O
, O
age O
, O
education O
, O
tumor O
factors O
, O
comorbidity O
, O
and O
other O
covariates O
. O
Anthracycline B-outcome
regimens I-outcome
were O
used O
by O
58 O
% O
of O
women O
treated O
on O
- O
trial O
vs. O
54 O
% O
of O
those O
treated O
off O
- O
trial O
. O
Women O
in O
the O
RCT O
reported O
an O
adjusted O
mean O
increase O
of O
13.7 B-iv-cont-mean
points I-iv-cont-mean
( O
95 O
% O
CI O
10.2 O
, O
17.1 O
) O
in O
global B-outcome
QoL I-outcome
at I-outcome
24 I-outcome
months I-outcome
( O
vs. O
mid O
- O
treatment O
) O
, O
while O
women O
treated O
off O
- O
trial O
had O
only O
an O
adjusted O
improvement O
of O
7.0 B-cv-cont-mean
points I-cv-cont-mean
( O
95 O
% O
CI O
3.5 O
, O
10.4 O
; O
p= O
. O
007 O
for O
difference O
in O
mean O
changes O
) O
. O
Women O
in O
the O
RCT O
had O
significantly O
greater O
improvement B-outcome
in I-outcome
emotional I-outcome
function I-outcome
than O
those O
treated O
off O
- O
trial O
, O
controlling O
for O
baseline O
; O
they O
also O
had O
greater O
reductions B-outcome
in I-outcome
therapy I-outcome
side I-outcome
effects I-outcome
and I-outcome
fatigue I-outcome
at O
24 O
months O
than O
women O
off O
- O
trial O
, O
controlling O
for O
covariates O
. O
There O
may O
be O
different O
QoL B-outcome
trajectories I-outcome
for O
older O
women O
undergoing O
breast O
cancer O
chemotherapy O
on- O
vs. O
off O
- O
trial O
. O
If O
confirmed O
, O
the O
results O
suggest O
that O
the O
extra O
monitoring O
and O
communication O
within O
an O
RCT O
could O
provide O
the O
infrastructure O
for O
interventions O
to O
address O
symptoms O
and O
improve O
QoL O
for O
the O
growing O
older O
cancer O
population O
. O

Satisfaction O
with O
care O
and O
adherence O
to O
treatment O
when O
using O
patient O
reported O
outcomes O
to O
individualize O
follow O
- O
up O
care O
for O
women O
with O
early O
breast O
cancer O
- O
a O
pilot O
randomized O
controlled O
trial O
. O
Background O
: O
The O
population O
of O
breast O
cancer O
survivors O
is O
increasing O
as O
a O
positive O
consequence O
of O
early O
detection O
and O
enhanced O
treatment O
. O
The O
disease O
and O
treatment O
associated O
side O
- O
effects O
or O
late O
- O
effects O
often O
impact O
on O
quality O
of O
life O
and O
daily O
life O
functions O
during O
survivorship O
. O
This O
calls O
for O
optimization O
of O
follow O
- O
up O
care O
. O
We O
aimed O
to O
evaluate O
the O
patients O
' O
satisfaction O
with O
the O
care O
provided O
, O
when O
using O
electronic O
patient O
reported O
outcomes O
( O
ePROs O
) O
to O
individualize O
follow O
- O
up O
care O
in O
women O
with O
early O
breast O
cancer O
receiving O
adjuvant O
endocrine O
therapy O
. O
Material O
and O
methods O
: O
Postmenopausal B-eligibility
women I-eligibility
treated I-eligibility
for I-eligibility
hormone I-eligibility
receptor I-eligibility
positive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
were O
included O
in O
a O
pilot O
randomized O
controlled O
trial O
and O
randomized O
to O
receive O
standard B-control
follow I-control
- I-control
up I-control
care I-control
with O
prescheduled O
consultations O
every O
six O
months O
or O
individualized B-intervention
follow I-intervention
- I-intervention
up I-intervention
care I-intervention
with O
the O
active O
use O
of O
ePROs O
to O
screen O
for O
the O
need O
of O
consultations O
. O
ePROs O
were O
distributed O
every O
third O
month O
over O
a O
two O
- O
year O
period O
. O
Primary O
outcomes O
were O
satisfaction B-outcome-measure
with I-outcome-measure
the I-outcome-measure
assigned I-outcome-measure
follow I-outcome-measure
- I-outcome-measure
up I-outcome-measure
care I-outcome-measure
and I-outcome-measure
unmet I-outcome-measure
needs I-outcome-measure
. O
Secondary O
outcomes O
were O
use B-outcome-measure
of I-outcome-measure
consultations I-outcome-measure
, O
adherence B-outcome-measure
to I-outcome-measure
treatment I-outcome-measure
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
. O
Results O
: O
Of O
the O
207 B-total-participants
consecutive O
patients O
who O
were O
potentially O
eligible O
for O
the O
study O
, O
134 B-total-participants
women O
were O
enrolled O
( O
65 O
% O
) O
. O
In O
total O
64 B-control-participants
women O
in O
standard O
care O
and O
60 B-intervention-participants
women O
in O
individualized O
care O
were O
analyzed O
. O
No O
statistically O
significant O
differences O
were O
reported O
in O
relation O
to O
satisfaction B-outcome
, O
unmet B-outcome
needs I-outcome
, O
adherence B-outcome
to I-outcome
treatment I-outcome
or O
quality B-outcome
of I-outcome
life I-outcome
. O
Women O
in O
standard O
care O
attended B-outcome
twice I-outcome
as I-outcome
many I-outcome
consultations I-outcome
during O
the O
two O
year O
follow O
- O
up O
period O
as O
women O
in O
individualized O
care O
; O
4.3 B-iv-cont-mean
( O
95 O
% O
CI O
3.9 O
- O
4.7 O
) O
versus O
2.1 B-cv-cont-mean
( O
95 O
% O
CI O
: O
1.6 O
- O
2.6 O
) O
, O
p O
< O
. O
001 O
. O
Conclusion O
: O
A O
significant O
reduction O
in O
consultations O
was O
observed O
for O
the O
group O
attending O
individualized O
care O
without O
compromising O
the O
patients O
' O
satisfaction O
, O
quality O
of O
life O
or O
adherence O
to O
treatment O
. O
For O
the O
majority O
of O
postmenopausal O
women O
treated O
for O
early O
breast O
cancer O
, O
implementation O
of O
ePROs O
to O
individualize O
follow O
- O
up O
care O
was O
feasible O
. O

Randomized O
, O
blinded O
trial O
of O
vitamin B-intervention
D I-intervention
3 I-intervention
for O
treating O
aromatase B-condition
inhibitor I-condition
- I-condition
associated I-condition
musculoskeletal I-condition
symptoms I-condition
( I-condition
AIMSS I-condition
) I-condition
. O
The O
purpose O
of O
the O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
vitamin O
D O
3 O
at O
4000 O
IU O
/ O
day O
as O
a O
treatment O
option O
for O
aromatase O
inhibitor O
- O
associated O
musculoskeletal O
symptoms O
( O
AIMSS O
) O
when O
compared O
with O
the O
usual B-control
care I-control
dose I-control
of O
600 O
IU O
D O
3 O
. O
We O
conducted O
a O
single O
site O
randomized O
, O
double O
- O
blind O
, O
phase O
3 O
clinical O
trial O
in O
women O
with O
AIMSS O
comparing O
change O
in O
symptoms O
, O
reproductive O
hormones O
and O
AI O
pharmacokinetics O
. O
Postmenopausal B-eligibility
women I-eligibility
â‰¥ I-eligibility
18 I-eligibility
Â  I-eligibility
years I-eligibility
with I-eligibility
stages I-eligibility
I I-eligibility
- I-eligibility
IIIA I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
taking I-eligibility
AI I-eligibility
and I-eligibility
experiencing I-eligibility
AIMSS I-eligibility
[ I-eligibility
breast I-eligibility
cancer I-eligibility
prevention I-eligibility
trial I-eligibility
symptom I-eligibility
scale I-eligibility
- I-eligibility
musculoskeletal I-eligibility
( I-eligibility
BCPT I-eligibility
- I-eligibility
MS I-eligibility
) I-eligibility
subscale I-eligibility
â‰¥ I-eligibility
1.5 I-eligibility
] I-eligibility
were O
admitted O
. O
Following O
randomization O
, O
116 B-total-participants
patients O
had O
a O
run O
- O
in O
period O
of O
1 O
month O
on O
600 O
IU O
D O
3 O
, O
then O
began O
the O
randomized O
assignment O
to O
either O
600 O
IU O
D O
3 O
( O
n O
= O
56 B-control-participants
) O
or O
4000 O
IU O
D O
3 O
( O
n O
= O
57 B-intervention-participants
) O
daily O
for O
6 O
months O
. O
The O
primary O
endpoint O
was O
a O
change B-outcome-measure
in I-outcome-measure
AIMSS I-outcome-measure
from O
baseline O
( O
after O
1 O
month O
run O
- O
in O
) O
on O
the O
BCPT O
- O
MS O
( O
general O
MS O
pain O
, O
joint O
pain O
, O
muscle O
stiffness O
, O
range O
for O
each O
question O
: O
0 O
= O
not O
at O
all O
to O
4 O
= O
extremely O
) O
. O
Groups O
had O
no O
statistically O
significant O
differences O
demographically O
or O
clinically O
. O
There O
were O
no O
discernable O
differences O
between O
the O
randomly O
allocated O
treatment O
groups O
at O
6 O
months O
in O
measures B-outcome
of I-outcome
AIMSS I-outcome
, O
pharmacokinetics B-outcome
of I-outcome
anastrozole I-outcome
and I-outcome
letrozole I-outcome
, O
serum B-outcome
levels I-outcome
of I-outcome
reproductive I-outcome
hormones I-outcome
, O
or O
adverse B-outcome
events I-outcome
. O
We O
found O
no O
significant O
changes B-outcome
in I-outcome
AIMSS I-outcome
measures I-outcome
between O
women O
who O
took O
4000 O
IU O
D O
3 O
daily O
compared O
with O
600 O
IU O
D O
3 O
. O
The O
4000 O
IU O
D O
3 O
did O
not O
adversely O
affect O
reproductive O
hormone O
levels O
or O
the O
steady O
state O
pharmacokinetics O
of O
anastrozole O
or O
letrozole O
. O
In O
both O
groups O
, O
serum O
25 O
( O
OH O
) O
D O
remained O
in O
the O
recommended O
range O
for O
bone O
health O
( O
â‰¥ O
30 O
ng O
/ O
mL O
) O
and O
safety O
( O
< O
50 O
ng O
/ O
mL O
) O
. O

Menopausal B-intervention
hormone I-intervention
therapy I-intervention
( I-intervention
HT I-intervention
) I-intervention
in O
patients O
with O
breast O
cancer O
. O
To O
assess O
the O
effect O
of O
menopausal O
hormone O
therapy O
( O
HT O
) O
on O
reoccurrence O
, O
cancer O
- O
related O
mortality O
, O
and O
overall O
mortality O
after O
a O
diagnosis O
of O
breast O
cancer O
. O
We O
performed O
a O
quantitative O
review O
of O
all O
studies O
reporting O
experience O
with O
menopausal O
HT O
for O
symptomatic O
use O
after O
a O
diagnosis O
of O
breast O
cancer O
. O
Rates O
of O
reoccurrence O
, O
cancer O
- O
related O
mortality O
, O
and O
overall O
mortality O
were O
calculated O
in O
this O
entire O
group O
. O
A O
subgroup O
analysis O
was O
performed O
in O
studies O
using O
a O
control O
population O
to O
assess O
the O
odds O
ratio O
of O
cancer O
reoccurrence O
and O
mortality O
in O
hormone O
users O
versus O
non O
- O
users O
. O
Fifteen O
studies O
encompassing O
1416 B-intervention-participants
breast O
cancer O
survivors O
using O
HT O
were O
identified O
. O
Seven O
studies O
included O
a O
control B-control
group I-control
comprised O
of O
1998 B-control-participants
patients O
. O
Among O
the O
1416 O
HT O
users O
, O
reoccurrence B-outcome
was O
noted O
in O
10.0 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
8.4 O
- O
11.6 O
% O
) O
. O
Cancer B-outcome
- I-outcome
related I-outcome
mortality I-outcome
occurred O
at O
a O
rate O
of O
2.6 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
1.8 O
- O
3.7 O
% O
) O
, O
while O
overall B-outcome
mortality I-outcome
was O
4.5 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
3.4 O
- O
5.8 O
% O
) O
. O
Compared O
to O
non O
- O
users O
, O
patients O
using O
HT O
had O
a O
decreased O
chance B-outcome
of I-outcome
reoccurrence I-outcome
and I-outcome
cancer I-outcome
- I-outcome
related I-outcome
mortality I-outcome
with O
combined O
odds O
ratio O
of O
0.5 O
( O
95 O
% O
CI O
: O
0.2 O
- O
0.7 O
) O
and O
0.3 O
( O
95 O
% O
CI O
: O
0.0 O
- O
0.6 O
) O
, O
respectively O
. O
In O
our O
review O
, O
menopausal O
HT O
use O
in O
breast O
cancer O
survivors O
was O
not O
associated O
with O
increased O
cancer B-outcome
reoccurrence I-outcome
, O
cancer B-outcome
- I-outcome
related I-outcome
mortality I-outcome
or I-outcome
total I-outcome
mortality I-outcome
. O
Despite O
conflicting O
opinions O
on O
this O
issue O
, O
it O
is O
important O
for O
primary O
care O
physicians O
to O
feel O
comfortable O
medically O
managing O
the O
increasing O
number O
of O
breast O
cancer O
survivors O
. O
In O
the O
subset O
of O
women O
with O
severe O
menopausal O
symptoms O
, O
HT O
options O
should O
be O
reviewed O
if O
non O
- O
hormonal O
methods O
are O
ineffective O
. O
Future O
trials O
should O
focus O
on O
better O
ways O
to O
identify O
breast O
cancer O
survivors O
who O
may O
safely O
benefit O
from O
HT O
versus O
those O
who O
have O
a O
substantial O
risk O
of O
reoccurrence O
with O
HT O
use O
. O

Long O
- O
term O
safety O
and O
survival O
outcomes O
from O
the O
Scandinavian O
Breast O
Group O
2004 O
- O
1 O
randomized O
phase O
II O
trial O
of O
tailored B-intervention
dose I-intervention
- I-intervention
dense I-intervention
adjuvant I-intervention
chemotherapy I-intervention
for O
early O
breast O
cancer O
. O
Although O
adjuvant O
polychemotherapy O
improves O
outcomes O
for O
early O
breast O
cancer O
, O
the O
significant O
variability O
in O
terms O
of O
pharmacokinetics O
results O
in O
differences O
in O
efficacy O
and O
both O
short O
and O
long O
- O
term O
toxicities O
. O
Retrospective O
studies O
support O
the O
use O
of O
dose O
tailoring O
according O
to O
the O
hematologic O
nadirs O
. O
The O
SBG O
2004 O
- O
1 O
trial O
was O
a O
randomized O
feasibility O
phase O
II O
study O
which O
assessed O
tailored O
dose O
- O
dense O
epirubicin O
and O
cyclophosphamide O
( O
EC O
) O
followed O
by O
docetaxel O
( O
T O
) O
( O
group O
A O
) O
, O
the O
same O
regimen O
with O
fixed O
doses O
( O
group O
B O
) O
and O
the O
TAC B-control
regimen I-control
( O
group O
C O
) O
. O
Women O
aged O
18 B-age
- I-age
65 I-age
Â  I-age
years I-age
, O
ECOG B-eligibility
PS I-eligibility
0 I-eligibility
- I-eligibility
1 I-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
one I-eligibility
positive I-eligibility
axillary I-eligibility
lymph I-eligibility
node I-eligibility
were O
randomized O
1 O
:1 O
:1 O
. O
The O
primary O
endpoint O
of O
the O
study O
was O
the O
safety B-outcome-measure
and I-outcome-measure
feasibility I-outcome-measure
of I-outcome-measure
the I-outcome-measure
treatment I-outcome-measure
. O
Toxicity O
was O
graded O
according O
to O
CTC O
- O
AE O
version O
3.0 O
. O
The O
design O
and O
short O
- O
term O
toxicity O
have O
been O
previously O
published O
. O
Here O
, O
we O
report O
safety O
and O
efficacy O
data O
after O
10 O
years O
of O
follow O
- O
up O
. O
A O
total O
of O
124 B-total-participants
patients O
were O
included O
in O
the O
study O
. O
After O
a O
median O
follow O
- O
up O
of O
10.3 O
years O
, O
the O
probability B-outcome
for I-outcome
10 I-outcome
-year I-outcome
survival I-outcome
was O
78.5 B-iv-bin-percent
, O
75.1 B-iv-bin-percent
, O
and O
63.4 B-cv-bin-percent
% I-cv-bin-percent
and O
for O
relapse B-outcome
free I-outcome
survival I-outcome
64.1 B-iv-bin-percent
, O
71.0 B-iv-bin-percent
, O
and O
59.5 B-cv-bin-percent
% I-cv-bin-percent
for O
groups O
A O
, O
B O
, O
and O
C O
, O
respectively O
. O
There O
were O
no O
cases O
of O
clinically O
diagnosed O
cardiotoxicity B-outcome
or I-outcome
hematologic I-outcome
malignancies I-outcome
. O
No O
patient O
was O
lost B-outcome
to I-outcome
follow I-outcome
- I-outcome
up I-outcome
. O
In O
this O
randomized O
phase O
II O
trial O
, O
tailored O
dose O
adjuvant O
chemotherapy O
was O
feasible O
, O
without O
an O
increased O
risk O
for O
long O
- O
term O
adverse O
events O
after O
a O
median O
follow O
- O
up O
of O
10 O
years O
. O

The O
effects O
of O
high B-intervention
- I-intervention
dose I-intervention
calcitriol I-intervention
and I-intervention
individualized I-intervention
exercise I-intervention
on O
bone O
metabolism O
in O
breast B-eligibility
cancer I-eligibility
survivors I-eligibility
on I-eligibility
hormonal I-eligibility
therapy I-eligibility
: O
a O
phase O
II O
feasibility O
trial O
. O
Cancer O
treatment O
- O
induced O
bone O
loss O
( O
CTIBL O
) O
is O
a O
long O
- O
term O
side O
effect O
of O
breast O
cancer O
therapy O
. O
Both O
calcitriol O
and O
weight O
- O
bearing O
exercise O
improve O
bone O
metabolism O
for O
osteoporotic O
patients O
, O
but O
are O
unproven O
in O
a O
breast O
cancer O
population O
. O
We O
used O
a O
novel O
high O
- O
dose O
calcitriol O
regimen O
with O
an O
individualized O
exercise O
intervention O
to O
improve O
bone O
metabolism O
in O
breast O
cancer O
survivors O
. O
We O
accrued O
41 B-total-participants
subjects O
to O
this O
open O
label O
, O
2 O
Ã— O
2 O
factorial O
, O
randomized O
feasibility O
trial O
. O
Breast O
cancer O
survivors O
were O
randomized O
to O
receive O
the O
following O
: O
( O
1 O
) O
calcitriol O
( O
45 O
micrograms O
/ O
week O
) O
, O
( O
2 O
) O
individualized O
exercise O
with O
progressive O
walking O
and O
resistance O
training O
, O
( O
3 O
) O
both O
, O
or O
( O
4 O
) O
a O
daily B-control
multivitamin I-control
( I-control
control I-control
condition I-control
) I-control
for O
12 O
weeks O
. O
Primary O
outcomes O
included O
changes B-outcome-measure
in I-outcome-measure
biomarkers I-outcome-measure
of I-outcome-measure
bone I-outcome-measure
formation I-outcome-measure
, O
bone B-outcome-measure
resorption I-outcome-measure
, O
and O
the O
bone B-outcome-measure
remodeling I-outcome-measure
index I-outcome-measure
, O
a O
composite O
measure O
of O
bone O
formation O
and O
resorption O
. O
Safety O
measures O
included O
clinical O
and O
biochemical O
adverse O
events O
. O
A O
main O
effect O
analysis O
was O
used O
for O
these O
endpoints O
. O
Hypercalcemia B-outcome
was O
limited O
to O
three O
grade O
I O
cases O
with O
no O
grade O
â‰¥ O
2 O
cases O
. O
Among O
exercisers O
, O
100 O
% O
engaged O
in O
the O
prescribed O
aerobic O
training O
and O
44.4 O
% O
engaged O
in O
the O
prescribed O
resistance O
training O
. O
Calcitriol O
significantly O
improved B-outcome
bone I-outcome
formation I-outcome
( O
Cohen O
's O
d O
= O
0.64 O
; O
p O
< O
0.01 O
) O
, O
resulting O
in O
a O
non O
- O
significant O
increase O
in O
the O
bone B-outcome
remodeling I-outcome
index I-outcome
( O
Cohen O
's O
d O
= O
0.21 O
; O
p O
= O
31 O
) O
. O
Exercise O
failed O
to O
improve B-outcome
any I-outcome
of I-outcome
the I-outcome
bone I-outcome
biomarkers I-outcome
. O
Both O
calcitriol O
and O
exercise O
were O
shown O
to O
be O
feasible O
and O
well B-outcome
tolerated I-outcome
. O
Calcitriol O
significantly O
improved O
bone B-outcome
formation I-outcome
, O
resulting O
in O
a O
net O
increase O
of O
bone O
metabolism O
. O
Compliance O
with O
the O
exercise O
intervention O
was O
sub O
- O
optimal O
, O
which O
may O
have O
led O
to O
a O
lack O
of O
effect O
of O
exercise O
on O
bone O
metabolism O
. O

A O
randomized O
, O
multi O
- O
center O
, O
open O
- O
label O
, O
phase O
III O
study O
of O
once O
- O
per O
- O
cycle O
DA- B-intervention
3031 I-intervention
, O
a O
pegylated O
G O
- O
CSF O
, O
in O
comparison O
with O
daily O
filgrastim B-control
in O
patients B-eligibility
receiving I-eligibility
TAC I-eligibility
chemotherapy I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
This O
multi O
- O
center O
, O
randomized O
, O
phase O
III O
study O
was O
conducted O
to O
demonstrate O
the O
non O
- O
inferiority O
of O
DA- O
3031 O
compared O
with O
daily O
filgrastim O
in O
patients O
during O
the O
first O
cycle O
of O
chemotherapy O
for O
breast O
cancer O
in O
terms O
of O
the O
duration O
of O
severe O
neutropenia O
( O
DSN O
) O
. O
Seventy B-total-participants
- I-total-participants
four I-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
receiving I-eligibility
combination I-eligibility
chemotherapy I-eligibility
with I-eligibility
docetaxel I-eligibility
, I-eligibility
doxorubicin I-eligibility
, I-eligibility
and I-eligibility
cyclophosphamide I-eligibility
( I-eligibility
TAC I-eligibility
) I-eligibility
were O
enrolled O
. O
All O
participants O
were O
randomized O
to O
receive O
either O
daily O
subcutaneous O
injections O
of O
filgrastim O
100 O
Î¼g O
/ O
m O
2 O
/ O
day O
for O
up O
to O
10 O
days O
or O
a O
single O
subcutaneous O
injection O
of O
DA- O
3031 O
at O
fixed O
doses O
of O
6 O
mg O
on O
day O
2 O
of O
each O
chemotherapy O
cycle O
. O
The O
mean B-outcome
duration I-outcome
of I-outcome
grade I-outcome
4 I-outcome
( I-outcome
G I-outcome
4 I-outcome
) I-outcome
neutropenia I-outcome
in I-outcome
cycle I-outcome
1 I-outcome
was O
2.08 B-cv-cont-mean
Â± O
0.85 B-cv-cont-sd
Â  I-cv-cont-sd
days I-cv-cont-sd
for O
the O
filgrastim O
group O
and O
2.28 B-iv-cont-mean
Â± O
1.14 B-iv-cont-sd
Â  I-iv-cont-sd
days I-iv-cont-sd
for O
the O
DA- O
3031 O
group O
. O
The O
difference O
between O
groups O
was O
0.2 O
Â± O
1.10 O
days O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
= O
- O
0.26 O
, O
0.66 O
) O
, O
which O
supported O
non O
- O
inferiority O
. O
No O
statistically O
significant O
differences O
were O
observed O
in O
nadir B-outcome
absolute I-outcome
neutrophil I-outcome
count I-outcome
( I-outcome
ANC I-outcome
) I-outcome
( O
154.34 B-cv-cont-mean
/mm I-cv-cont-mean
3 I-cv-cont-mean
and O
161.75 B-iv-cont-mean
/mm I-iv-cont-mean
3 I-iv-cont-mean
for O
the O
filgrastim O
and O
DA- O
3031 O
groups O
, O
respectively O
; O
P O
= O
0.8414 O
) O
or O
in O
time B-outcome
to I-outcome
ANC I-outcome
recovery I-outcome
( O
10.03 B-cv-cont-mean
Â± O
0.75 B-cv-cont-sd
and O
9.83 B-iv-cont-mean
Â± O
1.56 B-iv-cont-sd
Â  I-iv-cont-sd
days I-iv-cont-sd
in O
the O
filgrastim O
and O
DA- O
3031 O
groups O
, O
respectively O
; O
P O
= O
0.0611 O
) O
during O
cycle O
1 O
. O
Serious B-outcome
AEs I-outcome
occurred O
in O
six B-cv-bin-abs
( O
15.8 B-cv-bin-percent
Â  I-cv-bin-percent
% I-cv-bin-percent
) O
patients O
receiving O
filgrastim O
and O
in O
ten B-iv-bin-abs
( O
27.8 B-iv-bin-percent
Â  I-iv-bin-percent
% I-iv-bin-percent
) O
patients O
receiving O
DA- O
3031 O
; O
however O
, O
none O
was O
determined O
to O
be O
related O
to O
the O
study O
drug O
. O
DA- O
3031 O
and O
daily O
filgrastim O
are O
similar O
in O
regard O
to O
DSN O
and O
safety O
in O
breast O
cancer O
patients O
receiving O
TAC O
chemotherapy O
. O

[ O
Interest O
of O
a O
thrombin B-intervention
and I-intervention
fibrinogen I-intervention
combipatch I-intervention
in O
preventing O
breast O
cancer O
seroma B-condition
after O
lymph O
node O
dissection O
] O
. O
To O
evaluate O
the O
effect O
of O
combipatch O
TachoSil O
( O
Â® O
) O
in O
the O
prevention O
of O
seromas O
after O
axillary O
dissection O
in O
local O
breast O
cancer O
. O
PATIENTS O
ET O
MÃ‰THODES O
: O
A O
retrospective O
, O
case O
- O
control O
study O
conducted O
between O
January O
2007 O
and O
December O
2009 O
, O
in O
two O
departments O
of O
Obstetrics O
and O
Gynecology O
of O
the O
AP O
- O
HP O
. O
Sixty B-total-participants
- I-total-participants
six I-total-participants
patients O
( O
45 B-control-participants
in O
the O
control B-control
group I-control
and O
22 B-intervention-participants
in O
the O
group O
TachoSil O
( O
Â® O
) O
) O
who B-eligibility
have I-eligibility
undergone I-eligibility
an I-eligibility
axillary I-eligibility
dissection I-eligibility
alone I-eligibility
, I-eligibility
with I-eligibility
establishment I-eligibility
of I-eligibility
a I-eligibility
redon I-eligibility
or I-eligibility
with I-eligibility
lumpectomy I-eligibility
, O
were O
included O
. O
The O
total O
amount O
of O
lymph O
drained O
during O
the O
stay O
, O
the O
number O
of O
days O
of O
drainage O
, O
duration O
of O
hospitalization O
, O
the O
number O
of O
lymphoceles O
and O
the O
number O
of O
retrievals O
performed O
at O
the O
waning O
of O
hospitalization O
were O
collected O
. O
The O
population O
was O
similar O
in O
age O
, O
body O
mass O
index O
( O
BMI O
) O
, O
clinical O
and O
pathological O
data O
. O
There O
was O
no O
significant O
difference O
in O
terms O
of O
total B-outcome
volume I-outcome
of I-outcome
lymph I-outcome
drained I-outcome
( O
268.2 B-cv-cont-mean
Â± O
220.7 B-cv-cont-sd
mL I-cv-cont-sd
without O
TachoSil O
( O
Â® O
) O
and O
228.6 B-iv-cont-mean
Â± O
128.8 B-iv-cont-sd
mL I-iv-cont-sd
with O
TachoSil O
( O
Â® O
) O
, O
P O
= O
0.89 O
) O
and O
the O
number B-outcome
of I-outcome
days I-outcome
of I-outcome
drainage I-outcome
( O
3.9 B-cv-cont-mean
Â± O
1.6 B-cv-cont-sd
days I-cv-cont-sd
without O
TachoSil O
( O
Â® O
) O
and O
3.1 B-iv-cont-mean
Â± O
0.9 B-iv-cont-sd
days I-iv-cont-sd
with O
TachoSil O
( O
Â® O
) O
, O
P O
= O
0.10 O
) O
. O
The O
duration B-outcome
of I-outcome
hospitalization I-outcome
was O
significantly O
higher O
in O
the O
group O
TachoSil O
( O
Â® O
) O
( O
5 B-iv-cont-mean
Â± O
1.6 B-iv-cont-sd
days I-iv-cont-sd
with O
TachoSil O
( O
Â® O
) O
and O
3.8 B-cv-cont-mean
Â± O
1.1 B-cv-cont-sd
days I-cv-cont-sd
without O
TachoSil O
( O
Â® O
) O
, O
P O
= O
0.006 O
) O
. O
This O
study O
shows O
no O
benefit O
of O
combipatch O
( O
TachoSil O
( O
Â® O
) O
) O
in O
prevention O
of O
seromas O
after O
axillary O
lymph O
node O
dissection O
. O
A O
randomized O
study O
with O
large O
effective O
is O
necessary O
. O

A O
randomized O
trial O
of O
a O
telephone B-intervention
- I-intervention
delivered I-intervention
exercise I-intervention
intervention O
for O
non O
- O
urban O
dwelling O
women O
newly O
diagnosed O
with O
breast O
cancer O
: O
exercise O
for O
health O
. O
Physical O
activity O
is O
important O
following O
breast O
cancer O
. O
Trials O
of O
non O
- O
face O
- O
to O
- O
face O
interventions O
are O
needed O
to O
assist O
in O
reaching O
women O
living O
outside O
major O
metropolitan O
areas O
. O
This O
study O
seeks O
to O
evaluate O
the O
feasibility O
and O
effectiveness O
of O
a O
telephone O
- O
delivered O
, O
mixed O
aerobic O
and O
resistance O
exercise O
intervention O
for O
non O
- O
urban O
Australian B-ethinicity
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
. O
A O
randomized O
controlled O
trial O
comparing O
an O
8 O
-month O
intervention O
delivered O
by O
exercise O
physiologists O
( O
n O
= O
73 B-intervention-participants
) O
to O
usual B-control
care I-control
( O
n O
= O
70 B-control-participants
) O
. O
Sixty O
- O
one O
percent O
recruitment O
rate O
and O
96 O
% O
retention B-outcome
at O
12 O
months O
; O
79 O
% O
of O
women O
in O
the O
intervention O
group O
received O
at O
least O
75 O
% O
of O
calls O
; O
odds O
( O
OR O
, O
95 O
% O
CI O
) O
of O
meeting B-outcome
intervention I-outcome
targets I-outcome
favored O
the O
intervention O
group O
for O
resistance O
training O
( O
OR O
3.2 O
; O
1.2 O
, O
8.9 O
) O
and O
aerobic O
( O
OR O
2.1 O
; O
0.8 O
, O
5.5 O
) O
activity O
. O
Given O
the O
limited O
availability O
of O
physical O
activity O
programs O
for O
non O
- O
urban O
women O
with O
breast O
cancer O
, O
results O
provide O
strong O
support O
for O
feasibility O
and O
modest O
support O
for O
the O
efficacy O
of O
telephone O
- O
delivered O
interventions O
. O

Effects O
of O
prescribed O
aerobic B-intervention
exercise I-intervention
volume O
on O
physical O
activity O
and O
sedentary O
time O
in O
postmenopausal O
women O
: O
a O
randomized O
controlled O
trial O
. O
Physical O
activity O
has O
emerged O
as O
an O
important O
lifestyle O
factor O
for O
primary O
prevention O
of O
numerous O
diseases O
, O
including O
postmenopausal O
breast O
cancer O
. O
No O
study O
to O
date O
has O
assessed O
the O
acute O
and O
long O
- O
term O
effects O
of O
year O
- O
long O
aerobic O
exercise O
programs O
differing O
in O
prescribed O
exercise O
volume O
on O
physical O
activity O
and O
sedentary O
time O
in O
postmenopausal O
women O
. O
Therefore O
, O
we O
aimed O
to O
examine O
the O
effects O
of O
two O
moderate O
- O
vigorous O
intensity O
exercise O
doses O
on O
total O
, O
light O
and O
moderate O
- O
vigorous O
intensity O
physical O
activity O
times O
, O
and O
sedentary O
time O
in O
postmenopausal O
women O
during O
the O
year O
- O
long O
intervention O
and O
one O
year O
later O
. O
The O
Breast O
Cancer O
and O
Exercise O
Trial O
in O
Alberta O
( O
BETA O
) O
was O
a O
two O
- O
center O
, O
two O
- O
arm O
, O
12 O
-month O
randomized O
controlled O
trial O
that O
included O
400 B-total-participants
previously B-eligibility
inactive I-eligibility
postmenopausal I-eligibility
women I-eligibility
randomized O
to O
either O
150 O
( O
MODERATE O
) O
or O
300 O
( O
HIGH O
) O
minutes O
/ O
week O
of O
aerobic O
exercise O
. O
Physical O
activity O
and O
sedentary O
time O
were O
assessed O
at O
baseline O
, O
6 O
- O
( O
intervention O
mid O
- O
point O
) O
, O
12 O
- O
( O
prior O
to O
end O
of O
intervention O
) O
and O
24 O
-months O
( O
follow O
- O
up O
) O
with O
waist O
- O
mounted O
accelerometers O
( O
Actigraph O
GTX O
3 O
Ã‚ O
Â® O
) O
. O
Self O
- O
reported O
activity O
and O
sedentary O
time O
at O
baseline O
, O
12 O
- O
and O
24 O
-months O
was O
also O
assessed O
( O
Past O
Year O
Total O
Physical O
Activity O
Questionnaire O
and O
SIT O
- O
Q O
) O
. O
Intention O
- O
to O
- O
treat O
analyses O
were O
conducted O
using O
linear O
mixed O
models O
and O
adjusted O
for O
baseline O
variables O
. O
Both O
physical O
activity O
interventions O
led O
to O
increases O
in O
objective O
and O
subjective O
measures O
of O
total B-outcome
and I-outcome
moderate I-outcome
- I-outcome
vigorous I-outcome
intensity I-outcome
/ I-outcome
recreational I-outcome
physical I-outcome
activity I-outcome
time I-outcome
, O
coupled O
with O
decreases O
in O
sedentary B-outcome
time I-outcome
, O
at B-outcome
6 I-outcome
- I-outcome
and I-outcome
12 I-outcome
-months I-outcome
compared O
to O
baseline O
. O
Additionally O
, O
greater O
increases O
in O
accelerometry B-outcome
- I-outcome
derived I-outcome
total I-outcome
physical I-outcome
activity I-outcome
time I-outcome
at I-outcome
6 I-outcome
- I-outcome
and I-outcome
12 I-outcome
-months I-outcome
, O
and O
self B-outcome
- I-outcome
reported I-outcome
recreational I-outcome
activity I-outcome
time I-outcome
at I-outcome
12 I-outcome
-months I-outcome
, O
compared O
to O
baseline O
were O
noted O
in O
the O
HIGH O
versus O
MODERATE O
groups O
. O
Decreases O
in O
total B-outcome
, I-outcome
light I-outcome
and I-outcome
moderate I-outcome
- I-outcome
vigorous I-outcome
intensity I-outcome
physical I-outcome
activity I-outcome
time I-outcome
, I-outcome
and O
an O
increase O
in O
sedentary B-outcome
time I-outcome
, O
in O
both O
groups O
were O
noted O
at O
24 O
-months O
compared O
to O
12 O
-months O
. O
A O
decrease O
in O
light B-outcome
intensity I-outcome
physical I-outcome
activity I-outcome
time I-outcome
in O
both O
groups O
at B-outcome
24 I-outcome
-months I-outcome
compared O
to O
baseline O
was O
also O
noted O
. O
These O
findings O
have O
important O
health O
implications O
, O
suggesting O
that O
total O
physical O
activity O
time O
can O
be O
increased O
with O
greater O
volumes O
of O
prescribed O
exercise O
, O
but O
that O
additional O
support O
and O
resources O
could O
be O
used O
to O
promote O
the O
maintenance O
of O
these O
high O
levels O
of O
aerobic O
exercise O
participation O
following O
study O
completion O
. O
clinicaltrials.gov O
identifier O
: O
NCT O
01435005 O
( O
BETA O
Trial O
) O
. O
Registred O
September O
15 O
th O
2011 O
( O
retrospectively O
registered O
) O
. O

Long O
- O
term O
effects O
on O
the O
incidence O
of O
second O
primary O
cancers O
in O
a O
randomized O
trial O
of O
two O
and O
five O
years O
of O
adjuvant O
tamoxifen B-intervention
. O
Tamoxifen O
is O
a O
well O
established O
treatment O
for O
breast O
cancer O
, O
but O
its O
long O
- O
term O
effects O
on O
the O
incidence O
of O
secondary O
cancers O
are O
not O
fully O
evaluated O
. O
We O
have O
studied O
4128 B-total-participants
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
alive I-eligibility
and I-eligibility
free I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
recurrence I-eligibility
after I-eligibility
two I-eligibility
years I-eligibility
of I-eligibility
tamoxifen I-eligibility
, O
and O
who O
were O
randomized O
to O
receive O
totally O
two O
or O
five O
years O
of O
therapy O
. O
Compared O
to O
patients O
randomized O
to O
two O
years O
of O
tamoxifen O
the O
incidence B-outcome
of I-outcome
contralateral I-outcome
breast I-outcome
cancer I-outcome
[ O
hazard O
ratio O
( O
HR O
) O
0.73 O
; O
95 O
% O
CI O
0.56 O
- O
0.96 O
] O
and O
of O
lung B-outcome
cancer I-outcome
( O
HR O
0.45 O
; O
95 O
% O
CI O
0.27 O
- O
0.77 O
) O
, O
especially O
squamous O
cell O
and O
small O
cell O
lung O
cancer O
, O
were O
reduced O
in O
the O
five O
- O
year O
group O
, O
and O
similar O
results O
were O
seen O
when O
restricting O
the O
analysis O
to O
the O
10 O
-year O
period O
after O
treatment O
stopped O
. O
An O
increased O
incidence B-outcome
of I-outcome
endometrial I-outcome
cancer I-outcome
was O
observed O
in O
the O
five O
- O
year O
group O
, O
but O
the O
excess O
risk O
decreased O
over O
time O
. O
Further O
studies O
of O
the O
effects O
of O
tamoxifen O
on O
the O
risk O
of O
different O
histological O
types O
of O
lung O
cancer O
are O
needed O
. O

Endocrine B-intervention
therapy I-intervention
with I-intervention
or I-intervention
without I-intervention
whole I-intervention
breast I-intervention
irradiation I-intervention
in O
low O
- O
risk O
breast O
cancer O
patients O
after O
breast O
- O
conserving O
surgery O
: O
10 O
-year O
results O
of O
the O
Austrian O
Breast O
and O
Colorectal O
Cancer O
Study O
Group O
8 O
A O
trial O
. O
To O
investigate O
long O
- O
term O
results O
of O
patients O
with O
hormonal O
receptor O
- O
positive O
breast O
cancer O
treated O
with O
breast O
- O
conserving O
surgery O
( O
BCS O
) O
and O
consecutive O
endocrine O
therapy O
( O
ET O
) O
with O
or O
without O
whole O
breast O
irradiation O
( O
WBI O
) O
. O
Within O
the O
8 O
A O
trial O
of O
the O
Austrian B-location
Breast O
and O
Colorectal O
Cancer O
Study O
Group O
, O
a O
total O
of O
869 B-total-participants
patients O
received O
ET O
after O
BCS O
which O
was O
randomly O
followed O
by O
WBI O
( O
n O
= O
439 B-intervention-participants
, O
group O
1 O
) O
or O
observation B-control
( O
n O
= O
430 B-control-participants
, O
group O
2 O
) O
. O
WBI O
was O
applied O
up O
to O
a O
mean O
total O
dosage O
of O
50 O
Gy O
( O
+ O
/- O
10 O
Gy O
boost O
) O
in O
conventional O
fractionation O
. O
After O
a O
median O
follow O
- O
up O
of O
9.89 O
years O
, O
10 B-iv-bin-abs
in B-outcome
- I-outcome
breast I-outcome
recurrences I-outcome
( I-outcome
IBRs I-outcome
) I-outcome
were O
observed O
in O
group O
1 O
and O
31 B-cv-bin-abs
in O
group O
2 O
, O
resulting O
in O
a O
10 B-outcome
-year I-outcome
local I-outcome
recurrence I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
LRFS I-outcome
) I-outcome
of O
97.5 B-iv-bin-percent
% I-iv-bin-percent
and O
92.4 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
p O
= O
0.004 O
) O
. O
This O
translated O
into O
significantly O
higher O
rates B-outcome
for I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
: O
94.5 B-iv-bin-percent
% I-iv-bin-percent
group O
1 O
vs O
88.4 B-cv-bin-percent
% I-cv-bin-percent
group O
2 O
, O
p O
= O
0.0156 O
. O
For O
distant B-outcome
metastases I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DMFS I-outcome
) I-outcome
and O
overall B-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
, O
respective O
10 O
-year O
rates O
amounted O
96.7 B-iv-bin-percent
% I-iv-bin-percent
and O
86.6 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
1 O
versus O
96.4 B-cv-bin-percent
% I-cv-bin-percent
and O
87.6 B-cv-bin-percent
% I-cv-bin-percent
, O
for O
group O
2 O
( O
ns O
) O
. O
WBI B-outcome
( O
hazard O
ratio O
[ O
HR O
] O
: O
0.27 O
, O
p O
< O
0.01 O
) O
and O
tumour B-outcome
grading I-outcome
( O
HR O
: O
3.76 O
, O
p O
= O
0.03 O
) O
were O
found O
as O
significant O
predictors O
for O
IBR O
in O
multiple O
cox O
regression O
analysis O
. O
After O
a O
median O
follow O
- O
up O
of O
10 O
years O
, O
WBI O
resulted O
in O
a O
better O
local B-outcome
control I-outcome
and O
DFS B-outcome
compared O
with O
ET O
alone O
. O
The O
omission O
of O
WBI O
and O
tumour O
grading O
, O
respectively O
, O
were O
the O
only O
negative O
predictors O
for O
LRFS O
. O

Project O
connect O
online O
: O
user O
and O
visitor O
experiences O
of O
an O
Internet B-intervention
- I-intervention
based I-intervention
intervention I-intervention
for O
women O
with O
breast O
cancer O
. O
This O
study O
's O
purpose O
was O
to O
characterize O
the O
experience O
of O
patients O
with O
breast O
cancer O
randomly O
assigned O
to O
the O
intervention O
arm O
of O
Project O
Connect O
Online O
( O
PCO O
) O
, O
a O
randomized O
controlled O
trial O
of O
an O
Internet O
- O
based O
intervention O
, O
and O
to O
examine O
relationships O
between O
website O
use O
variables O
and O
psychosocial O
outcomes O
. O
In O
the O
larger O
PCO O
trial O
, O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
( O
n O
= O
88 B-total-participants
) O
were O
randomly O
assigned O
to O
an O
intervention O
or O
a O
waiting B-control
- I-control
list I-control
control I-control
. O
This O
report O
pertains O
to O
the O
46 B-intervention-participants
women O
in O
the O
intervention O
arm O
, O
a O
3 O
-h O
workshop O
for O
creation O
of O
personal O
websites O
with O
a O
blog O
function O
to O
communicate O
with O
their O
interpersonal O
network O
and O
chronicle O
their O
breast O
cancer O
experience O
. O
Participants O
completed O
assessments O
at O
1 O
and O
6 O
months O
. O
Visitors O
to O
the O
websites O
( O
n O
= O
66 B-total-participants
) O
completed O
an O
online O
questionnaire O
. O
Reactions B-outcome
to I-outcome
website I-outcome
use I-outcome
were O
positive O
, O
although O
lack O
of O
time O
was O
a O
barrier O
for O
some O
. O
Women O
with O
advanced O
cancer O
were O
more B-outcome
likely I-outcome
to I-outcome
use I-outcome
their I-outcome
websites I-outcome
. O
Women O
found B-outcome
the I-outcome
websites I-outcome
useful I-outcome
for O
telling O
the O
story O
of O
their O
experience O
and O
expressing O
emotions O
. O
Positive B-outcome
word I-outcome
use I-outcome
was O
associated O
with O
heightened B-outcome
positive I-outcome
mood I-outcome
at B-outcome
6 I-outcome
months I-outcome
; O
negative O
word O
use O
was O
associated O
with O
improved O
depressive B-outcome
symptoms I-outcome
. O
Visitors O
were O
most O
commonly O
female O
friends O
of O
participants O
who O
valued O
the O
websites O
as O
a O
way O
to O
connect O
emotionally O
with O
participants O
and O
receive O
information O
about O
their O
health O
. O
Specific O
aspects O
of O
patients O
' O
blogs O
predicted O
improvements O
in O
psychosocial O
functioning O
. O
Personal O
websites O
can O
help O
women O
with O
breast O
cancer O
construct O
a O
narrative O
of O
their O
experience O
, O
express O
emotions O
, O
and O
receive O
the O
social O
support O
they O
need O
, O
particularly O
from O
friends O
and O
extended O
family O
. O

Diagnostic O
accuracy O
of O
fiberoptic B-intervention
ductoscopy I-intervention
plus I-intervention
in I-intervention
vivo I-intervention
iodine I-intervention
staining I-intervention
for O
intraductal B-condition
proliferative I-condition
lesions I-condition
. O
Iodine O
staining O
during O
endoscopy O
has O
been O
successfully O
used O
to O
detect O
early O
carcinomatous O
and O
precancerous O
lesions O
in O
the O
esophagus O
, O
cervix O
, O
and O
oral O
cavity O
. O
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
diagnostic O
accuracy O
of O
fiberoptic O
ductoscopy O
( O
FDS O
) O
plus O
in O
vivo O
iodine O
staining O
for O
intraductal O
proliferative O
lesions O
of O
the O
breast O
. O
We O
performed O
periodic O
acid O
- O
Schiff O
( O
PAS O
) O
and O
in O
vitro O
iodine O
staining O
on O
52 O
and O
64 O
specimens O
of O
benign O
mammary O
hyperplasia O
, O
respectively O
, O
and O
57 O
and O
53 O
specimens O
of O
ductal O
carcinoma O
in O
situ O
( O
DCIS O
) O
, O
respectively O
. O
Next O
, O
FDS O
was O
performed O
on O
177 B-total-participants
recurrent B-eligibility
nipple I-eligibility
discharge I-eligibility
patients I-eligibility
who O
were O
randomly O
divided O
into O
two O
groups O
. O
One O
group O
was O
iodine O
- O
staining O
group O
in O
which O
92 B-intervention-participants
patients O
were O
randomly O
selected O
to O
undergo O
iodine O
staining O
during O
FDS O
, O
and O
the O
remaining O
85 B-control-participants
were O
assigned O
to O
the O
control B-control
group I-control
. O
Biopsy O
specimens O
of O
suspicious O
lesions O
were O
obtained O
and O
subjected O
to O
histopathological O
examination O
. O
Following O
PAS O
staining O
, O
benign B-outcome
mammary I-outcome
hyperplasia I-outcome
lesions I-outcome
were O
positively O
stained O
, O
while O
negligible O
PAS O
positivity O
was O
observed O
in O
the O
DCIS O
lesions O
( O
P O
< O
0.05 O
) O
. O
Following O
in O
vitro O
iodine O
staining O
, O
benign B-outcome
mammary I-outcome
hyperplasia I-outcome
specimens I-outcome
appeared O
dark O
brown O
, O
whereas O
DCIS O
samples O
appeared O
significantly O
lighter O
or O
unstained O
. O
Compared O
with O
the O
pathological O
examination O
results O
, O
FDS O
with O
iodine O
staining O
showed O
an O
agreement B-outcome
rate I-outcome
in I-outcome
the I-outcome
diagnosis I-outcome
of I-outcome
ductal I-outcome
intraepithelial I-outcome
neoplasia I-outcome
( I-outcome
DIN I-outcome
) I-outcome
, O
sensitivity B-outcome
, O
specificity B-outcome
, O
positive B-outcome
likelihood I-outcome
ratio I-outcome
, O
negative B-outcome
likelihood I-outcome
ratio I-outcome
, O
and O
Youden B-outcome
index I-outcome
of O
97.82 B-iv-bin-percent
% I-iv-bin-percent
, O
98.83 B-iv-bin-percent
% I-iv-bin-percent
, O
83.33 B-iv-bin-percent
% I-iv-bin-percent
, O
5.93 B-iv-bin-percent
, O
0.014 B-iv-bin-percent
, O
and O
0.8216 B-iv-bin-percent
, O
respectively O
; O
the O
corresponding O
values O
for O
FDS O
without O
iodine O
staining O
were O
88.24 B-cv-bin-percent
% I-cv-bin-percent
, O
89.16 B-cv-bin-percent
% I-cv-bin-percent
, O
50.00 B-cv-bin-percent
% I-cv-bin-percent
, O
1.78 B-cv-bin-percent
, O
0.217 B-cv-bin-percent
, O
and O
0.3916 B-cv-bin-percent
, O
respectively O
. O
FDS O
with O
iodine O
staining O
was O
superior O
to O
conventional O
FDS O
for O
the O
diagnosis O
of O
DIN O
and O
is O
valuable O
for O
breast O
cancer O
prevention O
. O

A O
randomized O
, O
double O
- O
blind O
, O
phase O
2 O
study O
of O
ruxolitinib B-intervention
or O
placebo B-control
in I-control
combination I-control
with I-control
capecitabine I-control
in O
patients O
with O
advanced O
HER O
2 O
- O
negative O
breast O
cancer O
and O
elevated O
C O
- O
reactive O
protein O
, O
a O
marker O
of O
systemic O
inflammation O
. O
The O
Janus O
- O
associated O
kinase O
( O
JAK O
) O
/ O
signal O
transducer O
and O
activator O
of O
transcription O
pathway O
is O
a O
key O
regulator O
of O
inflammatory O
signaling O
, O
associated O
with O
tumorigenesis O
, O
cell O
survival O
, O
and O
progression O
. O
This O
randomized O
phase O
2 O
trial O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
addition O
of O
ruxolitinib O
, O
a O
JAK O
1 O
/ O
JAK O
2 O
inhibitor O
, O
to O
capecitabine O
in O
patients O
with O
HER O
2 O
- O
negative O
advanced O
breast O
cancer O
and O
high O
systemic O
inflammation O
( O
modified O
Glasgow O
Prognostic O
Score O
[ O
mGPS O
] O
â‰¥ O
1 O
) O
. O
Patients B-eligibility
with I-eligibility
â‰¤ I-eligibility
â€‰ I-eligibility
2 I-eligibility
prior I-eligibility
chemotherapy I-eligibility
regimens I-eligibility
for I-eligibility
advanced I-eligibility
or I-eligibility
metastatic I-eligibility
disease I-eligibility
or I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
patients I-eligibility
with I-eligibility
disease I-eligibility
progression I-eligibility
on I-eligibility
prior I-eligibility
hormonal I-eligibility
therapies I-eligibility
were O
randomized O
1 O
:1 O
to O
21 O
-day O
cycles O
of O
ruxolitinib O
( O
n O
= O
76 B-intervention-participants
) O
or O
placebo O
( O
n O
= O
73 B-control-participants
) O
plus O
capecitabine O
. O
The O
primary O
endpoint O
was O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
Baseline O
characteristics O
were O
well O
balanced O
between O
groups O
. O
For O
ruxolitinib B-intervention
plus I-intervention
capecitabine I-intervention
versus O
placebo B-control
plus I-control
capecitabine I-control
, O
median B-outcome
OS I-outcome
was O
11.2 B-iv-cont-median
Â  I-iv-cont-median
months I-iv-cont-median
versus O
10.9 B-cv-cont-median
Â  I-cv-cont-median
months I-cv-cont-median
( O
log O
- O
rank O
test O
P O
= O
0.762 O
) O
; O
median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
was O
4.5 B-iv-cont-median
Â  I-iv-cont-median
months I-iv-cont-median
versus O
2.5 B-cv-cont-median
Â  I-cv-cont-median
months I-cv-cont-median
( O
log O
- O
rank O
test O
P O
= O
0.151 O
) O
; O
and O
overall B-outcome
response I-outcome
rate I-outcome
( I-outcome
ORR I-outcome
) I-outcome
was O
28.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
13.7 B-cv-bin-percent
% I-cv-bin-percent
( O
Cochran O
- O
Mantel O
- O
Haenszel O
test O
P O
= O
0.024 O
) O
, O
respectively O
. O
A O
more O
favorable O
change O
in O
health B-outcome
- I-outcome
related I-outcome
quality I-outcome
of I-outcome
life I-outcome
( O
HRQoL O
) O
was O
observed O
with O
ruxolitinib O
plus O
capecitabine O
versus O
placebo O
plus O
capecitabine O
. O
Both O
regimens O
were O
generally O
tolerable O
. O
A O
higher O
incidence B-outcome
of I-outcome
grade I-outcome
3 I-outcome
/ I-outcome
4 I-outcome
anemia I-outcome
( O
25.4 B-iv-bin-percent
% I-iv-bin-percent
vs O
5.6 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
a O
lower O
incidence B-outcome
of I-outcome
grade I-outcome
3 I-outcome
/ I-outcome
4 I-outcome
palmar I-outcome
- I-outcome
plantar I-outcome
erythrodysesthesia I-outcome
( O
1.4 B-iv-bin-percent
% I-iv-bin-percent
vs O
12.7 B-cv-bin-percent
% I-cv-bin-percent
) O
occurred O
with O
ruxolitinib O
plus O
capecitabine O
versus O
placebo O
plus O
capecitabine O
. O
The O
addition O
of O
ruxolitinib O
to O
capecitabine O
for O
patients O
with O
advanced O
breast O
cancer O
and O
high O
systemic O
inflammation O
was O
generally O
tolerable O
; O
ORR O
was O
numerically O
greater O
, O
a O
more O
favorable O
change O
in O
HRQoL O
was O
observed O
, O
but O
neither O
OS O
nor O
PFS O
was O
improved O
compared O
with O
placebo O
plus O
capecitabine O
. O

Trastuzumab B-intervention
decreases O
the O
incidence O
of O
clinical B-condition
relapses I-condition
in O
patients O
with O
early O
breast O
cancer O
presenting O
chemotherapy O
- O
resistant O
CK- O
19 O
mRNA O
- O
positive O
circulating O
tumor O
cells O
: O
results O
of O
a O
randomized O
phase O
II O
study O
. O
Since O
the O
detection O
of O
circulating O
tumor O
cells O
( O
CTCs O
) O
which O
express O
HER O
2 O
is O
an O
adverse O
prognostic O
factor O
in O
early O
breast O
cancer O
patients O
, O
we O
investigated O
the O
effect O
of O
trastuzumab O
on O
patients O
' O
clinical O
outcome O
. O
Seventy B-total-participants
five I-total-participants
women B-eligibility
with I-eligibility
HER I-eligibility
2 I-eligibility
( I-eligibility
- I-eligibility
) I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
detectable I-eligibility
CK I-eligibility
19 I-eligibility
mRNA I-eligibility
- I-eligibility
positive I-eligibility
CTCs I-eligibility
before I-eligibility
and I-eligibility
after I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
, O
were O
randomized O
to O
receive O
either O
trastuzumab O
( O
n= O
36 B-intervention-participants
) O
or O
observation B-control
( O
n= O
39 B-control-participants
) O
. O
CK O
19 O
mRNA O
- O
positive O
CTCs O
were O
detected O
by O
RT O
- O
PCR O
and O
double O
stained O
CK O
( O
+ O
) O
/ O
HER O
2 O
( O
+ O
) O
cells O
by O
immunofluorescence O
. O
The O
primary O
endpoint O
was O
the O
3 B-outcome-measure
-year I-outcome-measure
disease I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
rate I-outcome-measure
. O
Fifty O
- O
one O
( O
89 O
% O
) O
of O
the O
57 O
analyzed O
patients O
had O
HER O
2 O
- O
expressing O
CTCs O
. O
After O
trastuzumab O
administration O
, O
27 B-iv-bin-abs
of O
36 B-intervention-participants
( O
75 B-iv-bin-percent
% I-iv-bin-percent
) O
women O
became B-outcome
CK I-outcome
19 I-outcome
mRNA I-outcome
- I-outcome
negative I-outcome
compared O
to O
seven B-cv-bin-abs
of O
39 B-control-participants
( O
17.9 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
observation O
arm O
( O
p= O
0.001 O
) O
. O
After O
a O
median O
follow O
up O
time O
of O
67.2 O
months O
, O
four B-iv-bin-abs
( O
11 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
15 B-cv-bin-abs
( O
38 B-cv-bin-percent
% I-cv-bin-percent
) O
relapses B-outcome
were O
observed O
in O
the O
trastuzumab O
and O
observation O
arm O
, O
respectively O
( O
p= O
0.008 O
) O
; O
subgroup O
analysis O
indicated O
that O
this O
effect O
was O
mainly O
confined O
to O
women O
with O
> O
3 O
involved O
axillary O
lymph O
nodes O
( O
p= O
0.004 O
) O
. O
The O
median B-outcome
DFS I-outcome
was O
also O
significantly O
higher O
for O
the O
trastuzumab O
- O
treated O
patients O
( O
p= O
0.008 O
) O
. O
Administration O
of O
trastuzumab O
can O
eliminate O
chemotherapy O
- O
resistant O
CK O
19 O
mRNA O
- O
positive O
CTCs O
, O
reduce O
the O
risk O
of O
disease O
recurrence O
and O
prolong O
the O
DFS O
. O

Cardiovascular O
risk O
profile O
of O
patients O
with O
HER O
2 O
/ O
neu O
- O
positive O
breast O
cancer O
treated O
with O
anthracycline B-intervention
- I-intervention
taxane I-intervention
- I-intervention
containing I-intervention
adjuvant I-intervention
chemotherapy I-intervention
and/or I-intervention
trastuzumab I-intervention
. O
To O
evaluate O
the O
cardiovascular O
risk O
profile O
of O
a O
subset O
of O
patients O
with O
early O
- O
stage O
breast O
cancer O
treated O
with O
adjuvant O
taxane O
- O
anthracycline O
- O
containing O
chemotherapy O
and/or O
trastuzumab O
( O
Herceptin O
) O
. O
Twenty B-intervention-participants
- I-intervention-participants
six I-intervention-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
( O
mean O
, O
20 O
months O
postchemotherapy O
) O
and O
10 B-control-participants
healthy B-control
age O
- O
matched O
women O
were O
studied O
. O
We O
measured O
14 O
metabolic O
and O
vascular O
established O
cardiovascular O
disease O
( O
CVD O
) O
risk O
factors O
, O
body O
mass O
index O
, O
cardiorespiratory O
fitness O
, O
and O
left O
ventricular O
systolic O
function O
. O
All O
assessments O
were O
done O
within O
a O
14 O
-day O
period O
. O
Cardiac O
abnormalities O
were O
suggested O
by O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
< O
50 O
% O
in O
8 O
% O
of O
patients O
, O
LVEF O
remained O
> O
10 O
% O
below O
pretreatment O
values O
in O
38 O
% O
, O
whereas O
50 O
% O
presented O
with O
resting O
sinus O
tachycardia O
. O
Brain B-outcome
natriuretic I-outcome
peptide I-outcome
was O
significantly O
elevated O
in O
40 O
% O
of O
patients O
and O
was O
correlated O
with O
LVEF O
( O
r O
= O
- O
0.72 O
, O
P O
= O
or O
< O
0.001 O
) O
. O
For O
the O
majority O
of O
CVD O
risk O
factors O
, O
similar O
proportions O
of O
patients O
and O
controls O
( O
35 O
- O
60 O
% O
) O
were O
classified O
as O
" O
undesirable O
. O
" O
A O
significantly O
higher O
proportion O
of O
patients O
were O
classified O
with O
low B-outcome
cardiorespiratory I-outcome
fitness I-outcome
( O
46 B-iv-bin-percent
% I-iv-bin-percent
versus O
0 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.01 O
) O
, O
being O
overweight B-outcome
/ I-outcome
obese I-outcome
( O
72 B-iv-bin-percent
% I-iv-bin-percent
versus O
50 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.05 O
) O
, O
and O
having O
resting B-outcome
sinus I-outcome
tachycardia I-outcome
( O
50 B-iv-bin-percent
% I-iv-bin-percent
versus O
0 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.01 O
) O
compared O
with O
controls O
. O
Cardiorespiratory B-outcome
fitness I-outcome
and O
body B-outcome
mass I-outcome
index I-outcome
were O
correlated O
with O
CVD O
risk O
factors O
( O
r O
= O
- O
0.64 O
to O
0.63 O
, O
P O
< O
0.05 O
; O
r O
= O
- O
0.63 O
to O
0.67 O
, O
P O
< O
0.05 O
, O
respectively O
) O
. O
Exploratory O
analyses O
revealed O
several O
differences O
between O
CVD O
risk O
factors O
based O
on O
chemotherapy O
regimen O
. O
Breast O
cancer O
survivors O
treated O
with O
adjuvant O
chemotherapy O
are O
at O
a O
higher O
risk O
of O
developing O
late O
- O
occurring O
CVD O
than O
age O
- O
matched O
controls O
due O
to O
direct O
and O
indirect O
treatment O
- O
related O
toxicity O
. O

Comparison O
of O
rapidly O
cycled O
tandem O
high B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
plus I-intervention
peripheral I-intervention
- I-intervention
blood I-intervention
stem I-intervention
- I-intervention
cell I-intervention
support I-intervention
versus O
dose B-control
- I-control
dense I-control
conventional I-control
chemotherapy I-control
for O
adjuvant O
treatment O
of O
high O
- O
risk O
breast O
cancer O
: O
results O
of O
a O
multicentre O
phase O
III O
trial O
. O
Breast O
cancer O
with O
extensive O
axillary O
- O
lymph O
- O
node O
involvement O
has O
a O
poor O
prognosis O
after O
conventional O
treatment O
. O
In O
trials O
with O
historical O
controls O
, O
high O
- O
dose O
chemotherapy O
produced O
improved O
outcomes O
. O
We O
compared O
an O
intensive O
double O
- O
cycle O
high O
- O
dose O
chemotherapy O
regimen O
with O
an O
accelerated O
conventionally O
dosed O
regimen O
in O
high O
- O
risk O
breast O
cancer O
in O
a O
multicentre O
trial O
. O
Patients B-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
nine I-eligibility
positive I-eligibility
nodes I-eligibility
were O
randomly O
assigned O
either O
two O
courses O
of O
accelerated O
( O
2 O
-week O
intervals O
, O
with O
filgrastim O
support O
) O
, O
conventionally O
dosed O
epirubicin O
and O
cyclophosphamide O
followed O
by O
two O
courses O
of O
high O
- O
dose O
chemotherapy O
( O
epirubicin O
, O
cyclophosphamide O
, O
and O
thiotepa O
supported O
by O
peripheral O
- O
blood O
progenitors O
) O
or O
four O
identical O
cycles O
of O
epirubicin O
and O
cyclophosphamide O
followed O
by O
three O
cycles O
of O
accelerated O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
. O
The O
primary O
endpoint O
was O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Analyses O
were O
done O
both O
by O
intention O
to O
treat O
and O
per O
protocol O
. O
403 B-total-participants
patients O
were O
enrolled O
; O
201 B-intervention-participants
were O
assigned O
high O
- O
dose O
chemotherapy O
and O
202 B-control-participants
conventional O
treatment O
. O
The O
mean O
number O
of O
positive O
nodes O
was O
17.6 O
, O
and O
median O
follow O
- O
up O
was O
48.6 O
months O
. O
4 B-outcome
-year I-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
intention O
- O
to O
- O
treat O
analysis O
) O
was O
60 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
53 O
- O
67 O
) O
in O
the O
high O
- O
dose O
chemotherapy O
group O
and O
44 B-cv-bin-percent
% I-cv-bin-percent
( O
37 O
- O
52 O
) O
in O
the O
control O
group O
( O
p= O
0.00069 O
) O
. O
The O
corresponding O
overall B-outcome
survival I-outcome
was O
75 B-iv-bin-percent
% I-iv-bin-percent
( O
69 O
- O
82 O
) O
versus O
70 B-cv-bin-percent
% I-cv-bin-percent
( O
64 O
- O
77 O
; O
p= O
0.02 O
) O
. O
There O
were O
no B-outcome
treatment I-outcome
- I-outcome
related I-outcome
deaths I-outcome
. O
Our O
finding O
of O
significant O
improvements O
in O
both O
event O
- O
free O
and O
overall O
survival O
for O
high O
- O
dose O
chemotherapy O
compared O
with O
a O
dose O
- O
dense O
conventional O
regimen O
contrasts O
with O
the O
results O
of O
other O
studies O
. O
The O
discrepancy O
might O
be O
due O
partly O
to O
design O
differences O
( O
tandem O
, O
brief O
induction O
) O
between O
our O
regimen O
and O
those O
studied O
in O
other O
trials O
. O
This O
approach O
merits O
further O
study O
. O

Effects O
of O
music B-intervention
therapy I-intervention
on O
anxiety B-condition
of O
patients O
with O
breast O
cancer O
after O
radical O
mastectomy O
: O
a O
randomized O
clinical O
trial O
. O
This O
paper O
is O
a O
report O
of O
a O
clinical O
trial O
of O
the O
effects O
of O
music O
therapy O
on O
anxiety O
of O
female B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
following I-eligibility
radical I-eligibility
mastectomy I-eligibility
. O
There O
is O
insufficient O
evidence O
on O
the O
effects O
of O
music O
therapy O
on O
state O
anxiety O
of O
breast O
cancer O
patients O
following O
radical O
mastectomy O
. O
A O
Hall O
's O
Core O
, O
Care O
, O
and O
Cure O
Model O
- O
based O
clinical O
trial O
was O
conducted O
in O
120 B-total-participants
female O
breast O
cancer O
patients O
from O
March O
to O
November O
2009 O
. O
A O
randomized O
controlled O
design O
was O
utilized O
. O
The O
patients O
were O
randomly O
allocated O
to O
the O
experimental O
group O
( O
n O
= O
60 B-intervention-participants
) O
received O
music O
therapy O
in O
addition O
to O
routine O
nursing O
care O
, O
and O
the O
control O
group O
( O
n O
= O
60 B-control-participants
) O
only O
received O
routine B-control
nursing I-control
care I-control
. O
A O
standardized O
questionnaire O
and O
the O
State O
Anxiety O
Inventory O
were O
applied O
. O
The O
primary O
endpoint O
was O
the O
state B-outcome-measure
anxiety I-outcome-measure
score I-outcome-measure
measured O
at O
pretest O
( O
on O
the O
day O
before O
radical O
mastectomy O
) O
and O
at O
three O
post O
- O
tests O
( O
on O
the O
day O
before O
patients O
were O
discharged O
from O
hospital O
, O
the O
second O
and O
third O
time O
of O
admission O
to O
hospital O
for O
chemotherapy O
respectively O
) O
. O
The O
pretest O
score O
revealed O
that O
the O
majority O
of O
the O
patients O
had O
a O
moderate O
level O
( O
77 O
Â· O
5 O
% O
) O
and O
15 O
% O
had O
severe O
level B-outcome
of I-outcome
state I-outcome
anxiety I-outcome
. O
The O
repeated O
- O
measure O
ancova O
model O
analysis O
indicated O
that O
the O
mean B-outcome
state I-outcome
anxiety I-outcome
score I-outcome
was O
significantly O
lower O
in O
the O
experimental O
group O
than O
those O
in O
the O
control O
group O
at O
each O
of O
the O
three O
post O
- O
test O
measurements O
. O
The O
mean B-outcome
difference I-outcome
between O
the O
experimental O
and O
control O
group O
together O
with O
95 O
% O
confidence O
intervals O
were O
- O
4 O
Â· O
57 O
( O
- O
6 O
Â· O
33 O
, O
- O
2 O
Â· O
82 O
) O
, O
- O
8 O
Â· O
91 O
( O
- O
10 O
Â· O
75 O
, O
- O
7 O
Â· O
08 O
) O
and O
- O
9 O
Â· O
69 O
( O
- O
11 O
Â· O
52 O
, O
- O
7 O
Â· O
85 O
) O
at O
the O
1 B-outcome
st I-outcome
post I-outcome
- I-outcome
test I-outcome
, O
2 B-outcome
nd I-outcome
post I-outcome
- I-outcome
test I-outcome
and O
3 B-outcome
rd I-outcome
post I-outcome
- I-outcome
test I-outcome
respectively O
. O
Music O
therapy O
is O
found O
to O
have O
positive O
effects O
on O
decreasing O
state O
anxiety O
score O
. O

Thoracic B-intervention
paravertebral I-intervention
regional I-intervention
anesthesia I-intervention
for O
pain B-condition
relief I-condition
in O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
. O
The O
present O
study O
aimed O
to O
assess O
the O
efficacy O
and O
safety O
of O
thoracic O
paravertebral O
regional O
anesthesia O
( O
TPVBRA O
) O
in O
patients O
with O
breast O
cancer O
surgery O
. O
In O
total O
, O
72 B-total-participants
patients O
undergoing O
breast O
cancer O
surgery O
were O
randomly O
divided O
into O
an O
intervention O
group O
and O
a O
control B-control
group I-control
; O
each O
group O
contained O
36 B-intervention-participants
subjects O
. O
Both O
groups O
received O
TPVBRA O
with O
20 O
mL O
0.25 O
% O
bupivacaine O
. O
In O
addition O
, O
subjects O
in O
the O
intervention O
group O
also O
received O
an O
additional O
1 O
Î¼g O
/ O
kg O
dexmedetomidine O
. O
Heart O
rate O
( O
HR O
) O
, O
systolic O
blood O
pressure O
( O
SBP O
) O
, O
diastolic O
blood O
pressure O
( O
DBP O
) O
, O
pain O
intensity O
( O
measured O
by O
visual O
analogue O
scale O
, O
VAS O
) O
, O
and O
analgesic O
consumption O
were O
assessed O
; O
adverse O
events O
were O
also O
recorded O
. O
Significant O
differences O
were O
observed O
in O
HR O
( O
P O
< O
. O
05 O
) O
, O
SBP O
( O
P O
< O
. O
05 O
) O
, O
and O
DBP B-outcome
( O
P O
< O
. O
05 O
) O
at O
the O
30 O
-minute O
point O
during O
surgery O
between O
the O
2 O
groups O
. O
In O
addition O
, O
the O
time O
of O
the O
first O
administration O
of O
analgesia O
( O
P O
= O
. O
043 O
) O
and O
the O
mean B-outcome
consumption I-outcome
of I-outcome
analgesic I-outcome
agents I-outcome
( O
P O
= O
. O
035 O
) O
in O
the O
intervention O
group O
were O
much O
better O
than O
those O
in O
the O
control O
group O
. O
However O
, O
no O
significant O
differences O
in O
HR B-outcome
or I-outcome
VAS I-outcome
were O
found O
at O
any O
time O
point O
after O
surgery O
( O
P O
> O
. O
05 O
) O
. O
Furthermore O
, O
similar O
adverse B-outcome
events I-outcome
were O
detected O
in O
both O
groups O
( O
P O
> O
. O
05 O
) O
. O
The O
results O
of O
this O
study O
showed O
that O
TPVBRA O
combined O
with O
bupivacaine O
and O
dexmedetomidine O
can O
enhance O
the O
duration O
and O
quality O
of O
analgesia O
without O
serious O
adverse O
events O
. O

Abemaciclib B-intervention
Combined I-intervention
With I-intervention
Endocrine I-intervention
Therapy I-intervention
for O
the O
Adjuvant O
Treatment O
of O
HR+ O
, O
HER O
2 O
- O
, O
Node O
- O
Positive O
, O
High O
- O
Risk O
, O
Early O
Breast O
Cancer O
( O
monarchE O
) O
. O
Many O
patients O
with O
HR+ O
, O
HER O
2 O
- O
early O
breast O
cancer O
( O
EBC O
) O
will O
not O
experience O
recurrence O
or O
have O
distant O
recurrence O
with O
currently O
available O
standard O
therapies O
. O
However O
, O
up O
to O
30 O
% O
of O
patients O
with O
high O
- O
risk O
clinical O
and/or O
pathologic O
features O
may O
experience O
distant O
recurrence O
, O
many O
in O
the O
first O
few O
years O
. O
Superior O
treatment O
options O
are O
needed O
to O
prevent O
early O
recurrence O
and O
development O
of O
metastases O
for O
this O
group O
of O
patients O
. O
Abemaciclib O
is O
an O
oral O
, O
continuously O
dosed O
, O
CDK O
4 O
/ O
6 O
inhibitor O
approved O
for O
HR+ O
, O
HER O
2 O
- O
advanced O
breast O
cancer O
( O
ABC O
) O
. O
Efficacy O
and O
safety O
of O
abemaciclib O
in O
ABC O
supported O
evaluation O
in O
the O
adjuvant O
setting O
. O
This O
open O
- O
label O
, O
phase O
III O
study O
included O
patients B-eligibility
with I-eligibility
HR+ I-eligibility
, I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
, I-eligibility
high I-eligibility
- I-eligibility
risk I-eligibility
EBC I-eligibility
, I-eligibility
who I-eligibility
had I-eligibility
surgery I-eligibility
and I-eligibility
, I-eligibility
as I-eligibility
indicated I-eligibility
, I-eligibility
radiotherapy I-eligibility
and/or I-eligibility
adjuvant I-eligibility
/ I-eligibility
neoadjuvant I-eligibility
chemotherapy I-eligibility
. O
Patients O
with O
four O
or O
more O
positive O
nodes O
, O
or O
one O
to O
three O
nodes O
and O
either O
tumor O
size O
â‰¥ O
5 O
cm O
, O
histologic O
grade O
3 O
, O
or O
central O
Ki- O
67 O
â‰¥ O
20 O
% O
, O
were O
eligible O
and O
randomly O
assigned O
( O
1 O
:1 O
) O
to O
standard B-control
- I-control
of I-control
- I-control
care I-control
adjuvant O
endocrine O
therapy O
( O
ET O
) O
with O
or O
without O
abemaciclib O
( O
150 O
mg O
twice O
daily O
for O
2 O
years O
) O
. O
The O
primary O
end O
point O
was O
invasive B-outcome-measure
disease I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
IDFS I-outcome-measure
) I-outcome-measure
, I-outcome-measure
and O
secondary O
end O
points O
included O
distant B-outcome-measure
relapse I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
, O
and O
safety B-outcome-measure
. O
At O
a O
preplanned O
efficacy O
interim O
analysis O
, O
among O
5 B-total-participants
, I-total-participants
637 I-total-participants
randomly O
assigned O
patients O
, O
323 O
IDFS B-outcome
events I-outcome
were O
observed O
in O
the O
intent O
- O
to O
- O
treat O
population O
. O
Abemaciclib O
plus O
ET O
demonstrated O
superior O
IDFS B-outcome
versus O
ET O
alone O
( O
P O
= O
. O
01 O
; O
hazard O
ratio O
, O
0.75 O
; O
95 O
% O
CI O
, O
0.60 O
to O
0.93 O
) O
, O
with O
2 B-outcome
-year I-outcome
IDFS I-outcome
rates I-outcome
of O
92.2 B-iv-bin-percent
% I-iv-bin-percent
versus O
88.7 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
. O
Safety O
data O
were O
consistent O
with O
the O
known O
safety O
profile O
of O
abemaciclib O
. O
Abemaciclib O
when O
combined O
with O
ET O
is O
the O
first O
CDK O
4 O
/ O
6 O
inhibitor O
to O
demonstrate O
a O
significant O
improvement O
in O
IDFS O
in O
patients O
with O
HR+ O
, O
HER O
2 O
- O
node O
- O
positive O
EBC O
at O
high O
risk O
of O
early O
recurrence O
. O

The O
influence O
of O
the O
initiation O
of O
an O
exercise B-intervention
programme O
on O
seroma B-condition
formation I-condition
and I-condition
dehiscence I-condition
following O
breast O
cancer O
surgery O
. O
To O
verify O
whether O
early O
( O
first O
post O
- O
operative O
day O
) O
or O
late O
initiation O
( O
after O
removal O
of O
the O
continuous O
suction O
drain O
) O
of O
a O
functional O
rehabilitation O
exercise O
programme O
influences O
the O
incidence O
of O
seroma O
formation O
and O
dehiscence O
for O
women B-eligibility
after I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
. O
Benefits O
of O
early O
implementation O
of O
an O
exercise O
programme O
initiated O
with O
women O
in O
the O
first O
days O
following O
breast O
cancer O
surgery O
are O
widely O
known O
. O
However O
, O
the O
safe O
initiation O
of O
the O
exercises O
is O
still O
a O
controversial O
issue O
and O
some O
authors O
correlate O
early O
initiation O
of O
the O
exercises O
with O
an O
increase O
in O
seroma O
formation O
. O
A O
prospective O
, O
randomised O
, O
controlled O
clinical O
trial O
. O
Seventy B-total-participants
- I-total-participants
seven I-total-participants
women O
were O
randomly O
assigned O
to O
initiate O
the O
programme O
on O
post O
- O
operative O
day O
1 O
( O
early O
group O
= O
40 B-intervention-participants
) O
or O
after O
removal O
of O
the O
drain O
( O
late B-control
group I-control
= O
37 B-control-participants
) O
and O
were O
monitored O
until O
the O
45 O
th O
post O
- O
operative O
day O
. O
Patients O
in O
the O
early O
group O
were O
instructed O
to O
perform O
the O
exercises O
daily O
at O
home O
, O
beginning O
on O
post O
- O
operative O
day O
1 O
, O
while O
those O
of O
the O
late O
group O
began O
the O
exercises O
after O
the O
drain O
was O
removed O
. O
The O
assessment O
for O
seroma O
formation O
and O
dehiscence O
was O
performed O
on O
post O
- O
operative O
days O
7 O
and O
45 O
. O
There O
was O
no O
statistically O
significant O
difference O
regard O
to O
seroma B-outcome
formation I-outcome
between O
early O
group O
and O
late O
group O
. O
Also O
there O
was O
no O
association O
between O
the O
presence B-outcome
of I-outcome
dehiscence I-outcome
and O
early O
exercises O
. O
The O
early O
initiation O
of O
the O
exercises O
for O
women O
, O
following O
breast O
cancer O
surgery O
, O
constitutes O
a O
safe O
practice O
for O
the O
rehabilitation O
. O
However O
, O
these O
findings O
need O
to O
be O
further O
explored O
and O
confirmed O
in O
a O
larger O
sample O
. O
Studies O
showing O
evidence O
that O
early O
functional O
rehabilitation O
process O
is O
a O
safe O
practice O
for O
women O
having O
surgery O
for O
breast O
cancer O
, O
as O
well O
as O
the O
present O
research O
, O
are O
of O
interest O
to O
health O
professionals O
who O
care O
for O
these O
patients O
and O
contribute O
to O
the O
wider O
global O
clinical O
community O
. O

A O
multicentre O
, O
randomized O
pilot O
trial O
comparing O
vascular B-intervention
access I-intervention
strategies I-intervention
for O
early O
stage O
breast O
cancer O
patients O
receiving O
non O
- O
trastuzumab O
containing O
chemotherapy O
. O
All O
vascular O
access O
strategies O
foradministering O
chemotherapy O
in O
early O
stage O
breast O
cancer O
( O
EBC O
) O
are O
associated O
with O
risks O
and O
benefits O
. O
As O
the O
most O
effective O
type O
of O
access O
is O
unknown O
a O
feasibility O
trial O
, O
prior O
to O
conducting O
a O
large O
pragmatic O
trial O
, O
was O
undertaken O
. O
The O
trial O
methodology O
utilized O
broad O
eligibility O
criteria O
and O
the O
integrated O
consent O
model O
incorporating O
oral O
consent O
. O
EBC B-eligibility
patients I-eligibility
receiving I-eligibility
non I-eligibility
- I-eligibility
trastuzumab I-eligibility
- I-eligibility
containing I-eligibility
chemotherapy I-eligibility
were O
randomized O
to O
peripheral O
access O
or O
central B-control
line I-control
insertion I-control
. O
The O
a O
priori O
definition O
of O
feasibility O
was O
: O
> O
25 O
% O
of O
patients O
approached O
agreed O
to O
randomisation O
and O
> O
25 O
% O
of O
physicians O
approached O
patients O
. O
Secondary O
outcomes O
included O
rates B-outcome-measure
of I-outcome-measure
line I-outcome-measure
- I-outcome-measure
associated I-outcome-measure
complications I-outcome-measure
. O
Of O
159 B-total-participants
patients O
approached O
, O
150 B-total-participants
( O
94.3 O
% O
) O
agreed O
to O
randomisation O
, O
77 B-intervention-participants
( O
51.3 O
% O
) O
were O
randomized O
to O
peripheral O
and O
73 B-control-participants
( O
48.7 O
% O
) O
to O
central O
access O
. O
6 O
/ O
26 O
( O
23.1 O
% O
) O
of O
medical O
oncologists O
approached O
patients O
. O
Rates B-outcome
of I-outcome
complications I-outcome
per O
chemotherapy O
cycles O
in O
the O
peripheral O
vs O
central O
access O
groups O
with O
risk O
difference O
( O
RD O
) O
( O
95 O
% O
CI O
) O
were O
: O
thrombotic B-outcome
events I-outcome
requiring I-outcome
anticoagulation I-outcome
[ O
1 B-iv-bin-abs
( O
0.3 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
3 B-cv-bin-abs
( O
1.0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
RD O
- O
0.7 O
( O
- O
1.9 O
, O
0.5 O
) O
] O
, O
line B-outcome
infections I-outcome
[ O
0 B-iv-bin-abs
( O
0 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
1 B-cv-bin-abs
( O
0.3 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
RD O
- O
0.3 O
( O
- O
0.9 O
, O
0.3 O
) O
] O
, O
phlebitis B-outcome
[ O
2 B-iv-bin-abs
( O
0.6 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
0 B-cv-bin-abs
( O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
RD O
0.3 O
( O
- O
0.3 O
, O
0.8 O
) O
] O
, O
and O
tissue B-outcome
infiltrations I-outcome
[ O
4 B-iv-bin-abs
( O
1.1 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
1 B-cv-bin-abs
( O
0.3 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
RD O
0.8 O
( O
- O
0.4 O
, O
2.1 O
) O
] O
. O
Overall O
, O
8.0 B-iv-bin-percent
% I-iv-bin-percent
( O
6 B-iv-bin-abs
/ O
75 B-intervention-participants
) O
and O
7.7 B-cv-bin-percent
% I-cv-bin-percent
( O
5 B-cv-bin-abs
/ O
65 B-control-participants
) O
of O
patients O
had O
at O
least O
one O
of O
these O
complications B-outcome
in O
the O
peripheral O
and O
central O
access O
arms O
respectively O
[ O
RD O
- O
0.9 O
( O
- O
9.4 O
, O
7.6 O
) O
] O
. O
The O
study O
was O
terminated O
early O
due O
to O
slow O
accrual O
. O
While O
meeting O
its O
a O
priori O
feasibility O
criteria O
for O
patient O
engagement O
, O
the O
slow O
accrual O
means O
that O
conducting O
a O
large O
pragmatic O
trial O
would O
require O
overcoming O
the O
barriers O
to O
physician O
recruitment O
. O
NCT O
02688998 O
. O

Ribociclib B-intervention
plus I-intervention
fulvestrant I-intervention
for O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
, O
human O
epidermal O
growth O
factor O
receptor O
2 O
-negative O
advanced O
breast O
cancer O
in O
the O
phase O
III O
randomized O
MONALEESA- O
3 O
trial O
: O
updated O
overall O
survival O
. O
Ribociclib O
plus O
fulvestrant O
demonstrated O
significant O
progression O
- O
free O
survival O
( O
PFS O
) O
and O
overall O
survival O
( O
OS O
) O
benefits O
in O
patients O
with O
hormone O
receptor O
- O
positive O
, O
human O
epidermal O
growth O
factor O
receptor O
2 O
-negative O
( O
HR+ O
/ O
HER O
2 O
- O
) O
advanced O
breast O
cancer O
( O
ABC O
) O
. O
Here O
we O
present O
a O
new O
landmark O
in O
survival O
follow O
- O
up O
for O
a O
phase O
III O
cyclin O
- O
dependent O
kinases O
4 O
and O
6 O
inhibitor O
clinical O
trial O
in O
patients O
with O
ABC O
( O
median O
, O
56.3 O
months O
) O
. O
This O
phase O
III O
, O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
was O
conducted O
at O
174 O
sites O
( O
30 O
countries O
) O
. O
Patients O
were O
men B-eligibility
and I-eligibility
postmenopausal I-eligibility
women I-eligibility
( I-eligibility
age I-eligibility
â‰¥ I-eligibility
18 I-eligibility
years I-eligibility
) I-eligibility
with I-eligibility
histologically I-eligibility
/ I-eligibility
cytologically I-eligibility
confirmed I-eligibility
HR+ I-eligibility
/ I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
ABC I-eligibility
. O
Patients O
could O
have O
received O
â‰¤ O
1 O
line O
of O
endocrine O
therapy O
( O
ET O
) O
but O
no O
chemotherapy O
for O
ABC O
. O
Patients O
, O
assigned O
2 O
:1 O
, O
were O
stratified O
by O
the O
presence O
/ O
absence O
of O
liver O
/ O
lung O
metastases O
and O
previous O
ET O
. O
Patients O
received O
intramuscular O
fulvestrant O
( O
500 O
mg O
, O
day O
1 O
of O
each O
28 O
-day O
cycle O
plus O
day O
15 O
of O
cycle O
1 O
) O
with O
oral O
ribociclib O
( O
600 O
mg O
/ O
day O
, O
3 O
weeks O
on O
, O
1 O
week O
off O
) O
or O
placebo B-control
. O
Efficacy O
analyses O
were O
by O
intention O
to O
treat O
. O
Safety O
was O
assessed O
in O
patients O
receiving O
â‰¥ O
1 O
dose O
study O
treatment O
. O
OS B-outcome-measure
was O
a O
secondary O
endpoint O
. O
MONALEESA- O
3 O
is O
registered O
with O
ClinicalTrials O
. O
gov O
( O
NCT O
02422615 O
; O
no O
longer O
enrolling O
) O
. O
Between O
18 O
June O
2015 O
and O
10 O
June O
2016 O
, O
726 B-total-participants
patients O
were O
randomly O
assigned O
( O
484 B-intervention-participants
, O
ribociclib O
; O
242 B-control-participants
, O
placebo O
) O
. O
At O
data O
cut O
- O
off O
( O
30 O
October O
2020 O
) O
, O
median B-outcome
OS I-outcome
( I-outcome
mOS I-outcome
) I-outcome
was O
53.7 B-iv-cont-median
months I-iv-cont-median
( O
ribociclib O
) O
versus O
41.5 B-cv-cont-median
months I-cv-cont-median
( O
placebo O
) O
[ O
hazard O
ratio O
( O
HR O
) O
, O
0.73 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.59 O
- O
0.90 O
] O
. O
Subgroup O
analyses O
were O
consistent O
with O
overall O
population O
. O
In O
the O
first O
- O
line O
setting O
, O
most O
patients O
in O
the O
ribociclib O
arm O
( O
âˆ¼ O
60 O
% O
) O
lived O
longer O
than O
median O
follow O
- O
up O
; O
mOS B-outcome
was O
51.8 B-cv-cont-median
months I-cv-cont-median
in O
the O
placebo O
arm O
( O
HR O
, O
0.64 O
; O
95 O
% O
CI O
0.46 O
- O
0.88 O
) O
. O
In O
the O
second O
- O
line O
setting O
, O
mOS B-outcome
was O
39.7 B-iv-cont-median
months I-iv-cont-median
( O
ribociclib O
) O
versus O
33.7 B-cv-cont-median
months I-cv-cont-median
( O
placebo O
) O
( O
HR O
, O
0.78 O
; O
95 O
% O
CI O
0.59 O
- O
1.04 O
) O
. O
No O
apparent O
drug O
- O
drug O
interaction O
between O
ribociclib O
and O
fulvestrant O
or O
new O
safety O
signals O
were O
observed O
. O
This O
analysis O
reported O
extended O
OS O
follow O
- O
up O
in O
MONALEESA- O
3 O
. O
mOS O
was O
âˆ¼ O
12 O
months O
longer O
in O
patients O
with O
HR+ O
/ O
HER O
2 O
- O
ABC O
treated O
with O
ribociclib O
plus O
fulvestrant O
compared O
with O
fulvestrant O
monotherapy O
. O

Phase O
III O
comparison O
of O
tamoxifen B-intervention
versus O
tamoxifen B-control
plus I-control
ovarian I-control
function I-control
suppression I-control
in O
premenopausal O
women O
with O
node O
- O
negative O
, O
hormone O
receptor O
- O
positive O
breast O
cancer O
( O
E- O
3193 O
, O
INT- O
0142 O
) O
: O
a O
trial O
of O
the O
Eastern O
Cooperative O
Oncology O
Group O
. O
The O
effects O
of O
ovarian O
function O
suppression O
( O
OFS O
) O
on O
survival O
and O
patient O
- O
reported O
outcomes O
were O
evaluated O
in O
a O
phase O
III O
trial O
in O
which O
premenopausal O
women O
were O
randomly O
assigned O
to O
tamoxifen O
with O
or O
without O
OFS O
. O
Premenopausal B-eligibility
women I-eligibility
with I-eligibility
axillary I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
, I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
tumors I-eligibility
measuring I-eligibility
â‰¤ I-eligibility
3 I-eligibility
cm I-eligibility
were O
randomly O
assigned O
to O
tamoxifen O
alone O
versus O
tamoxifen O
plus O
OFS O
; O
adjuvant O
chemotherapy O
was O
not O
permitted O
. O
Primary O
end O
points O
were O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
and O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
included O
toxicity B-outcome-measure
and I-outcome-measure
patient I-outcome-measure
- I-outcome-measure
reported I-outcome-measure
outcomes I-outcome-measure
. O
Patient O
- O
reported O
outcome O
data O
included O
health O
- O
related O
quality O
of O
life O
, O
menopausal O
symptoms O
, O
and O
sexual O
function O
. O
These O
were O
evaluated O
at O
baseline O
, O
6 O
months O
, O
12 O
months O
, O
and O
then O
annually O
for O
up O
to O
5 O
years O
after O
registration O
. O
In O
all O
, O
345 B-total-participants
premenopausal O
women O
were O
enrolled O
: O
171 B-intervention-participants
on O
tamoxifen O
alone O
and O
174 B-control-participants
on O
tamoxifen O
plus O
OFS O
. O
With O
a O
median O
follow O
- O
up O
of O
9.9 O
years O
, O
there O
was O
no O
significant O
difference O
between O
arms O
for O
DFS B-outcome
( O
5 O
-year O
rate O
: O
87.9 B-iv-bin-percent
% I-iv-bin-percent
v O
89.7 B-cv-bin-percent
% I-cv-bin-percent
; O
log O
- O
rank O
P O
= O
. O
62 O
) O
or O
OS B-outcome
( O
5 O
-year O
rate O
: O
95.2 B-iv-bin-percent
% I-iv-bin-percent
v O
97.6 B-cv-bin-percent
% I-cv-bin-percent
; O
log O
- O
rank O
P O
= O
. O
67 O
) O
. O
Grade B-outcome
3 I-outcome
or I-outcome
higher I-outcome
toxicity I-outcome
was O
more O
common O
in O
the O
tamoxifen O
plus O
OFS O
arm O
( O
22.4 B-cv-bin-percent
% I-cv-bin-percent
v O
12.3 B-iv-bin-percent
% I-iv-bin-percent
; O
P O
= O
. O
004 O
) O
. O
Patients O
treated O
with O
tamoxifen O
plus O
OFS O
had O
more O
menopausal B-outcome
symptoms I-outcome
, O
lower O
sexual B-outcome
activity I-outcome
, O
and O
inferior O
health B-outcome
- I-outcome
related I-outcome
quality I-outcome
of I-outcome
life I-outcome
at I-outcome
3 I-outcome
-year I-outcome
follow O
- O
up O
( O
P O
< O
. O
01 O
for O
all O
) O
. O
Differences O
diminished O
with O
further O
follow O
- O
up O
. O
When O
added O
to O
tamoxifen O
, O
OFS O
results O
in O
more O
menopausal O
symptoms O
and O
sexual O
dysfunction O
, O
which O
contributes O
to O
inferior O
self O
- O
reported O
health O
- O
related O
quality O
of O
life O
. O
Because O
of O
early O
closure O
, O
this O
study O
is O
underpowered O
for O
drawing O
conclusions O
about O
the O
impact O
on O
survival O
when O
adding O
OFS O
to O
tamoxifen O
. O

Phase O
III O
study O
comparing O
exemestane B-intervention
with O
tamoxifen B-control
as O
first O
- O
line O
hormonal O
treatment O
of O
metastatic O
breast O
cancer O
in O
postmenopausal O
women O
: O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Breast O
Cancer O
Cooperative O
Group O
. O
This O
phase O
III O
randomized O
open O
- O
label O
clinical O
trial O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
the O
steroidal O
aromatase O
inactivator O
exemestane O
versus O
the O
antiestrogen O
tamoxifen O
as O
first O
- O
line O
treatment O
for O
metastatic O
breast O
cancer O
( O
MBC O
) O
in O
postmenopausal O
women O
. O
The O
study O
was O
conducted O
at O
81 O
centers O
and O
enrolled O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
measurable I-eligibility
hormone I-eligibility
- I-eligibility
sensitive I-eligibility
metastatic I-eligibility
or I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Prior O
adjuvant O
chemotherapy O
and/or O
tamoxifen O
were O
allowed O
. O
One O
previous O
chemotherapy O
regimen O
and O
no O
prior O
hormone O
therapy O
for O
advanced O
disease O
were O
permitted O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
exemestane O
25 O
mg O
or O
tamoxifen O
20 O
mg O
orally O
once O
daily O
until O
disease O
progression O
or O
unacceptable O
toxicity O
occurred O
. O
A O
total O
of O
371 B-total-participants
patients O
enrolled O
at O
79 O
sites O
( O
182 B-intervention-participants
exemestane O
, O
189 B-control-participants
tamoxifen O
) O
were O
included O
in O
the O
analysis O
. O
Both O
treatments O
were O
generally O
well O
tolerated O
without O
major O
toxicity O
. O
Overall B-outcome
response I-outcome
rate I-outcome
was O
greater O
for O
exemestane O
than O
for O
tamoxifen O
treatment O
( O
46 B-iv-bin-percent
% I-iv-bin-percent
v O
31 B-cv-bin-percent
% I-cv-bin-percent
; O
odds O
ratio O
= O
1.85 O
; O
95 O
% O
CI O
, O
1.21 O
to O
2.82 O
; O
P O
= O
. O
005 O
) O
. O
Median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
was O
longer O
with O
exemestane O
( O
9.9 B-cv-cont-median
months I-cv-cont-median
; O
95 O
% O
CI O
, O
8.7 O
to O
11.8 O
months O
) O
than O
with O
tamoxifen O
( O
5.8 B-iv-cont-median
months I-iv-cont-median
; O
95 O
% O
CI O
, O
5.3 O
to O
8.1 O
months O
) O
. O
However O
, O
these O
early O
differences O
( O
Wilcoxon O
P O
= O
. O
028 O
) O
did O
not O
translate O
to O
a O
longer O
- O
term O
benefit O
in O
PFS B-outcome-measure
, O
the O
primary O
study O
end O
point O
( O
log O
- O
rank O
P O
= O
. O
121 O
) O
. O
There O
was O
also O
no O
difference O
in O
survival B-outcome
between O
both O
study O
arms O
. O
Exemestane O
is O
an O
effective O
and O
well O
- O
tolerated O
first O
- O
line O
hormonal O
treatment O
for O
postmenopausal O
women O
with O
MBC O
and O
offers O
significant O
early O
improvement O
in O
time O
to O
tumor O
progression O
when O
compared O
with O
tamoxifen O
. O

